Non-Canonical Targets, Reaction Kinetics, And Cellular Potency Of Amino Acid-Linked Platinum(ii) Compounds by Kimutai, Bett
Wayne State University 
Wayne State University Dissertations 
January 2020 
Non-Canonical Targets, Reaction Kinetics, And Cellular Potency Of 
Amino Acid-Linked Platinum(ii) Compounds 
Bett Kimutai 
Wayne State University 
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations 
 Part of the Chemistry Commons 
Recommended Citation 
Kimutai, Bett, "Non-Canonical Targets, Reaction Kinetics, And Cellular Potency Of Amino Acid-Linked 
Platinum(ii) Compounds" (2020). Wayne State University Dissertations. 2360. 
https://digitalcommons.wayne.edu/oa_dissertations/2360 
This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has 




NON-CANONICAL TARGETS, REACTION KINETICS, AND CELLULAR POTENCY 





Submitted to Graduate School  
of Wayne State University 
Detroit, Michigan 
in partial fulfillment of the requirements  
for the degree of 
DOCTOR OF PHILOSOPHY 
           2020 

































Foremost, I would like to thank my doctoral advisor, Dr. Christine Chow, for taking me into 
her research lab. Since I joined, Dr. Chow has provided immense guidance and advice that 
enabled me to grow in research.  Dr. Chow also created an enabling environment and 
opportunities to explore various career paths in preparation of life after graduate school for which 
I am grateful. I am thankful to all my dissertation committee members, including Dr. Young-Hoon 
Ahn, Dr. M. T. Rodgers, and Dr. Weilong Hao for their commitment and advice through my PhD 
dissertation. I also acknowledge Dr. Louis Romano who had earlier served in my committee until 
his retirement and grateful to Dr. Y. H. Ahn for having accepted to join the committee later on. I 
acknowledge Dr. M. T. Rodgers and her lab for the collaborative research projects that we had 
together for a number of years. I am grateful for the great expertise and contribution of Dr. M. T. 
Rodgers and her former student, Dr. C. C. He, toward the collaboration. The collaboration was 
very fruitful and enabled us to have publications. Working alongside Dr. C. C. He was also a great 
experience as I learnt a lot from her talent and knowledge. I would also like to thank Dr. Y. H. Ahn 
for allowing me to use a number of his research instruments and lab space. I am also grateful to 
his former student, Dr. Fidelis Ndombera, for training me to perform mammalian cell experiments. 
During my time as a graduate student I was surrounded by supportive and friendly 
colleagues. I am grateful to my past labmates including Dr. Jun Jiang, Dr. Xun Bao, Dr. Gayani 
Dedduwa-Mudalige, Dr. Danielle Dremann, Dr. Hyosuk Seo, Dr. Nisansala Muthunayake, Dr. 
Supuni Thalalla Gamage, and Dr. Prabuddha Madubashitha for their advice, expertise, and 
training on various lab techniques. I am thankful to Dr. Supuni Thalalla Gamage for the fruitful 
discussions that we had in our collaborative projects and appreciate her talented input in some of 
the challenging experiments. I am also appreciative of the current Chow lab members including 
Evan Jones, Rabiul Islam, Alan Mlotkowski, and Deepak Shrestha for being collaborative in our 
research and providing valuable input from their areas of expertise. All the past and current 
labmates exemplified comradery in day to day activities that enabled us to grow in science and 
iv 
 
also to be great friends outside of lab. I would like to thank all the former and current 
undergraduate students in our lab whom I worked with including Andrew Roberts, Marcel L. 
Jones, Ken Dada, Nicolas Nunez, and Mateusz Sileski. Each of them was very helpful and 
provided valuable contributions in various projects. I am also grateful to all the past and current 
members of Dr. Ahn and Dr.  Bhagwat labs for the fruitful interactions that we had while assisting 
each other in various lab activities or discussions. 
I would like to thank the staff at Lumigen instrument center (LIC) for providing me with the 
training and guidance on how to run various instruments. I particularly acknowledge Dr. Dennis 
Anderson, Evan Jones, Dr. Jun Jiang, and Dr. Phil Martin for their expertise and assistance in 
collecting some of the data. I am also grateful to Dr. Johnna Birbeck, Dr. Olena Danylyuk, and Dr. 
Nicholas Peraino for training me on the use of various mass spectrometry techniques.  I am 
thankful for some of the materials provided generously by a number of labs including Dr. Y. H. 
Ahn, Dr. Kenneth V. Honn, and Dr. Zhihui Qin from where I acquired mammalian cell lines. I am 
also grateful for some chemical supplies provided generously by Dr. Klaus Friedrich from 
University of Detroit Mercy. 
I acknowledge WSU-BEST and ReBUILDetroit programs for the career development 
opportunities that they provided. In winter 2018, I had a semester-long internship to explore a 
teaching career through these programs. I worked and interacted with exceptional people 
including Dr. Jazhara Mayes Otoo and Dr. Jeanne Andreoli from University of Detroit Mercy, and 
Dr. Andrea Matti from Wayne State University during this teaching internship. They provided such 
immerse guidance and environment for career development. I am also grateful to my advisor, Dr. 
Chow, and Dr. Heidi Kenaga who were an integral part of the BEST program and its opportunities. 
I would also like to acknowledge the WSU chapter of NOBCChE, its officials, and members for 
working together towards its mission and goals. Personally, being part of this incredible team 
gave me an opportunity to develop leadership skills and other soft career skills especially when I 
served as its vice-president. 
v 
 
I am grateful to Wayne State University and the Chemistry department for the opportunity 
to be part of this institution and the department. I am thankful for the environment and all the 
resources provided by WSU and the department for me to work on my PhD dissertation. I thank 
Melissa Rochon for her time and resourcefulness through the entire process. 
I would like to thank my parents, Joseph Langat and Florence Langat, their love and 
support through all the years. I would also like to thank Hellen Jones and my friend Dr. Ezra Mutai 
at Cornell University who have always been encouraging in my professional and personal life. 
Lastly, I would like to thank my wife, Mercy Langat, for her love, support and patience. She has 



















TABLE OF CONTENTS 
DEDICATION…………………..…………………………………………...…………………………… ii  
ACKNOWLEDGEMENTS……………………………………………...……………………………….iii  
LIST OF TABLES……………………………………………………………..…………………………x  
LIST OF FIGURES …………………………………………………………………….…...………….xi  
LIST OF SCHEMES…………………………………………………………………….……………...xv  
LIST OF ABBREVIATIONS………………………………………………………..…………………xvi  
CHAPTER 1- INTRODUCTION …………………………………………………..…………….……...1 
1.1 Abstract…………………………………………………………………………..…………………...1  
1.2 Introduction to discovery, mechanism of action, and kinetics of cisPt …………………..…….2 
1.2.1   Discovery of cisPt and its application in cancer therapy…………………………….2 
1.2.2   Structural components of cisPt…………………………………………………………4 
1.2.3 Mechanism of action, reaction kinetics, and adduct formation of cisPt……………..4  
1.3 Introduction to alternative biological targets of cisPt……………………………………………12 
1.3.1 RNA as a target of platinum-based compounds……………………………………12 
1.3.2 Proteins as targets of platinum-based compounds………………………………...14  
1.4 Cellular resistance and toxicity of cisPt; development of cisPt analogues……………………..15 
1.4.1 Toxicity and low selectivity of platinum-based cancer agents……………………...15 
1.4.2 Cellular resistance to cisPt…………………………………………………………….17 
1.4.3  Development of cisPt analogues for anticancer therapeutics…………………….19 
1.4.4 Platinum(IV)-based compounds as antitumor agents………………………………23 
1.5 Thesis objectives……………………………………………………………………………………25 
CHAPTER 2- AMINO ACID-LINKED PLATINUM(II) COMPOUNDS: SYNTHESIS, 
CHARACTERIZATION, AND METHODS TO INVESTIGATE THEIR KINETICS, ADDUCTS, 
AND CELLULAR ACTIVITIES ………………………………………….…………………………….29 
 
2.1 Abstract ..………………………………………………………………………..…………………..29 
2.2 Introduction ...……………………………………………………………………………………….30  
vii 
 
2.2.1 Application of amino acids as ligands of cisplatin analogues………………….……30  
2.2.2 Formation and characterization of non-canonical AAPt-nucleic acids adducts ..…33 
2.2.3 Kinetics of AAPt with DNA/RNA nucleosides and oligonucleotides………………..34 
2.2.4 Impact of AAPt compounds on glycosidic bond stability of adducts……………….34 




2.3.1 Chemicals………………………………………………………………………...………36  
2.3.2 Human cell lines and cell culture supplies…………………………………………….36 
2.3.3 Instrumentation ...………………………………………………………………………..37 
2.4 Methods ..…………………………………………………..……………………………………….38 
2.4.1 Synthesis and characterization of AlaPt ……………………………………………...38 
2.4.2 Synthesis and characterization of OrnPt………………………………………………43 
2.4.3 Synthesis and characterization of ArgPt………………………………………………48 
2.4.4 Preparation of aquated AAPt compounds…………………………………………….51 
2.4.5 Preparation of nucleosides and oligonucleotides…………………………………….52 
2.4.6 Pseudo-first-order reaction kinetics………………………………………………..…..55 
2.4.7 Fitting data into a kinetic equation……………………………………………………..56 
2.4.8 Mass analysis of HPLC isolated AAPt-nucleoside adducts ...………………………57 
2.4.9 NMR spectroscopy of AAPt-nucleoside adducts……………………………………..57 
2.4.10 Mass analysis of HPLC isolated AAPt-oligonucleotide adducts…………………..58 
2.4.11 Reactions of AAPt with poly(Ado) RNA, ethanol precipitation, and LC-MS 
characterization of adducts……………………………………………………………………58 
 
2.4.12 Energy-resolved collision-induced dissociation (ER-CID) experiments and survival 
yield analyses…………………………………………………………………………………...59 
 
2.4.13 MTT cytotoxicity assays in human cell lines .……………………………………….60 
viii 
 
2.4.14 Quantification of cellular accumulation of platinum compounds…………………..61 
CHAPTER 3- CHARACTERIZATION OF NON-CANONICAL ADDUCTS FORMED BY AMINO 
ACID-LINKED PLATINUM(II) COMPOUNDS ……………………………………………………...63 
 
3.1 Abstract ...……………………………………………………………………………………………63 
3.2 Introduction ………………………………………………………………………………………….64 
3.3 Results and discussion ……………………………………………………………………...…….67 
3.3.1 Characterization of AAPt-nucleoside adducts ………………………………………...67  
3.3.2 Characterization of AAPt-RNA adducts ……………………………………………….79 
3.3.2 Structural isomers of AAPt adducts ………….…………………………………………87 
3.4 Conclusions………………………………………………………………………………………….90 
CHAPTER 4- REACTION KINETICS OF AMINO ACID-LINKED PLATINUM(II) COMPOUNDS 
WITH DNA/RNA NUCLEOSIDES AND OLIGONUCLEOTIDES …………………………………91 
 
4.1 Abstract ……………………………………………………………………………………………..91 
4.2 Introduction ………………………………………………………………………………………….91 
4.3 Results and discussion …………………………………………………………………………….94 
4.3.1 Kinetics of platination reactions with DNA/RNA purine nucleosides ………………..94 
4.3.2 Kinetics of platination reactions with DNA/RNA oligonucleotides …………………...98 
4.4 Conclusions ………………………………………………………………………………………..106 
CHAPTER 5- IMPACT OF AMINO ACID-LINKED PLATINUM(II) COMPOUNDS ON 




5.3 Results and discussion…………………………………………………………………………...112 
5.3.1 Non-canonical AAPt-Ado adduct isomers and their differential fragmentation 
patterns………………………………………………………………………………………...112 
 




CHAPTER 6- POTENCY AND ACCUMULATION OF AMINO ACID-LINKED PLATINUM 




6.3 Results and discussion…………………………………………………………...……………….126 
6.3.1 Potency of AAPt compounds in human cancer and normal cells……………...……126 
6.3.2 Quantification of platinum abundance in cells…………………………………..……133 
6.4 Conclusions……………………………………………………………….……………………….137 
CHAPTER 7- CONCLUSIONS AND FUTURE DIRECTIONS…………………………..………..139 



















LIST OF TABLES 
Table 1.1. Clinically approved cancer platinum-based drugs……………………………………….23 
Table 3.1. Downfield shifts of protons (in ppm) of AlaPt-Ado adducts relative to Ado protons……76 
Table 3.2. Downfield shifts of protons (in ppm) of OrnPt-Ado adducts relative to Ado protons…..77 
Table 3.3. Downfield shifts of protons (in ppm) of ArgPt-Ado adducts relative to Ado protons…...78 
Table 4.1. Pseudo-first-order rate constants………………………………………………………….97 
Table 4.2. Rate constants of cisPt reactions with various DNA/RNA constructs…………………99 
Table 4.3. Pseudo-first-order rate constants………………………………………………………...103 
Table 6.1. IC50 (μM) values of cisPt, carboplatin, and oxaliplatin in human cancer cell lines……123 
Table 6.2. Comparison of potency of AAPt compounds, cisPt, and carboplatin in DU145 cell 
line……………………………………………………………………………………………………….128 
 
Table 6.3. Comparison of potency of cisPt and ArgPt in normal and cancer cell lines…………..130 
Table 6.4. IC50 (μM) values ArgPt in comparison with cisPt………………………………………..132 
Table 6.5. Accumulation of platinum compounds in prostate cancer and normal cells………….134 















LIST OF FIGURES 
Figure 1.1. Timeline for discovery, development, and applications of cisPt………………………..3 
Figure 1.2. The structures of cisplatin (cisPt) and transplatin with their respective 
configurations……………………………………………………………………………………………..3 
 
Figure 1.3. The structural components of cisPt……………………………………………………….4 
Figure 1.4. Mode of action of cisPt……………………………………………………………………..6 
Figure 1.5. Reaction kinetics of cisPt and DNA……………………………………………………….7 
Figure 1.6. Potential DNA coordination sites for cisPt………………………………………………..9 
Figure 1.7. Various types of DNA adducts that are formed by cisPt…………..…………………….10 
Figure 1.8. Structure of cisPt-nucleoside adducts…………………………………………………...11 
Figure 1.9. Crystal structure of cisPt bound to 50S RNA…………………...………………………13  
Figure 1.10. Crystal structure cisPt bound to a protein……………………………………………..15  
Figure 1.11. Nucleotide repair mechanism to remove cisPt adducts……………………………...19 
Figure 1.12. Antitumor platinum-based compounds………………………………………………...20 
Figure 1.13. Platinum drugs bound to dGuo residues in the major groove of DNA……………...21 
Figure 1.14. Ligands of Pt(IV)-based complexes and their roles…………………………………...24 
Figure 1.15. Structures of Pt(IV)-based anticancer agents………………………………………….24 
Figure 1.16. The structures of cisPt and amino acid-linked platinum(II) compounds, AlaPt, OrnPt, 
and ArgPt………………………………………………………………………………………………...26 
Figure 2.1. Possible structures of AAPt compounds………………………………………………....32 
Figure 2.2. The structures of amino acid-linked platinum(II) compounds…………………………33 
Figure 2.7. The 1H-NMR spectra of L-alanine and AlaPt……………………………………………39 
Figure 2.8. The 13C-NMR spectra of L-alanine and AlaPt………………...………………..………..40 
Figure 2.9. The 13C-NMR time course of AlaPt aquation…………………………………….……...41 
Figure 2.10. The 195Pt-NMR spectrum of potassium tetrachloroplatinate(II) and AlaPt……….…42 
Figure 2.11. ESI mass spectrum of AlaPt………………………………………………….………….42 
Figure 2.12. The 1H-NMR spectra of L-ornithine and OrnPt…………………………….….………..44 
xii 
 
Figure 2.13. The 13C-NMR specta of L-ornithine and OrnPt…………………………….….………..45 
Figure 2.14. The 1H-NMR spectra of OrnPt in D2O and DMSO…………………………….….……46 
Figure 2.15. ESI mass spectrum of OrnPt…………………………………………………….….……47 
Figure 2.16. Crystal structure of OrnPt…………………………………………………………..…….48 
Figure 2.17. The 1H-NMR spectra of L-arginine and ArgPt…………………………………………49  
Figure 2.18. The 13C-NMR spectra of L-arginine and ArgPt…………………………………..……..50 
Figure 2.19. Mass analysis of ArgPt using FT-ICR MS……………………………………….……..51  
Figure 2.20. HPLC analysis of 5′-d(TTATT)-3′………………………………………………….…….53  
Figure 2.21. MALDI-MS mass spectrum of 5′-d(TTATT)-3′…………………………………….…...53 
Figure 2.22. HPLC analysis of 5′-UUAUU-3′…………………………………………………….……54  
Figure 2.23. MALDI-MS mass spectrum of the 5′-UUAUU-3′…………………………………..……54 
Figure 2.24. HPLC calibration curves for Ado and Guo…………………………………………..….56 
Figure 3.1. Possible coordination sites for cisPt in DNA…………………………………………..…65 
Figure 3.2. The structures of cisPt and amino acid-linked platinum(II) (AAPt) compounds…...….66 
Figure 3.3. HPLC analysis (C18) of platination products……………………………………...……69 
Figure 3.4. Mass spectra of the AlaPt-AdoN1/N3 and AlaPt-AdoN7 fractions……………………….70 
Figure 3.5. Wide range mass spectra of the AlaPt-Ado fractions………………………………….71 
Figure 3.6. Mass spectra of the OrnPt-AdoN1/N3 and OrnPt-AdoN7 fractions………………………72 
Figure 3.7. Wide range mass spectra of the OrnPt-Ado fractions…………………………………72 
Figure 3.8. Mass spectra of the ArgPt-AdoN1/N3 and ArgPt-AdoN7 fractions………………………73 
Figure 3.9. Wide range mass spectra of the ArgPt-Ado fractions…………………………………74 
Figure 3.10. Mass spectrum of ArgPt-Adomix fraction……………………………………………….74 
Figure 3.11. The 2D heteronuclear single quantum correlation (HSQC) of OrnPt-AdoN7 and OrnPt-
AdoN1/N3 …………………………………………………………………………………………………. 75 
 
Figure 3.12. Aromatic region of 1H-NMR spectra of AlaPt-Ado HPLC fractions..........................76 
Figure 3.13. Aromatic region of 1H-NMR spectra of OrnPt-Ado HPLC fractions.........................77 
xiii 
 
Figure 3.14. Aromatic region of 1H-NMR spectra of ArgPt-Ado HPLC fractions.........................78 
Figure 3.15. HPLC analysis (C18) of AlaPt-UUAUU platination products………………………...80 
Figure 3.16. ESI mass spectrum of isolated AlaPt-UUAUU-1 product……………………………81 
Figure 3.17. Adducts formed by AAPt compounds with 5′-UUAUU-3′ RNA………………………81 
Figure 3.18. HPLC analysis (C18) of OrnPt-UUAUU platination products………………………...82 
Figure 3.19. MALDI mass spectrum of HPLC isolated OrnPt-UUAUU-1 product…………………83 
Figure 3.20. MALDI mass spectrum of isolated OrnPt-UUAUU-2 and OrnPt-UUAUU-3 HPLC 
fractions…………………………………………………………………………………………………..84 
 
Figure 3.21. HPLC analysis (C18) of ArgPt-UUAUU platination products………………………….85 
Figure 3.22. MALDI mass spectrum of isolated ArgPt-UUAUU reaction mixtures………………...85 
Figure 3.23. LC spectrum of ArgPt-poly(Ado) reaction products……………………………………86 
Figure 3.24. LC-MS spectra of ArgPt-poly(Ado) reaction products…………………………………87 
Figure 3.25. Representative geometric and constitutional isomers of AAPt-Ado adducts………..88 
Figure 3.26. Possible adduct structures formed by AAPt with purines……………………………..89 
Figure 4.1. The structures of cisPt (cisPt) and amino acid-linked platinum(II) compounds, AlaPt, 
OrnPt, and ArgPt………………………………………………………………………………………...92 
 
Figure 4.2. Reaction rates of monoaquated AlaPt, OrnPt, and ArgPt with purine nucleosides…..96 
Figure 4.3. Comparisons of rate constants (k) for reaction of monoaquated cisPt and AAPt 
compounds with DNA/RNA purine nucleosides………………………………………………………97 
 
Figure 4.4. HPLC analysis (C18) of platinated RNA products……………………………………..100 
Figure 4.5. HPLC analysis (C18) of platinated DNA products………………………..……………101  
Figure 4.6. Reaction rates of AlaPt, OrnPt, and ArgPt with RNA and DNA oligonucleotides……102 
Figure 4.7. Comparison of reactivity of platinum-based compounds with oligonucleotides…….104 
Figure 5.1 Structure of monofunctional AAPt-Ado adduct………………………………………….110 
Figure 5.2. Schematic representation of the ER-CID experiment…………………………………111 
Figure 5.3. Activation of AAPt-Ado adduct towards cleavage……………………………………...113 
Figure 5.4. CID fragmentation patterns of AlaPt-Ado adducts……………………………………..114 
xiv 
 
Figure 5.5. CID fragmentation patterns of OrnPt-Ado adducts…………………………………….114 
Figure 5.6. CID fragmentation patterns of ArgPt-Ado adducts…………………………………….115 
Figure 5.7. Glycosidic bond survival yield curves of AlaPt adduct isomers……………………….116 
Figure 5.8. Glycosidic bond survival yield curves of OrnPt adduct isomers………………………118 
Figure 6.1. The structures of cisPt and AAPt compounds………………………………………….124 
Figure 6.2. Dose-response curves of AAPt compounds (and cisPt) in prostate cancer (DU145) 
cell line…………..………………………………………………………………………………………127 
 
Figure 6.3. Dose-response curves of cisPt and ArgPt in normal prostate (RWPE-1) cell lines…129 
Figure 6.4. Dose-response curves of cisPt and ArgPt in breast cancer cell lines…………..…….131 
Figure 6.5. Dose-response curves of ArgPt and cisPt in cervical and lung cancer cell 
lines………………………………………………………………………………………………….….133 
Figure 6.6. Accumulation of platinum-based compounds in prostate normal (DU145) and cancer 
(RWPE-1) cell lines…………………………………………………………………………..………..136 
 
Figure 1A. ICP-MS Calibration graph with no gas tune mode………………………….…………..149 
Figure 2A. ICP-MS calibration graph in helium tune mode…………………………………………150 
Figure 3A. ICP-MS calibration graph in high energy helium (HEHe) tune mode……………...….151 













LIST OF SCHEMES 
Scheme 2.1. Aquation of platinum compounds……………………………………………….……...52  
Scheme 3.1. Aquation of platinum compounds and subsequent platination of purine residues….67 
Scheme 4.1.  Aquat ion of  p lat inum compounds and subsequent  p lat inat ion of 
nucleosides/oligonucleotides…………………………………………………………………..………92 
 























LIST OF ABBREVIATIONS 
DNA              deoxyribonucleic acid  
RNA              ribonucleic acid 
cisPt,            cis-diamminedichloridoplatinum(II) 
dGuo             2′-deoxyguanosine 
dAdo              2′-deoxyadenosine 
Guo                guanosine 
Ado                adenosine 
dThd              2′-deoxythymidine 
dCyd              2′-deoxycytidine 
Cyd                cytidine 
Urd                 uridine 
AAPt              amino acid-linked platinum(II) compounds 
AlaPt              alanine-linked platinum(II) compound 
OrnPt             ornithine-linked platinum(II) compound 
ArgPt             arginine-linked platinum(II) compound 
HSAB             hard-soft acid-base  
rRNA              ribosomal RNA  
tRNA              transfer RNA  
mRNA            messenger RNA 
lncRNA           long noncoding RNA 
GSH               glutathione  
NER                nucleotide excision repair 
AKI                  acute kidney injury 
hSOD              human superoxide dismutase 
ROS                reactive oxygen species 
xvii 
 
HPLC  high performance liquid chromatography 
NMR             nuclear magnetic resonance 
HSQC             heteronuclear single quantum correlation 
ESI-MS           electrospray ionization mass spectrometry 
MALDI             matrix-assisted laser desorption ionization 
LC-MS             liquid chromatography-mass spectrometry 
ICP-MS           inductively coupled plasma mass spectrometry 
ICP-OES         inductively coupled plasma optical emission spectroscopy 
MTT                3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide  
MTS                3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4sulfophenyl)-2H- 
                        tetrazolium  
XTT                 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5carboxanilide  
WST                2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H- 
                        tetrazolium 
DMSO             dimethylsulfoxide  
3-HPA             3-hydroxypicolinic acid   
DACH             1,2-diamminocylohexane 
DMSO             dimethylsulfoxide 
ER-CID           energy-resolved collision-induced dissociation 
PBS                 phosphate-buffered saline 
FBS                 fetal bovine serum  








DNA serve as an ideal target where drugs such as cisplatin (cisPt) bind and exert their 
anticancer activities. CisPt is known to preferentially coordinate with DNA leading to formation of 
cisPt-deoxyguanosine (dGuo) adducts. The adducts distort the DNA structure and contribute to 
inhibition of DNA-mediated cellular functions and ultimately cancer cell death. Despite its 
utilization as an anticancer drug, cisPt has a number of drawbacks, which include toxic side effects 
and cellular resistance. Resistance occurs through processes such as repair of damaged DNA 
and inactivation of cisPt present in the cell. To overcome these challenges, the aim of this thesis 
work was to synthesize and investigate compounds that coordinate to different sites from those 
targeted by cisPt, including sites found in RNA. In this highly collaborative dissertation project, 
amino acid-linked platinum(II) compounds were synthesized and studied as alternatives to cisPt. 
The reactivity preferences of these compounds towards DNA/RNA nucleosides and 
oligonucleotides were determined through pseudo-first-order kinetics. The products formed by the 
reactions of amino acid-linked platinum(II) compounds with DNA and RNA were studied by 
electrospray ionization mass spectrometry (ESI-MS) to determine the type of adducts formed by 
the compounds. NMR spectroscopy was used to determine the non-canonical adducts formed by 
the compounds that include platination of the N1, N3, or N7 positions of RNA adenosine (Ado) 
residues. Features of amino acid-linked platinum(II) compounds that impact the glycosidic bond 
stability of Ado residues were explored by using tandem mass spectrometry in collaboration with 
the Rodgers laboratory. Furthermore, cytotoxicity assays and inductively coupled plasma mass 
spectrometry (ICP-MS) were used to determine the potency and accumulation of the compounds 
in cancer cells. Altogether, the unique characteristics of the amino acid-linked compounds such 
as altered reactivity preferences, formation of adducts at non-canonical residues, destabilization 





features that could circumvent drug resistance faced by the currently available platinum-based 
drugs. 
1.2 Introduction to discovery, mechanism of action, and kinetics of cisPt 
1.2.1 Discovery of cisPt and its application in cancer therapy 
CisPt, cis-diamminedichloridoplatinum(II), is a widely used platinum-based antitumor drug 
[1] that has come a long way since it was first synthesized in 1844 by an Italian chemist, Michele 
Peyrone (Fig.1.1) [2]. Peyrone was interested in the synthesis and reactivity of various platinum-
based compounds. He documented some of the physical and chemical properties of cisPt, which 
at the time was called Peyrone’s salt [3]. Although Peyrone described some of the properties of 
cisPt, the structure of the compound was not fully elucidated at that time [2]. In 1893, Alfred 
Werner, a scientist interested in the coordination chemistry of inorganic compounds proposed 
that the structure of cisPt consists of a square-planar geometry [4]. After Werner’s findings, cisPt 
went into obscurity for many years until the 1960s when crystallographic studies of the compound 
were done [5] . A crystal structure confirmed the cis configuration of cisPt, while also revealing 
that transplatin (trans-diamminedichloridoplatinum(II), is an isomer of cisPt with the trans 
configuration (Fig. 1.2). 
The biological applications of cisPt were not realized until the 1960s when Barnett 
Rosenberg serendipitously discovered its antitumor activity [6-7]. This discovery occurred while 
Rosenberg and coworkers were investigating the effects of electrical fields on the growth of E. 
coli. They observed inhibition of cell division, along with dramatic changes in the cell morphology, 
when the bacteria were exposed to an electrical current with platinum electrodes in an ammonium 
chloride buffer [6]. Further investigation revealed that these effects were not due to the electric 
current, but rather because cisPt was being formed from a reaction between the buffer and the 
platinum electrodes [6]. Using cisPt and related platinum-based compounds, Rosenberg, 
VanCamp, and co-workers carried out antitumor testing with animal models [7]. They treated 





had remarkable tumor regression after low doses of cisPt. This work contributed to discovery of 
the antitumor activity of cisPt in mammals, and led to the introduction of cisPt as a clinical 
platinum-based antitumor candidate in 1969 [7-8]. After more clinical investigation was done, cisPt 
was approved by the FDA in 1978 to be used for treatment of testicular and bladder cancer, 
becoming the first platinum-based anticancer drug [9]. 
 
 
Figure 1.1. Timeline for discovery, development, and applications of cisPt. CisPt was first 
synthesized more than 150 years ago, but its application in human cancer therapy did not take 




          cisplatin (cisPt)       transplatin 
 
Figure 1.2. The structures of cisplatin (cisPt) and transplatin with their respective 
configurations. Both of the isomeric compounds assume a square-planar geometry. 
 
Since its approval by the FDA, cisPt has been used for treatment of several other forms 
of cancer, including testicular, ovarian, colorectal, prostate, lung, breast, and head and neck 





tissue to another. Testicular cancer is the most responsive, with a cure rate of 90-100%, especially 
when discovered and treated with cisPt early [11-12]. Other forms of cancer such as non-small 
lung cancer are not as responsive, and cancer regression can be hampered by development of 
cisPt resistance with each round of dosage given to the patient [13-14]. 
1.2.2 Structural components of cisPt 
CisPt, [PtCl2(NH3)2], is a platinum-based complex with a square-planar cis geometry (Fig. 
1.3). The platinum metal element has atomic number 78 and exists as various stable isotopes 
with the most abundant being 195Pt. Platinum has two valence states, (II) and (IV), which have 
different numbers of coordinated ligands. CisPt has a Pt(II) center coordinated by two ammine 
and two chlorido ligands. According to the hard-soft acid-base (HSAB) principle, the platinum is 
a soft acid that prefers coordination to softer bases such as amines compared to chlorine [15]. 
Because coordination to the N-containing ligands is more thermodynamically stable, the two 
ammines are referred to as ‘non-leaving groups’, whereas the two chlorido ligands are referred to 
as the ‘leaving groups’ (Fig. 1.3). These two different ligand types determine the various chemical 
properties of cisPt, ranging from the kinetic reactivities of the compound to the preferred biological 
targets [16-17].  
 
Figure 1.3. The structural components of cisPt. The two chlorido ligands are referred to as 
leaving groups, because they can be replaced during reactions with the target. The two ammines 
are thermodynamically stable and remain coordinated. 
 
1.2.3 Mechanism of action, reaction kinetics, and adduct formation of cisPt 
The mechanism of action of cisPt has been studied extensively over the past 50 years in 
an effort to understand its clinical efficacy [16, 18]. CisPt is administered intravenously into the 
bloodstream from where it can enter cells through various modes, including passive diffusion [19-





(Fig. 1.4) [20-21]. Other modes of cisPt uptake are active and facilitated transport. For example, 
copper transporters in cancer cells facilitate the regulation and intake of cisPt [22-24]. Presence 
of such facilitated transport is crucial to the biological activity of cisPt, since upregulation of copper 
transporters increases the sensitivity of cancer cells to cisPt [22]. Downregulation of facilitated 
transporters and reliance on passive diffusion is one factor that may lead to cellular resistance to 
cisPt treatment [22].  
Blood serum has a high chloride concentration of approximately 100 mM, which inhibits 
the loss of the chlorido ligands of cisPt and enables the compound to reach the cell membrane in 
its intact neutral form, [PtCl2(NH3)2]0 [25]. However, aquation (replacement with an aqua ligand) 
occurs once cisPt is inside the cell where the chloride concentration is much lower (2-30 mM) [25] 
(Fig. 1.4). The aquated cisPt can include the monoaquated form, [PtCl(H2O)(NH3)2]+, or the bis-
aquated form, [Pt(H2O)2(NH3)2]2+, in which either one or both of the chlorido ligands are replaced 
by aqua ligands, respectively [19]. The aquated forms of cisPt are positively charged and can 
interact with negatively charged nucleic acids through electrostatic interactions before 
coordination to the nucleobase occurs [19]. The aquated forms of cisPt preferentially coordinate 
to neighboring dGuo residues of DNA [26-27]. Formation of these adducts alters the DNA 
structure and inhibits biological processes such as replication and transcription [11]. The adducts 
trigger other cellular responses, including cell cycle arrest, DNA repair, and apoptosis [1]. Aside 
from DNA, cisPt can also coordinate with other cellular biomolecules including RNA, thiol 
containing metabolites, and S-containing proteins (Fig. 1.4) [28-30]. These interactions play 
different roles, from contributing to the potent activity of cisPt in the cell to cellular resistance 






Figure 1.4. Mode of action of cisPt. The mechanism of cisPt antitumor activity includes uptake, 
aquation, formation of adducts with DNA, inhibition of cellular processes, apoptosis, and possible 
resistance due to factors such as drug efflux, reactions with other cellular components, and DNA 
repair. Inhibition of cellular processes such as replication, occurs when cisPt adduct block DNA 
polymerase. Repair of damaged DNA occurs when the cell removes the platinum adducts using 
an excision repair complex. 
 
Reactions of the aquated cisPt species with DNA occur under kinetic control, leading to stable 
adduct formation at the preferred dGuo sites [30, 32]. The coordination of cisPt with DNA involves 
a number of steps that contribute to the overall reaction rates (Fig.1.5). The replacement of the 
first chlorido ligand with an aqua ligand is the rate-determining step that leads to formation of 
monoaquated species, [PtCl(H2O)NH3]+ [32]. The monoaquated cisPt coordinates with DNA at 
the N7 position of dGuo residues to form a monofunctional adduct, [PtCl(N7-dGuo)NH3]+ [32]. The 
monofunctional adduct is then hydrolyzed through replacement of the second chlorido to form 





(preferably at N7) of the second dGuo residue, leading to formation of a bifunctional adduct, 
[Pt(N7-dGuo)2NH3]2+ (Fig. 1.5) [32].  
 
Figure 1.5. Reaction kinetics of cisPt and DNA. CisPt loses the first chlorido ligand to form a 
monoaquated species. The monoaquated species coordinates with DNA at the N7 position of a 
dGuo residue. The second chlorido of cisPt is then replaced by another aqua ligand. This step is 
followed by coordination of the complex to the adjacent dGuo residue at the N7 position. The rate 
constants for each step are indicated [32]. The structures and numbering of dGuo and dAdo are 
shown on the right. 
 
All of the steps of cisPt coordination to DNA contribute to the kinetics of DNA platination and 
are therefore important in the cellular activity of cisPt (and other platinum-based compounds as 
well) [33-36]. For example, cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) (carboplatin) 
is less potent than cisPt, which is partly attributed to its 100-fold slower adduct formation with 






Figure 1.6. Potential DNA coordination sites for cisPt. The site preference is dictated by 
nucleophilicity and accessibility, with the major groove being more accessible to the platinum 
compounds. Atoms involved in hydrogen bonding between the nucleotide bases are less likely to 
participate in platinum coordination. 
 
There are several potential binding sites in the DNA for cisPt to coordinate with varying 





deoxyadenosine (dAdo), are soft bases that provide nucleophilic sites to which the platinum 
center can coordinate. Coordination occurs preferentially at the N7 position of dGuo due to its 
high nucleophilicity compared to the nitrogens of other nucleosides or positions of dGuo [10, 37-
38]. Furthermore, the N7 position of dGuo is found in the major groove of the DNA, which makes 
it more accessible for adduct formation by cisPt compared to other sites such as N3 of the same 
nucleoside [18, 39]. 
As mentioned above, cisPt can lose two chlorido ligands leading to formation of cross-
links. CisPt forms the DNA bifunctional adducts by coordinating to two adjacent dGuo residues at 
their N7 positions [32, 37, 40]. Of the DNA adducts that are formed, 90–95% are intrastrand cross-
links (Fig. 1.7). Further analysis shows that 60–65% are 1,2-(dGuo-p-dGuo), 25% are 1,2-(dAdo-
p-dGuo), and 5% are 1,3-(dGuo-p-Nuo-p-dGuo) intrastrand cross-links in which the coordination 
occurs at neighboring nucleotides (1,2) on the same strand or with an intervening nucleotide 
(1,Nuo,3) (p indicates the phosphate ester bond). The rest of the adducts are a small percentage 
comprising interstrand cross-links (across two strands of DNA) and monofunctional adducts (Fig. 
1.7) [37, 41].  
Compared to cisPt, transplatin has a different DNA adduct profile owing to its trans 
configuration and therefore large angle (180°) between available coordination sites. While a 
majority of the adducts formed by cisPt (95%) are bifunctional adducts that are formed by cisPt 
coordinating with two adjacent nucleosides [37], transplatin forms predominantly monofunctional 
adducts [38, 42-43].  The cis configuration is more compatible with coordination to adjacent sites 
[37-38, 42]. The angle imparted by the platinum metal center leads to DNA bending [11, 38]. Since 








Figure 1.7. Various types of DNA adducts that are formed by cisPt. CisPt coordinates with 
purines at the N7 position and forms intrastrand and interstrand cross-links, and monofunctional 
adducts with varying abundance [41]. 
 
The overall process of cisPt adduct formation such as aquation and DNA platination [34, 36] 
is influenced by a number of factors associated with the non-leaving group ligand (typically an 
ammine), including coordination type and hydrogen-bonding properties [35-36]. These factors 
play roles in target preferences and the types of adducts that are formed. The adducts that are 
formed when cisPt reacts with dGuo are kinetically inert [27, 35, 44]. The adducts form when the 
aqua ligand of cisPt is substituted by a nucleobase atom (typically a nitrogen) via a trigonal-
bipyramidal transition state [45]. Hydrogen bonding is implicated in the kinetic control of platination 
[36, 46] and can stabilize the transition state of the cisPt-dGuo reaction [27]. It was demonstrated 





between its ammine ligand and the oxo at the 6 position of dGuo (Fig. 1.8) [27]. As such, this 
hydrogen-bonding interaction together with charge-charge interactions results in preferential 
coordination of cisPt to dGuo residues of DNA [27]. In contrast, formation of the cisPt-dAdo adduct 
is less favored because the dAdo has an amine at the 6 position, which cannot hydrogen bond 
with the cisPt ammine ligand [27]. 
 
 
Figure 1.8. Structure of cisPt-nucleoside adducts. CisPt binds to the N7 position of dGuo and 
forms a hydrogen bond between its ammine ligand and the 6-oxo of dGuo. A hydrogen bond 
would not form in the cisPt-dAdo adduct. 
 
The binding of cisPt in the DNA major groove results in distortion of the helical structure 
[38]. The distortion of the helix induces the recruitment of proteins that recognize the damage of 
the DNA structure. These proteins, which include the high-mobility-group (HMG) proteins, 
recognize and bind to the bent DNA structures and further increase the bend angle [47-48]. The 
binding of the HMG proteins leads to a cascade of downstream effects that are correlated with 
cancer cell death and hence mediate the antitumor activity of cisPt [48]. The adducts that are 
formed also disrupt normal DNA-protein recognition leading to inhibition of important cellular 








1.3 Introduction to alternative biological targets of cisPt 
1.3.1 RNA as a target of platinum-based compounds 
Previous studies have shown that RNA is also a biomolecular target of cisPt [49-54]. While 
the interaction of DNA and cisPt has been largely studied, investigation of the platination of RNA 
by cisPt and its role in cellular toxicity has been minimal. In recent years there has been increased 
interest in RNA-cisPt interactions [49-54]. RNA is an important biomolecule that plays crucial roles 
in cellular functions ranging from translation to regulation of gene expression. Therefore, RNA 
modifications or damage by small molecules could adversely affect the functions of RNA. By 
extension, disruption of the RNA integrity and its functions could lead to a cascade of events that 
ultimately lead to cell death [29, 55-56].  
There are various reasons why cellular RNA is a plausible target for cisPt. Unlike DNA, 
RNA abundance and localization in a cell are not limited to the nucleus, and rRNA, mRNA, and 
other forms of regulatory RNA can be found in the cytoplasm. Since cisPt is activated to generate 
its reactive monoaquated species in the cytoplasm, it could interact with cytoplasmic components, 
including the readily available cytoplasmic RNAs [29, 50, 53-56]. One of the important features 
that enables coordination of cisPt to DNA nucleotides is their nucleophilicity. RNA also has 
nucleophilic sites such as the N7 position of guanosine (Guo) residues where cisPt could bind, 
and therefore modify the RNA and trigger apoptosis [29, 51, 53, 56]. 
Investigation of the interaction of cisPt with various forms of RNA has been carried out 
using various techniques. CisPt has been shown to bind to Guo residues of RNAs of varying 
sizes, structures, and cellular locations, including the ribosome, mRNA, and tRNA [50, 53, 57-58]. 
Melnikov and coworkers reported a 2.6 Å-resolution X-ray crystal structure of cisPt bound to 70S 
ribosomes. The structure revealed nine ribosomal target sites in which cisPt coordinated RNA, 
including six in the 50S subunit (Fig. 1.9), two in the 30S subunit, and one on ribosomal L9 protein 





that is in direct contact with the mRNA [51]. In inductively coupled plasma mass spectrometry 
(ICP-MS) quantification of the abundance of cisPt bound to DNA vs. RNA after cellular treatment, 
it was observed that there is more than four-fold higher accumulation of cisPt on RNA than DNA 
[59]. The abundance of cisPt adducts on RNA also varies from one form of RNA to another. For 
example, cells treated with cisPt have up to six-fold higher platinum accumulation on rRNA 
compared to mRNA [59]. A comparison of the reactivity of small RNA and DNA hairpins with 
platinum-based compounds indicated that RNA is the kinetically preferred target [49]. Platination 
of tRNA has also been observed with cisPt coordination occurring at the Guo-Cyd (cytidine) rich 
regions of the RNA [58]. The platination of long noncoding RNA (lncRNA) has also gained interest 
due to the importance of lncRNAs in regulation of cellular functions. Previous studies have shown 
that binding of cisPt to lncRNA  plays a role in modulating cancer resistance [60]. 
 
Figure 1.9. Crystal structure of cisPt bound to 50S RNA (PDB ID: 5J4B) [51]. Residues 
modified by cisPt in the 50S subunit of the ribosome are shown by red spheres. The 50S subunit 
has six cisPt adducts and one adduct on the L9 ribosomal protein (where cisPt binds with a 






Since clinical use of cisPt has become challenging due to cellular resistance through 
processes such as DNA repair, targeting RNA may provide another avenue for triggering 
apoptosis while averting resistance. Similar to the target preferences in DNA, aquated cisPt 
coordinates to accessible Guo residues of RNA [49-54]. Analogues of cisPt that exhibit altered 
mechanisms of action, such as targeting RNA over DNA, modifying alternative nucleosides rather 
than dGuo/Guo or altering RNA levels through induced decay pathways, may play a role in 
circumventing cellular resistance [29, 55-56]. 
1.3.2 Proteins as targets of platinum-based compounds 
There is evidence that cisPt interacts and forms adducts with proteins, especially at 
locations with sulfur-, nitrogen-, and oxygen-containing amino acids such as cysteine, methionine, 
and histidine [61]. The coordination of cisPt to cellular proteins plays a role in cisPt uptake, side 
effects, and resistance [30, 61-62]. As noted earlier in Section 1.2.3, proteins such as copper 
transporters are crucial for the uptake of cisPt, and their role in facilitating transport causes the 
cell to be more sensitive towards cisPt treatment [22-24]. Besides facilitating transport, some 
cellular proteins are biomolecular targets of cisPt and other platinum-based compounds [30, 61-
62]. Considering hard-soft acid-base (HSAB) principle, platinum is a soft acid and has a high 
affinity for soft bases such as sulfur and nitrogen, and therefore readily coordinates to sulfur- and 
nitrogen-containing biomolecules [15]. Various proteins are rich in sulfur-containing residues such 
as methionine and cysteine. Therefore, cisPt can coordinate to proteins through such residues. 
For example, it has been reported that cisPt binds to human superoxide dismutase (hSOD) 
protein through a cysteine residue (Cys111) (Fig.1.10) [61, 63]. 
Various biochemical and analytical tools have been used to characterize possible 
platination sites of proteins by cisPt and other platinum-based compounds, and to understand the 
downstream effects of such platination events [62]. The reactivity of cisPt with proteins such as 
cytochrome c, superoxide dismutase, lysozyme, myoglobin and ubiquitin have been investigated 





optical emission spectroscopy (ICP-OES), and X-ray crystallography [61, 64-67]. These studies 
have shown that cisPt coordinates with the proteins through their cysteine, histidine, and proline 
residues [61-63, 68]. 
 
Figure 1.10. Crystal structure cisPt bound to a protein. Crystal structure of human superoxide 
dismutase (hSOD) subunit with cisPt coordinated to its cysteine residue (PDB code 3RE0) [63]. 
The cisPt coordinates with hSOD through the sulfur atom of Cys111. Cysteine is represented in 




1.4 Cellular resistance and toxicity of cisPt; development of cisPt analogues 
1.4.1 Toxicity and low selectivity of platinum-based cancer agents 
Despite cisPt being used to treat a variety of cancer types, its clinical use may be limited 
by adverse side effects [69-71]. One of the major side effects of cisPt is nephrotoxicity, which 
results from cisPt being toxic to cells in several parts of the kidney [69]. CisPt nephrotoxicity 
includes serious acute kidney injury (AKI), which affects 20–30% of patients [72]. Nephrotoxicity 





and causes injury to normal renal epithelial cells, leading to unwanted cell death [72]. Since the 
effectiveness of cisPt is dose dependent, it is desirable to maximize its dosage for maximal 
efficacy. However, the effect of nephrotoxicity is also dependent on the dosage and the frequency 
at which the compound is administered to the patient [72]. Therefore, due to this risk of toxicity, 
the dosage has to be limited in order to avoid causing renal cell injury [70]. 
CisPt causes cell death either through apoptosis or necrosis. Apoptosis is programmed 
cell death, which is induced by cytotoxic drugs such as cisPt [73, 70]. Necrosis is cell death that 
is caused by damage or injury to the cells [74]. It has been observed that low concentrations (10–
100 μM) of cisPt induce apoptosis [70], whereas higher concentrations of cisPt (200–800 μM) 
lead to necrosis [70, 72, 75]. Nephrotoxins, including cisPt at high concentrations, cause injuries 
to renal tabular cells, which is characterized by swelling and rupturing [76]. This injury ultimately 
leads to cell death and activation of an inflammatory response [70, 72, 75-76]. To reduce the 
nephrotoxic effects of cisPt, the drug is sometimes administered clinically followed by thiol-
containing compounds shortly after to react and inactivate excess cisPt in the cells [70, 77]. Such 
sulfur-containing compounds include methimazole, which reduces nephrotoxicity without 
reducing the efficacy of cisPt [70, 78]. 
CisPt can cause other forms of toxicity that are associated a high cellular concentration of 
the drug. Ototoxicity, which is a form of toxicity that leads to hearing loss, is a side effect of many 
drugs [10, 79]. High dosages of cisPt induce formation of reactive oxygen species (ROS) in the 
cochlea cells [10, 79]. The ROS further cause inflammation of the cochlea cells, which ultimately 
leads to ototoxicity. CisPt has also been implicated in hepatoxicity, which is an effect on the liver 
[80]. Through a process enhanced by cytochrome P450 2E1, cisPt induces increased levels of 
ROS and oxidative stress, leading to hepatoxicity [80]. Other forms of cisPt toxicities and side 
effects that have been noted include nausea, vomiting, hair loss, diarrhea, and cardiotoxicity, 






1.4.2 Cellular resistance to cisPt  
The use of cisPt as a clinical anticancer drug is also limited by cellular resistance [69-71]. 
Resistance occurs when cancer cells do not undergo apoptosis with the clinically relevant drug 
dose [71]. There are several factors that lead to cellular resistance, including reduced drug 
accumulation, inactivation of the drug, and increased DNA repair by the cell [71].  
Cancer cells with reduced drug accumulation of cisPt by 20–72% have significant 
resistance to the compound [81]. There are two main causes of reduced cisPt concentrations in 
the cell: (1) increased drug efflux from the cell, and (2) inhibition or reduced drug uptake [71]. One 
or both mechanisms may contribute to resistance [71]. Reduced drug uptake may occur due to a 
defect in the cell’s permeability during passive diffusion or due to aberrant proteins that regulate 
facilitated transport of cisPt [71]. Development of cisPt resistance due to increased drug efflux is 
mostly caused by exporter proteins. Multidrug resistance-associated proteins (MRP), found on 
cellular membranes, have been shown to be upregulated in cancer cells, and have been 
associated with cellular efflux of various drugs [82]. A member of this protein family called MRP2 
is highly abundant in resistant tumor cells, with its upregulation being linked to cisPt resistance 
[83]. Other proteins that have been linked to cisPt efflux include two copper-transporting Ptype 
ATPases, ATP7A and ATP7B, which are upregulated in cisPt resistant cancer cells [84-85]. 
Transfection of ATP7B into tumor cells induces a nine-fold cisPt resistance due to increased drug 
efflux [85]. 
CisPt is inactivated when it reacts with certain cytoplasmic nucleophilic metabolites [71], 
which are usually sulfur-containing. The metabolites that primarily inactivate cisPt include 
glutathione (GSH) and the cysteine-rich metallothionein [71]. Aquated cisPt is highly reactive 
towards these metabolites, which then renders it unreactive with DNA. GSH is highly elevated in 
cancer cells that have chronic exposure to cisPt [71], and therefore can induce resistance by 
decreasing cisPt levels available for interaction with DNA. Increased levels of GSH in cisPt-





which has sulfur-rich sites for cisPt coordination, has also been demonstrated to have a five-fold 
higher abundance in cisPt-resistant human tumor cells [86]. 
Formation and sustaining cisPt-DNA adducts is important for inducing apoptosis. 
However, the cell can also circumvent cisPt-induced apoptosis by triggering repair of the 
damaged DNA [71]. Increased rates of removal of the adducts have been shown to attenuate 
cisPt-induced cytotoxicity [71]. The cell can remove the platinum adducts and repair the damaged 
DNA through a process known as nucleotide excision repair (NER) [87]. The NER pathway is 
activated when DNA residues are modified by helix-distorting adducts (Fig. 1.11) [87]. First, the 
adducts are recognized by a sensor complex that includes the XPE protein, followed by 
recruitment of the excision repair complex [87]. The complex then excises a patch of nucleotides 
from the region overlapping with the adduct in the damaged DNA (Fig. 1.11) [87]. This excision 
removes approximately 24 nucleotides on the 5′ end of the adduct and three nucleotides on the 
3′ side. The remaining complementary single strand is then used as a template for new DNA 
synthesis (Fig. 1.11). After polymerization occurs, the new oligonucleotide is ligated to the rest of 
the DNA to complete the repair [87]. Studies have shown that aberrant NER proteins or repair 
pathways lead to sensitivity of a cell to cisPt treatment and that by re-establishing NER, the 
sensitivity to cisPt returns to original levels [88-89]. Furthermore upregulation of proteins involved 
in the NER complex lead to an increase in the repair of DNA and cellular resistance to cisPt [89]. 
Besides NER, a resistant cell can employ other mechanisms to tolerate platinum damage. These 
include enhancing the DNA replication machinery to replicate past the platinum adducts and 







Figure 1.11. Nucleotide repair mechanism to remove cisPt adducts. The NER pathway is 
activated when the DNA helical structure is distorted by adducts (represented by x). Excision of 
nucleotides removes approximately 24 nucleotides from the 5′ and 3′ ends of the adduct. DNA 
polymerization then occurs using the complementary single strand as a template. This step is 
followed by ligation to complete the DNA repair. 
 
1.4.3 Development of cisPt analogues for anticancer therapeutics  
Chemoresistance of cancer cells to cisPt and toxic effects to normal cells have led to the 
development of new platinum-based compounds [90]. Numerous cisPt analogues have been 
developed to combat the limitations of the parent compound. These analogues exhibit structure-
activity relationships that enable them to retain biological activity in cells. More specifically, the 
active Pt(II) or Pt(IV) complexes are typically coordinated to their ligands in a cis geometry and 
have the general formula cis-[PtX2Z2] or cis-[PtX2Y2Z2], in which X is the leaving group ligand, Z 
is a non-leaving group with at least one N-H moiety, and Y is the axial ligand [91]. Despite these 
consensus structures, exceptions do exist that violate this structure-activity relationship, and 
those compounds have been developed using a different approach than for cisPt. Even though 
thousands of cisPt analogues have been synthesized, only a small number have gone into clinical 
trials [91]. Carboplatin, oxaliplatin, and nedaplatin are a few examples that have been approved 







Figure 1.12. Antitumor platinum-based compounds. Aside from cisPt, these platinum(II)-
based compounds have been clinically used for antitumor targeting either worldwide or in a few 
regions of the world. 
 
Carboplatin (cis-diammine-1,1-cyclobutanedicarboxylate platinum(II)) (Fig. 1.12) is a 
second-generation platinum-based drug with reduced toxic side effects compared to cisPt [33-
36]. However, in cancer cells, carboplatin is not as potent as cisPt at similar concentrations [33-
36]. The structure of carboplatin consists of a chelating cyclobutanedicarboxylate ligand instead 
of the two chlorido ligands (in the case of cisPt). The cyclobutanedicarboxylate ligand plays a 
number of roles such as modulating the rate of aquation and adduct formation, and increasing 
the solubility of carboplatin, which is important for cell penetration [91]. The chelate ring in the 
cyclobutanedicarboxylate stabilizes the ligand and slows the reaction rate for ligand exchange 
with H2O by two orders of magnitude compared to cisPt [91-92]. The rate of adduct formation with 
DNA is also 100-fold slower for carboplatin than for cisPt, due to the slower aquation rate [34]. 
The chemical characteristics of carboplatin have given the compound certain advantages over 





to a lower abundance of adducts, carboplatin has a reduced efficacy compared to cisPt, meaning 
that a much higher dose is required in order to achieve the same effect [16]. Clinically, it has been 
noted that up to four times as much carboplatin is needed to acquire the same effect as cisPt [16]. 
 
 
Figure 1.13. Platinum drugs bound to dGuo residues in the major groove of DNA. Oxaliplatin 
has a large DACH ligand that protrudes into the major grove and interferes with DNA replication 
and transcription machinery (PDB code 1PG9). Compared to oxaliplatin, cisPt forms a smaller 
adduct that does not efficiently block replication and transcription machinery (PDB code 2NPW). 
 
Oxaliplatin was approved worldwide due to its persistent activity in cisPt-resistant cancers 
and absence of nephrotoxicity [93]. The non-leaving group ligand of oxaliplatin is a chelated 1,2-
diamminocylohexane (DACH) ligand (Fig. 1.12). This ligand gives the complex a unique structure-
activity relationship that is crucial in averting cellular resistance that challenges utilization of cisPt 
[91]. As mentioned before, one form of cellular resistance occurs when a cell tolerates the adducts 
and enables the replication machinery to bypass and read through the platinum adducts [94-95]. 





protrudes into the major groove of DNA and is more effective at preventing the replication 
machinery from bypassing the adducts [96, 94] (Fig. 1.13). Although oxaliplatin does not exhibit 
nephrotoxicity, it causes other side effects including neurological toxicity [95]. Oxaliplatin is also 
not fully effective by itself and normally requires combination therapy with other anticancer agents 
such as 5-fluorouracil and cisPt [95]. 
There are several second-generation platinum-based drugs that have received approval 
in various regions of the world (Table 1.1) [93]. Nedaplatin, diammine[hydroxyacetato(2-)-O,Ó] 
platinum(II), was approved in Japan in 1995 for treatment of lung, oesophageal, and head and 
neck cancers [93]. It has an added advantage of being more soluble than cisPt as well as having 
lower nephrotoxicity [97]. Heptaplatin is an approved platinum-based drug used in Korea for 
treatment of gastric cancer [93]. It also has higher solubility in water and a lower toxicity profile. 
Lobaplatin, which is used to target chronic myeloid leukemia, has received regional approval in 
China [93]. Lobaplatin is also in clinical trials in other parts of the world, including the US, South 
Africa, EU, and Australia, for treatment of breast, ovarian, chronic myeloid leukemia, and lung 
cancer [93]. The advantage of lobaplatin over cisPt is that its mode of action involves altering the 
expression of genes that modulate apoptosis, oncogenesis, and cell proliferation [98]. Picoplatin, 
which entered clinical trials in 1997, has an interesting structural feature that enables aversion of 
resistance [91]. It has a 2-methylpyridine ring that can tilt by about 102.7°, which results in 
positioning of the methyl group over the square plane [19, 91] This structural positioning causes 
steric hindrance to thiol-containing deactivating agents such as glutathione. The tilt can therefore 
block these metabolites from effectively reacting with the complex. The blocking of the thiol-
containing agents is important for circumventing inactivation, so that the platinum complex can 













approved types of cancer treated 
carboplatin 1989 worldwide ovarian, brain, head, neck, cervical, testicular, breast 
nedaplatin 1995 Japan oesophageal, head, neck, lung 
oxaliplatin 1996 worldwide colon 
heptaplatin 1999 Korea advanced gastric 
lobaplatin 2010 China small cell lung, breast, chronic myeloid leukemia 
 
1.4.4 Platinum(IV)-based compounds as antitumor agents 
In addition to Pt(II)-based complexes, there are also Pt(IV)-based compounds that exhibit 
anticancer activity [99]. The Pt(IV) complexes are generally inert and only act as prodrugs that 
can exert their therapeutic activity after reduction to the reactive Pt(II) complex form [19, 99]. 
These complexes have the ability to be administered orally in their inactive form, and are 
converted into the reactive form once in the cell, with potentially high potent activity and low 
toxicity [99]. 
As shown in Fig. 1.14, Pt(IV) complexes have an octahedral geometry with two cis non-
leaving ligands (usually ammine ligands), two cis leaving groups, and two axial ligands [10, 19]. 
The Pt(IV) complex can be converted to Pt(II), which by extension leads to the loss of the axial 
ligands [19]. There are a number of Pt(IV) complexes that have gone into clinical trials for 
antitumor therapy. Iproplatin has a structure with ligands (including two axial OH groups) that play 
a role in its high solubility, broad range of activity, and lower toxicity in animal studies (Fig. 1.15) 
[100]. However, iproplatin was dropped in clinical trials after it did not show clear advantages over 
carboplatin [100]. Tetraplatin (Fig. 1.15) is another Pt(IV)-based compound that exhibits 
advantages over cisPt in animal studies in that it is less nephrotoxic and circumvents cellular 
resistance. However, it was also abandoned in clinical trials due to severe neurotoxicity in humans 





refractory prostate cancer due to its reduced nephrotoxicity and neurotoxicity [19]. Satraplatin was 
designed to be an inactive prodrug that can be administered orally, giving it an advantage over 
the intravenously administered cisPt [19]. Its stability as a prodrug enables it to be distributed in 
blood plasma in the inactive form before being converted into the active form once inside the cells. 
It was observed that with oral administration of satraplatin, its cellular potency was comparable to 
intravenously administered cisPt and carboplatin [100]. 
 
Figure 1.14. Ligands of Pt(IV)-based complexes and their roles. Pt(IV)-based antitumor 
agents have three types of ligands, including leaving group, non-leaving group, and axial ligands. 




Figure 1.15. Structures of Pt(IV)-based anticancer agents. Iproplatin, tetraplatin, and 






In summary, the currently approved antitumor platinum-based drugs have shown 
significant success in cancer therapies and some analogues have advantages over cisPt in terms 
of reduced toxic side effects and the ability to circumvent resistance. However, there are still 
challenges with cancer therapies involving platinum compounds, ranging from DNA repair and 
off-target inactivation to various forms of toxicity. The reduced toxicity of the second-generation 
platinum-based drugs is overshadowed by their reduced effectiveness in cells. It is therefore 
important to develop new cisPt analogues that have alternative biomolecular targets, altered 
reactivity preferences, and a balance between high efficacy and reduced toxicity. 
1.5 Thesis objectives 
 CisPt exerts its anticancer activity by preferentially coordinating to dGuo residues within 
DNA [38]. The dGuo adducts that are formed alter the DNA structure and contribute to inhibition 
of functions such as replication and transcription that ultimately lead to cancer cell death [1, 11]. 
Nevertheless, cisPt has a number of drawbacks such as cellular resistance that reduce its efficacy 
[71]. Analogues of cisPt that exhibit altered reactivity with other cellular targets such as RNA or 
form non-canonical adducts with alternative DNA residues could be useful in circumventing 
resistance by causing irreparable damage and triggering apoptosis [29, 55].  
Aim 1: Synthesize and characterize amino acid-linked platinum(II) compounds 
In this thesis work, platinum-based compounds with diversified structures, ligand sizes, 
and charge distributions were synthesized by coordinating amino acids with platinum. The thesis 
hypothesis is that modification of cisPt with amino acid ligands of varying sizes and charges will 
alter the reaction kinetics and nucleoside binding preferences. The amino acids linked to 
platinum(II) provide an array of compounds (AAPt) with diverse ligands and chemical 
characteristics. The platinum(II) compounds generated with their corresponding amino acid 
ligands are AlaPt (alanine), OrnPt (ornithine), and ArgPt (arginine). The amino acid-linked 





1.16. The compounds were characterized by using NMR spectroscopy (1H, 13C, 195Pt), mass 
spectrometry, and X-ray crystallography. 
 
 
Figure 1.16. The structures of cisPt and amino acid-linked platinum(II) compounds, AlaPt, OrnPt, 
and ArgPt, are shown. 
 
Aim 2: Characterize non-canonical adducts formed by amino acid-linked platinum(II) 
compounds with DNA and RNA residues 
When cisPt coordinates with DNA, it predominantly platinates the N7 position of dGuo 
[101-102]. Platinum-based compounds may form intrastrand or interstrand adducts, depending 
on whether they coordinate to the same strand or two strands, respectively [18, 41]. Adducts can 
also be defined as monofunctional, bifunctional, or doubly platinated, depending on the 
platinum:nucleoside ratio (i.e., 1:1, 1:2, or 2:1, respectively). The adduct types also vary, 
depending on the site of platination on the nucleobase (e.g., N1, N3, or N7). We sought to 
determine the binding site preferences and to characterize the types of adducts formed by amino 
acid-linked platinum(II) compounds in DNA and RNA residues. The structures and corresponding 
chemical properties of various amino acid-linked platinum(II) compounds may alter the preferred 
sites of reactivity versus those targeted by cisPt. In this work, mass spectrometry was used to 
determine the composition and type (e.g., mono- or bifunctional) of adducts formed by the 
platinum-based compounds, and 1H-NMR spectroscopy was used for characterization of the 
platination sites on the nucleoside. In collaboration with Dr. M. T. Rodgers’ laboratory, we also 
sought to evaluate the effect of platination on the relative glycosidic bond strengths of these non-





Aim 3: Determine reaction kinetics of amino acid-linked platinum(II) compounds with 
DNA/RNA nucleosides and oligonucleotides 
The nucleophilicity and accessibly of the N7 position in dGuo residues of DNA is thought 
to be favorable for cisPt adduct formation [102]. Less is known about reactivity of other positions 
such as N7, N3, or N1 of dAdo. The reaction kinetics of three amino acid-linked platinum 
compounds (AlaPt, OrnPt, and ArgPt) were examined. The rate constants obtained were used to 
determine how the chemical structures and physical properties of the functional groups of the 
amino acid ligands relate to reactivity the platinum-based complexes with DNA/RNA nucleosides 
and oligonucleotides. The DNA/RNA nucleosides or oligonucleotides were reacted with a 50-fold 
excess of AAPt compound for pseudo-first-order reaction conditions. An HPLC equipped with a 
C-18 column was utilized to quantify levels of reacted nucleoside/oligonucleotide and the data 
were analyzed to give the pseudo-first-order kinetics of the platinum compounds. The peak area 
of unreacted nucleoside/oligonucleotide was monitored over time and the diminishing ratio to the 
product peaks was determined. The data were fit using an exponential equation assuming 
pseudo-first-order kinetics. The reaction rate constants obtained from reactions in the nucleoside 
and oligonucleotide levels were compared in order to understand the reactivity preferences and 
selectivities of the compounds. 
Aim 4: Determine potency of amino acid-linked platinum(II) compounds and quantify their 
accumulation in cancer and normal cells 
At the cellular level, it is important to develop analogues that are more selective than cisPt 
and can strike a balance between selective potency in cancer cells and reduced toxicity in normal 
cells. An understanding of the cellular activity of amino acid-linked platinum(II) compounds is 
important for determining which structural features of the compounds are critical for achieving 
selective potency and accumulation in cancer cells. The potency of AAPt in human cancer and 
normal cell lines was determined using the MTT (3-(4,5-dimethylthiaxol-2-yl)-2,5-





of cell lines with varying concentrations of AAPt compounds (and cisPt for comparison). To 
determine the cellular abundance of platinum-based compounds, the cell lines were treated with 
AAPt compounds and cisPt followed by chemical digestion. The abundance of platinum in each 
sample was then quantified by using ICP-MS. This research will drive the development of new 



























AMINO ACID-LINKED PLATINUM(II) COMPOUNDS: SYNTHESIS, CHARACTERIZATION, 
AND METHODS TO INVESTIGATE THEIR KINETICS, ADDUCTS, AND CELLULAR 
ACTIVITIESǂ 
ǂAdapted from Kimutai B, He CC, Roberts A, Jones ML, Bao X, Jiang J, Yang Z, Rodgers MT, 
Chow CS (2019) J Biol Inorg Chem 24:985-997. 
2.1 Abstract 
The work in this thesis focuses on synthesis, characterization, adduct formation, kinetics, 
and biological activity of cisplatin (cisPt) analogues. CisPt analogues can be generated with 
simple ligand modifications. Small modifications may alter the reactivity preferences of the 
analogues towards residues that are not preferentially targeted by cisPt. In this work, amino acids 
are used as ligands and coordinated to a platinum metal center to generate amino acid-linked 
platinum(II) (AAPt) compounds. The amino acids provide a range of ligands with varied sizes and 
charge distributions. The AAPt compounds generated may in turn have diversified reactivity 
profiles compared to cisPt.  AAPt compounds that are derivatives of alanine, ornithine, and 
arginine were synthesized. These compounds are referred to as AlaPt, OrnPt, and ArgPt, 
respectively. The compounds were characterized using different methods, including 1H-, 13C-, and 
195Pt-NMR spectroscopy, mass spectrometry, and X-ray crystallography. A variety of techniques 
described in this chapter were also used to determine the kinetics of adduct formation, adduct 
structures, and biological activities of the synthesized compounds. Non-canonical adducts formed 
by AAPt compounds with nucleosides/oligonucleotides were characterized using mass 
spectrometry and NMR spectroscopy. The reaction kinetics were determined using HPLC 
analysis. The influence of AAPt compounds on glycosidic bond stability were investigated using 
tandem mass spectrometry and survival yield analysis (in collaboration with Dr. M. T. Rodgers’ 





dimethylthiaxol-2-yl)-2,5-diphenyltetrazolium bromide) assays, and their cellular accumulation 
was quantified using inductively coupled plasma mass spectrometry (ICP-MS). 
2.2 Introduction 
2.2.1 Application of amino acids as ligands of cisplatin analogues 
Despite the application of cisPt in treatment of a variety of cancer types, its clinical use is 
limited by cellular resistance and adverse side effects emanating from toxicity to normal cells [69-
71]. Furthermore, DNA repair and reduced accumulation of cisPt allow cancer cells to continue 
propagating despite drug treatment [71]. There has been research and development of numerous 
cisPt analogues aimed at circumventing the limitations of cisPt. However, with thousands of cisPt 
analogues having been synthesized, only a small number have made it to clinical trials. The few 
analogues that have been approved for clinical use worldwide include carboplatin, oxaliplatin, and 
nedaplatin [91]. Therefore, there is still need to develop platinum-based compounds that not only 
have a balance between potency in cancer cells and toxicity in normal cells, but also have 
alternative biological targets from those targeted by cisPt. 
Amino acids are a great source of ligands with diversified sizes and charge distributions. 
Based on the chemical and physical properties of their side chains, naturally occurring amino 
acids can be categorized into groups such as basic, acidic, hydrophobic, and polar. Amino acids 
with basic side chains include lysine and arginine, whereas the acidic group includes aspartate 
and glutamate. The nonpolar group includes alanine, leucine, isoleucine, valine, and 
phenylalanine.  Amino acids with polar side chains include serine and cysteine. These amino 
acids can be linked with a platinum metal center to generate amino acid-linked platinum(II) (AAPt) 
compounds [103-106]. The diversity of the side chain functional groups together with the 
contribution of backbone atom metal coordination means that the AAPt compounds can 
potentially have a wider range of reactivity and targets, which could give them advantages over 
cisPt. The amino acids are also inexpensive and readily available starting materials, which not 





There have been a number of previous reports on the synthesis and characterization of 
AAPt compounds, either with naturally occurring or modified amino acid derivatives [103-104, 
107-112]. In these studies, platinum-based derivatives of histidine, serine, methionine, arginine, 
lysine, and ornithine were synthesized and characterized [103-104, 107-112]. The techniques 
used for characterization of these platinum-based compounds include 195Pt-NMR spectroscopy, 
X-ray crystallography, and mass spectrometry. Previous reports focused mainly on the synthesis 
and characterization of the compounds, but not on the biological applications [107-108, 110, 113]. 
The platinum(II) metal center was observed to coordinate with the soft bases (nitrogen and sulfur 
atoms) as well as hard bases (oxygen atoms) of the amino acids [103-104, 107, 110-111]. The 
general structures of the Pt(II) complexes consist of one chelating amino acid and two chlorine 
atoms coordinating with the metal center [103-104, 107, 110-111]. Chelation of the amino acid 
through the backbone nitrogen and oxygen atoms with the Pt(II) center leads to a five-membered 
ring (N,O binding mode) (Fig. 2.1) [103-104, 107, 110-111]. The platinum metal center may also 
coordinate with the side chain, especially if there is a soft base such as a sulfur atom to form (N,S) 
type of binding (Fig. 2.1) [109].  The presence of an amine in the side chain (e.g., lysine and 
ornithine) may lead to formation of (N,N) type structures, in which the platinum center coordinates 
to the nitrogen atoms in the backbone and side chain (Fig. 2.1). Even though the (N,N) type 
structures have not been observed in crystal structures of ornithine and lysine derivatives, they 









Figure 2.1. Possible structures of AAPt compounds. The platinum(II) metal center can chelate 
with the amino acid through the backbone or side-chain atoms. 
 
There have been a few applications of AAPt compounds in biological studies. Cellular 
activity and toxicity of lysine, ornithine, histidine, and methionine derivatives in cancer cell lines 
were found to be generally lower than that of cisPt [104, 109, 103, 111-112]. Biological 
applications of the compounds have been minimal and only focused on a few different cell lines 
and DNA as the biological target [104, 109, 112]. Further studies on the interactions of AAPt 
compounds with alternative biological targets, as well as comprehensive cellular studies with 
cisPt-resistant cell lines, are necessary. Previous studies in our lab showed that several AAPt 
compounds (ornithine and arginine derivatives) interact and form adducts with RNA [106]. There 
is still a need to understand how the chemical structures and physical properties of the functional 
groups of the AAPt complexes relate to their reactivity and target preference. Understanding the 
role of the ligands in target preferences will be important for the rational development of novel 
compounds that have improved cellular activities and effectiveness. 
In this chapter, the synthesis and characterization of several AAPt compounds is 
described. The derivatives of alanine, ornithine, and arginine (AlaPt, OrnPt, and ArgPt) were 
successfully synthesized and characterized. These compounds were used in subsequent work to 
study their reactivities with nucleic acids and also to screen their cellular potency in cancer cells. 
The synthesized compounds were characterized using 1H-,13C-, and 195Pt-NMR spectroscopy, 
mass spectrometry, and X-ray crystallography. It was hypothesized that the structures of the 





platinum(II) center coordinates with the backbone nitrogen and oxygen atoms of the amino acid 
(Fig. 2.2).  
 
 
Figure 2.2. The structures of amino acid-linked platinum(II) compounds. The AAPt 
compounds consist of a platinum(II) metal center coordinated to a chelating amino acid and two 
chlorido ligands. 
 
2.2.2 Formation and characterization of non-canonical AAPt-nucleic acids adducts 
The AAPt compounds form adducts by coordinating with dAdo/Ado residues of DNA and 
RNA [105-106]. In this thesis work, the adducts formed by AlaPt, OrnPt, and ArgPt with 
nucleosides and oligonucleotides were characterized to determine the adduct types and sites of 
platination. AAPt (or cisPt) compounds were first activated to form monoaquated species, which 
were then reacted with target nucleosides/oligonucleotides. The reactions could result in 
formation of different types of products that vary in composition, platination sites (N1, N3, or N7), 
and geometry. The reactions and products formed were monitored using HPLC. The fractions 








2.2.3 Kinetics of AAPt with DNA/RNA nucleosides and oligonucleotides 
Modifications to cisPt may alter its reactivity and direct the compound towards alternative 
biological targets. Different behaviors of the platinum-based compounds can be achieved by 
modifying the ligands to favor different interactions such as hydrogen bonding, charge-charge 
interactions, and steric hindrance, among others. For example, an analogue of cisPt with a 
heteroaromatic ligand, 4,4′-dipyrazolylmethane, shows a reactivity preference for the dAdo/dThd-
rich regions of DNA rather than the dGuo-rich regions [114].  In this thesis work, the reaction 
kinetics of three AAPt compounds (AlaPt, OrnPt, and ArgPt) were examined to determine how 
the chemical structures and physical properties of the functional groups of the amino acids relate 
to reactivity and nucleoside preferences. The hypothesis is that modification of cisPt with amino 
acid ligands of varying sizes and charges will alter the reaction kinetics and nucleic acid target 
preferences. Influence of the oligonucleotide local environment was also investigated since the 
nucleotides surrounding the target nucleotide may modulate the binding kinetics of cisPt and AAPt 
and lead to different platination rates and profiles. Timecourse reactions of the AAPt compounds 
with nucleosides/oligonucleosides were monitored by using HPLC equipped with a C18 column. 
Pseudo-first-order kinetics were used to compare the preferences of three AAPt compounds (and 
cisPt) with purine nucleosides and also to understand the impact of local nucleic acid environment 
on their reactivity with oligonucleotides. 
2.2.4 Impact of AAPt compounds on glycosidic bond stability of adducts 
Platination of nucleic acids may have unique influences on the chemical properties of the 
nucleosides such as bond strengths. For example, modifications such as alkylation or protonation 
of DNA residues have previously been observed to weaken the glycosidic bond and accelerate 
the process of depurination [115-118]. Thus, hydrolytic instability of purine glycosidic bonds may 
impact nucleoside integrity, particularly under varying pH and ionic strength conditions and 
modification states [116, 119-121]. Stability of the glycosidic bond may also be influenced 





AlaPt and OrnPt adducts on relative glycosidic bond strengths of adducts is investigated by 
employing energy-resolved collision-induced dissociation (ER-CID) tandem mass spectrometry 
and survival yield analysis [116, 122-125]. 
2.2.5 Potency and accumulation of AAPt compounds in human cancer and normal cells 
Application of cisPt in cancer therapy has had major drawbacks due to resistance and 
adverse side effects, including nephrotoxicity [69-71]. Clinical analogues of cisPt such as 
carboplatin have low potency, meaning that a higher dose is required to achieve the same 
effectiveness as cisplatin [16]. Development of new platinum-based compounds will focus on not 
only maintaining the efficacy of cisPt, but also having reduced side effects and selectivity for 
cancer cells. Based on Lipinski rules [126], the AAPt compounds could provide another class of 
metal-based compounds with oral drug-like features. The anticancer potency of AAPt compounds 
can be evaluated by determining the IC50 values in several human cancer cell lines using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [127]. This assay utilizes 
viable cells to convert MTT into a purple-colored formazan. The NAD(P)H-dependent cellular 
oxidoreductase enzymes in viable cells convert MTT into insoluble purple formazan. The 
formazan is dissolved by solvents such as DMSO and the optical density (OD) measurements of 
the resulting solutions are taken using a uv-visible spectrophotometer. The OD measurements 
are used to determine the percentage of viable cells present following exposure to a given 
concentration of the cytotoxic compound. 
Accumulation of platinum-based compounds inside cells drives the pharmacological 
impact of the anticancer compound. Low accumulation of cisplatin in cells leads to reduced DNA 
damage and could potentially stimulate resistance rather than apoptosis [71]. The cellular 
accumulation of AAPt compounds in comparison to cisplatin in both cancer and normal prostate 
cells was investigated in this work. Cells were treated with either AAPt compounds or cisPt 
followed by quantitative measurements of cellular platinum concentrations with inductively 







Potassium tetrachloroplatinate(II), L-alanine, trimethylsilyl propionate (TSP), 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 3-hydroxypicolinic acid (3-HPA), 
and HCl were purchased from Sigma-Aldrich (St. Louis, MO). L-Ornithine, L-arginine, and cis-
diamminedichloridoplatinum(II) were from Alfa Aesar (Haverhill, MA). Deuterium oxide (D2O), 
chloroform-D, and acetonitrile-D3 were from Cambridge Isotope Laboratories (Tewksbury, MA). 
Silver nitrate, acetonitrile, ammonium acetate, ethanol, methanol, dimethylsulfoxide, and nitric 
acid (trace metal grade) were obtained from Fisher Chemical (Hampton, NH).  Poly(Ado) RNA 
was from Pharmacia LKB Biotechnology (Uppsala, Sweden). Sodium phosphate, monobasic and 
dibasic, were obtained from EMD Millipore (Kankakee, IL). All amino acid-linked platinum(II) 
compounds were synthesized in the lab (described in Section 2.4). 
All nucleosides (deoxyguanosine (dGuo), guanosine (Guo), deoxyadenosine (dAdo), and 
adenosine (Ado)) were purchased from Sigma-Aldrich (St. Louis, MO). Oligonucleotide strands, 
5′-d(TTATT)-3′ and 5′-UUAUU-3′, were purchased from Integrated DNA Technologies (Coralville, 
IA). 
2.3.2 Human cell lines and cell culture supplies 
The cancer cell lines HeLa (cervical), H1299 (non-small cell lung), MDA-MB-231 (breast), 
and MDA-MB-453 (breast) [128-132] were obtained from Dr. Young-Hoon Ahn’s lab, Wayne State 
University. DU145 (prostate cancer) [133] was received from Dr. K. V. Honn’s lab, Wayne State 
University. RWPE-1 (normal prostate cell line) [134] was acquired from Dr. Zhihui Qin’s lab, 
Wayne State University. Dulbecco's modified eagle medium (DMEM), keratinocyte serum free 
medium (K-SFM), human recombinant epidermal growth factor 1-53 (EGF 1-53), bovine pituitary 
extract (BPE), phosphate buffered saline (PBS), and trypsin-EDTA (0.25%) were purchased from 





acquired from USA Scientific (Ocala, FL). Cell culture dishes (60 x 15 mm and 100 x 20 mm) were 
purchased from Sigma Aldrich (St. Louis, MO). 
2.3.3 Instrumentation 
Proton and 13C-NMR spectra of the AAPt compounds were recorded on an Agilent MR-
400 MHz spectrometer in the Wayne State University Lumigen Instrument Center 
(LIC). The 195Pt-NMR spectrum of the AlaPt compound was recorded on a Varian VNMRS-500 
MHz spectrometer in the LIC. Absorption of nucleosides and oligonucleosides were measured 
on Beckman Coulter DU730 UV/Vis spectrophotometer (Brea, CA). The 1H and 13C NMR spectra 
of the AAPt-nucleoside adducts, and two-dimensional heteronuclear single quantum coherence 
(HSQC) spectroscopy of OrnPt-nucleoside adducts were recorded on a Bruker Avance 700 MHz 
spectrometer equipped with a TXI cryoprobe in the LIC. The MS analyses were performed by Dr. 
C. C. He on a 7T Fourier transform ion cyclotron mass spectrometer (FT-ICR MS, solariX, 
Bruker Daltonics, Billerica, MA) in Dr. M. T. Rodgers’ laboratory. X-ray crystallography was 
performed by Dr. P. Martin on an X-ray single-crystal diffractometer (Bruker X8 APEX) in the LIC. 
MALDI-MS characterization was performed on a Bruker UltrafleXtreme MALDI-TOF/TOF mass 
spectrometer (Billerica, MA) in the LIC. HPLC analysis was carried out on a Waters 600 LC with 
a 717plus autosampler (Milford, MA) fitted with a Sigma-Aldrich Supelco Discovery C18 column 
(5 μm particle diameter; 4.6 mm × 250 mm, St. Louis, MO) and UV detector set at 254 nm. 
Platinum-195 quantification was performed on an Agilent 7700X ICP-MS equipped with an ASX-
500 series autosampler and Agilent MassHunter software (Santa Clara, CA) (LIC). Orbitrap-MS 
spectra were obtained on a ThermoScientific LTQ Orbitrap XL (Waltham, MA) (LIC). LC-MS 
characterization was performed on a Shimadzu 8040 triple quadrupole (Columbia, MD) equipped 
with ESI (LIC) and a Waters C18 Acquity HSS T3 100 mm column (Milford, MA). Energy-resolved 
collision-induced dissociation (ER-CID) and survival yield experiments were performed by Dr. C. 
C. He on a Bruker Daltonics amaZon ETD quadrupole ion trap mass spectrometer (Billerica, MA) 





Daltonics DataAnalysis 4.0 (Billerica, MA). Survival yield data analysis was performed by Dr. C. 
C. He using Systat Software SigmaPlot 10.0 (San Jose, CA) and custom software developed in 
Dr. M. T. Rodgers’ laboratory. Optical density measurements for cytotoxicity experiments were 
performed using a BioTek synergy H1 hybrid reader (Winooski, VT) in Dr. Y. H. Ahn’s laboratory. 
2.4 Methods 
2.4.1 Synthesis and characterization of AlaPt  
Synthesis of AlaPt was carried out following a previously described procedure, but with 
some modifications to improve yield and minimize undesired side reactions [104]. First, 0.17 
mmoles (70 mg) of K2PtCl4 and five equivalents of L-alanine (75 mg) were dissolved in 2 mL of 
double-distilled water (ddH2O) and heated at 50 °C overnight on a Fisher thermoshaker at 950 
rpm. The crude product was filtered and vacuum dried for approximately 12 h. Next, 3.0 mL of ice 
cold ddH2O was added to the resulting solid, and the solution was mixed by vortexing for one 
minute, followed by centrifugation at 14,000 rpm for 10 min. The supernatant was removed and 
discarded. To the pellet was added 3.0 mL of cold 95% ethanol, followed by vortexing and 
centrifugation at 14,000 rpm for 8 min and removal of the supernatant; this procedure was 
repeated three times. The solid precipitate was then dried under vacuum overnight. To the dried 
sample was added 250 µL of 100 mM NaOH, followed by vortexing and filtering under 
centrifugation (Millipore 10 kDa centrifugal filter) at 14,000 rpm for 10 min to remove high 
molecular weight aggregates. The filtrate was collected and vacuum dried to obtain a light-yellow 
product. The final product, obtained in 47% yield (28 mg), was characterized by 1H-NMR 
spectroscopy, 13C-NMR, 195Pt-NMR, and high-resolution mass spectrometry. Melting point, 249-
251 °C; δ/ppm (1H-NMR, D2O, 400 MHz), 3.50 (1 H, q, J=7.1 Hz, =CHCH3), 1.28 (3 H, d, J=7.0 
Hz, -CH3); δ/ppm (13C-NMR, D2O, 400 MHz) 193 ((-COO)CH=), 57 (=CHCH3), 20 (=CHCH3); 
δ/ppm (195Pt-NMR, D2O, 500 MHz, -1639); m/z (electrospray ionization mass spectrometry (ESI-
MS)) 352.943 Da/e [M]¯; calculated exact mass 352.942 Da [M]¯; chemical formula PtC3H6Cl2NO2 





The synthesized AlaPt was characterized by using 1H-, 13C-, and 195Pt-NMR spectroscopy. 
The 1H-NMR spectrum of AlaPt was analyzed in comparison to the 1H-NMR spectrum of L-alanine 
(Fig. 2.7). The Hα proton peak of alanine has a chemical shift of 3.61 ppm, whereas the 
corresponding Hα peak for AlaPt is shifted upfield by 0.11 ppm (δ 3.50 ppm). The Hβ proton peak 
of L-alanine has a chemical shift of 1.31 ppm, whereas the corresponding Hβ peak for AlaPt is 
shifted slightly upfield by 0.03 ppm (δ 1.28 ppm). The changes in chemical shifts are consistent 
with coordination of the amino acid to the platinum center.  
 
Figure 2.7. The 1H-NMR spectra of L-alanine (top) and AlaPt (bottom). For L-alanine; δ/ppm 
(1H-NMR, D2O, 400 MHz), 3.61 (1 H, q, J=7.7 Hz, =CHCH3), 1.31 (3 H, d, J=7.6 Hz, -CH3). For 
AlaPt; δ/ppm (1H-NMR, D2O, 400 MHz), 3.50 (1 H, q, J=7.1 Hz, =CHCH3), 1.28 (3 H, d, J=7.0 Hz, 
-CH3). 
 
In the 13C-NMR spectrum, the carboxylate carbon peak for alanine has a chemical shift of 
176 ppm, whereas the corresponding peak for AlaPt is at 193 ppm (Fig. 2.8). The Cα and Cβ are 
shifted less (from 50 to 57 ppm and 16 to 20 ppm, respectively) because they are further away 
from the platinum center. The 13C-NMR spectrum of AlaPt also has extra peaks that are possibly 
from the aquated AlaPt species. AlaPt is relatively soluble and as much as 100 mg can be 





aqua) can occur rapidly. It was observed that when an equivalent ratio of AgNO3 is added to an 
AlaPt solution, a white precipitate (AgCl) is rapidly formed, possibly due to the fast aquation. To 
further monitor the presence of aquated species in solution by NMR spectroscopy, AlaPt was 
mixed with an equivalent ratio of AgNO3 for varying time points of 1, 2, 6, and 24 h. After each 
time point, the sample was centrifuged to precipitate the AgCl. The supernatant was then 
characterized with 13C-NMR spectroscopy. It was observed that with increasing time, the peak 
pattern changed to reflect the diminishing non-aquated AlaPt and the formation of mono- and bis-
aquated species (Fig. 2.9). 
 
Figure 2.8. The 13C-NMR spectra of L-alanine (top) and AlaPt (bottom). For L-alanine; δ/ppm 
(13C-NMR, D2O, 400 MHz) 176 ((-COO)CH=), 50 (=CHCH3), 16 (=CHCH3); For AlaPt; δ/ppm (13C-
NMR, D2O, 400 MHz) 193 ((-COO)CH=), 57 (=CHCH3), 20 (=CHCH3). The minor peaks are due 
to possible aquation of AlaPt which occurs in a H2O or D2O environment as described in the 
introduction (Section 1.2.3). 
 
In the 195Pt-NMR spectrum, the chemical shift of the platinum(II) center of AlaPt is 
compared to that of potassium tetrachloroplatinate(II), which is the starting material for AlaPt 
synthesis (Fig. 2.10). The 195Pt-NMR spectrum shows a 195Pt peak at -1607 ppm for potassium 








Figure 2.9. The 13C-NMR time course of AlaPt aquation. The spectrum of aquated AlaPt 
changes over time with different species diminishing or forming at varying proportions. The non-
aquated species (black asterisks) are diminished with time. The monoaquated species (red 
circles) also diminish over time while the bis-aquated species (green triangles) become dominant 
at longer time periods. 
 
AlaPt was also characterized by using ESI mass spectrometry. The mass analysis gives 
an observed m/z of 352.9 Da/e. This result agrees with the calculated exact mass of 352.9 Da for 
a singly charged (negative) AlaPt product with a chemical formula PtC3H6Cl2NO2 (Fig. 2.11).  The 
mass data are consistent with one amino acid and two chlorido ligands coordinated to a platinum 








Figure 2.10. The 195Pt-NMR spectrum of potassium tetrachloroplatinate(II) and AlaPt. For 
potassium tetrachloroplatinate(II) (top), δ/ppm (195Pt-NMR, D2O, 400 MHz) is -1607 (PtCl4); for 
AlaPt (bottom), δ/ppm (195Pt-NMR, D2O, 400 MHz) is -1639 (PtCl2(NH2)O).  The 195Pt chemical 
shift for AlaPt is in the same region where peaks for other comparable platinum-based compounds 
are found [110, 135]. Assistance to obtain these spectra was provided by Dr. Dennis Anderson in 




Figure 2.11. ESI mass spectrum of AlaPt. m/z (ESI-MS) 352.9 Da/e [AlaPt]¯; calculated exact 
mass 352.9 Da [AlaPt]¯; chemical formula PtC3H6Cl2NO2 ([AlaPt]¯, at neutral pH). The spectrum 






2.4.2 Synthesis and characterization of OrnPt 
Synthesis of OrnPt was carried out as described previously [104]. First, 0.17 mmoles of 
K2PtCl4 and two equivalents of L-ornithine (44 mg) were dissolved in 2 mL of ddH2O. The mixture 
was heated at 50 °C overnight on a thermoshaker and afterwards dried under vacuum. The crude 
product was washed with ice-cold ddH2O and vacuum dried again. The product, obtained in 40% 
yield (27 mg), was characterized by 1H-NMR spectroscopy, 13C-NMR spectroscopy and high-
resolution mass spectrometry. A sample of OrnPt product was also crystallized to be used for 
solving its crystal structure through X-ray crystallography. The crystals were first grown through 
the slow evaporation method. A 10 mM concentration of OrnPt dissolved in ddH2O was placed in 
a capped glass tube fitted with a needle-sized hole at the top. The tube was kept in the dark for 3 
weeks at room temperature with minimal disturbance. Shiny yellow rod-like crystals were 
obtained. The biggest crystal was selected, and the structure was solved using a Bruker D8 
diffractometer. δ/ppm (1H-NMR, D2O, 400 MHz), 3.54 (1 H, t, J=6.3 Hz, -CH(NH2)CH2-), 2.89 (2 
H, t, J=7.9 Hz, -CH2NH3), 1.84–1.69 (4H, m, -CH(NH2)CH2CH2-); m/z (ESI-MS) 395.986 Da/e [M–
H]¯; calculated exact mass 395.984 Da [M–H]¯; chemical formula PtC5H11Cl2N2O2 ([M–H]¯, at 
neutral pH). The crystal structure shows that the Pt center is coordinated with nitrogen and oxygen 
of the amino acid. 
The OrnPt was characterized by using 1H- and 13C-NMR spectroscopy, mass 
spectrometry, and X-ray crystallography. The 1H-NMR spectrum of OrnPt was compared to that 
of L-ornithine (Fig. 2.12). The chemical shift of the L-ornithine Hα proton peak is 3.60 ppm. The 
close proximity of the metal center shifts the corresponding Hα proton for OrnPt upfield to 3.50 
ppm. The platinum-induced chemical shift is subtle for the Hβ and Hγ protons, likely because they 






Figure 2.12. The 1H-NMR spectra of L-ornithine (upper) and OrnPt (lower). For L-ornithine, 
δ/ppm (1H-NMR, D2O, 400 MHz) is 3.63 (1 H, t, J=6.3 Hz, -CH(NH3)CH2-), 2.90 (2 H, t, J=8.0 Hz, 
-CH2NH3), 1.82 – 1.52 (4H, m, -CH(NH3)CH2CH2-). For OrnPt; δ/ppm (1H-NMR, D2O, 400 MHz), 
3.54 (1 H, t, J=6.3 Hz, -CH(NH2)CH2-), 2.89 (2 H, t, J=7.9 Hz, -CH2NH3), and 1.84 – 1.69 (4H, m, 
-CH(NH2)CH2CH2-). The chemical shifts are consistent with a previously described 
characterization of OrnPt [104]. 
 
In the 13C-NMR spectrum, the peaks from L-ornithine were compared to those for OrnPt. 
The Cα, Cβ, Cγ, and Cδ peaks for L-ornithine are more upfield in comparison to OrnPt (54 to 58 
ppm, 37 to 38 ppm, 27 to 29 ppm, and 22 to 23 ppm, respectively) (Fig. 2.13). The carboxylate 
carbon peak for L-ornithine has a chemical shift of 174 ppm. The corresponding peak for OrnPt 
was not fully resolved likely due to the low solubility of OrnPt in D2O. OrnPt has moderate solubility 
in D2O and gets saturated at approximately 5 mg/mL.  
Other solvents that were used to dissolve OrnPt for possible 13C-NMR spectroscopic 





while the solubility of OrnPt is also very low in deuterated-acetonitrile and CDCl3, the DMSO 
solvent likely reacts with the compound due to the presence of the sulfur, which has been 
observed to occur when DMSO is mixed with cisPt [136]. The reactivity of OrnPt with DMSO was 
confirmed by 1H-NMR spectroscopy in which a change in the NMR spectrum is observed (Fig. 
2.14). For future 13C-NMR analysis, perhaps the carboxylate carbon could be resolved by running 
the analysis for a longer time period (approx. 24 h in D2O) or with other solvents such as 
deuterated-methanol, which can dissolve the compound at higher concentrations. 
 
 
Figure 2.13. The 13C-NMR spectra of L-ornithine and OrnPt. The 13C chemical shifts change 
between L-ornithine and OrnPt due to coordination of the amino acid with the platinum(II) center. 
The Cα, Cβ ,Cγ, and Cδ are shifted from 54 to 58 ppm, 37 to 38 ppm, 27 to 29 ppm, and 22 to 23 
ppm, respectively. The carboxylate carbon peak for OrnPt is not observed due to the relatively 








Figure 2.14. The 1H-NMR spectra of OrnPt in D2O and DMSO. DMSO reacts with OrnPt, 
resulting in an altered 1H-NMR spectrum (bottom) compared to that of OrnPt dissolved in D2O 
(top). 
 
Analysis of OrnPt using ESI mass spectrometry gave an observed m/z of 395.986 Da/e 
(Fig. 2.15), which is consistent with the calculated exact mass of 395.984 Da for the OrnPt product 
with the chemical formula PtC5H11Cl2N2O2. A dimer, [2(OrnPt)-H]¯, is also observed at 794.975 
Da/e. The mass data for OrnPt support a structure with one ornithine and two chlorido ligands 






Figure 2.15. ESI mass spectrum of OrnPt. m/z (ESI-MS) 395.986 Da/e [M-H]¯; calculated exact 
mass 395.984 Da [M-H]¯; chemical formula PtC5H11Cl2N2O2 ([OrnPt-H]¯; at neutral pH); a dimer 
[2(OrnPt)-H]¯ is observed at 794.975 Da/e. This spectrum was obtained by Dr. C. C. He in Dr 
M.T. Rodgers’ lab. 
 
While the above data are consistent with the coordination of one amino acid to a metal 
center, the spectra do not reveal whether the structure is (N,O) or (N,N) type. In the (N,N) type 
structure, the propylamine side chain of ornithine could coordinate to the metal center through its 
nitrogen atom. The structure of OrnPt was therefore analyzed by using X-ray crystallography (Fig. 
2.16), which shows that the platinum(II) maintains a square-planar geometry and is part of a five-
membered ring with (N,O) coordination, consistent with a previous report [104]. The crystallization 
conditions for OrnPt may favor the (N,O) type, but the presence of (N,N) type structures in solution 






Figure 2.16. Crystal structure of OrnPt. The structure is consistent with a previously described 
(Nb,Ob) binding structure [104], in which the platinum maintains its square-planar geometry in a 
five-membered chelation ring. The structure was obtained by Dr. Phil Martin in the Wayne State 
University Lumigen Instrument Center. 
 
2.4.3 Synthesis and characterization of ArgPt 
Synthesis of ArgPt was carried out using L-arginine and K2PtCl4 as the starting materials 
and following the OrnPt synthesis protocol above with several modifications to optimize purity. 
First, 0.17 mmol of K2PtCl4 and one equivalent of L-arginine (29 mg) were mixed in 2 mL ddH2O. 
An equivalent amount of KCl (13 mg) was also added to the mixture to inhibit disproportionation 
of K2PtCl4 [112]. The mixture was heated at 50 °C overnight on a thermoshaker at 950 rpm, 
followed by vacuum drying. The crude product was washed with 1 mL ice-cold ddH2O three times 
and vacuum dried again to obtain a light greenish product. The product was obtained in a 23% 
yield (17 mg) and characterized by 1H-NMR spectroscopy, 13C-NMR, and mass spectrometry. 
δ/ppm (1H-NMR, D2O, 400 MHz), 3.49 (1 H, t, J=6.7 Hz, -CH(NH2)CH2-), 3.14 (2 H, t, J=6.8 Hz, -
CH2NH-), 1.90 – 1.48 (4H, m, -CH(NH)CH2CH2-). m/z (ESI-MS) 439.007 Da/e [M+H]+; calculated 








Figure 2.17. The 1H-NMR spectra of L-arginine and ArgPt. For L-arginine (upper); δ/ppm (1H-
NMR, D2O, 400 MHz), 3.10 (1 H, t, J=5.5 Hz, -CH(NH3)CH2-), 3.04 (2 H, t, J=6.3 Hz, -CH2NH-), 
1.53 – 1.40 (4 H, m, -CH(NH)CH2CH2-). For ArgPt (lower); δ/ppm (1H-NMR, D2O, 400 MHz), 3.49 
(1 H, t, J=6.7 Hz, -CH(NH2)CH2-), 3.14 (2 H, t, J=6.8 Hz, -CH2NH-), 1.90 – 1.48 (4 H, m, -
CH(NH)CH2CH2-). 
 
The ArgPt was characterized by using 1H- and 13C-NMR spectroscopy, and mass 
spectrometry. The 1H-NMR spectrum of ArgPt was analyzed in comparison to that of L-arginine 
(Fig. 2.17). The chemical shift of the L-arginine Hα proton peak is at 3.10 ppm, whereas the 
corresponding Hα proton for ArgPt is shifted downfield to 3.49 ppm due to the close proximity of 
the metal center. Since the Hβ and Hγ protons are further away from the metal center, their 
platinum-induced chemical shift is relatively smaller. In the 13C-NMR spectrum, the peaks from L-
arginine were compared to those for ArgPt. The Cα, Cβ, Cγ, and Cδ peaks for L-arginine are shifted 
in comparison to ArgPt (55.5 to 57.8 ppm, 40.8 to 40.5 ppm, 31.5 to 29.3 ppm, and 24.3 to 23.7 





chemical shifts of 156.8 and 183.2 ppm, respectively. Similar to OrnPt, the corresponding peaks 
for ArgPt were not fully resolved likely due to the low solubility of ArgPt in D2O (ArgPt is saturated 
at approximately 5 mg/mL). 
 
Figure 2.18. The 13C-NMR spectra of L-arginine and ArgPt. The chemical shifts for carbons 
change between L-arginine and ArgPt due to coordination of the amino acid with the platinum 
center. The Cα, Cβ, Cγ, and Cδ of L-arginine and ArgPt change from 55.5 to 57.8 ppm, 40.8 to 40.5 
ppm, 31.5 to 29.3 ppm, and 24.3 to 23.7 ppm, respectively. The Cε and Ci (carboxylate carbon) 
peaks for ArgPt are not observed likely due to low solubility of the compound in D2O compared to 
L-arginine. 
 
Analysis of ArgPt using ESI mass spectrometry gave an observed m/z of 439.007 Da/e 
(Fig. 2.19), which is consistent with the calculated exact mass of 439.015 Da for ArgPt with a 





arginine and two chlorido ligands coordinated to the platinum(II) center. A dimer, [2(ArgPt)+Cl]+, 
is observed at 914.993 Da/e. A species, [(ArgPt)+Cl]+, with 474.982 Da/e is also observed. 
 
 
 Figure 2.19. Mass analysis of ArgPt using FT-ICR MS. m/z (ESI-MS) 439.007 Da/e [M+H]+; 
calculated exact mass 439.014 Da [M+H]+; chemical formula  PtC6H14Cl2N4O2 ([M+H]+, at neutral 
pH); Other species include a dimer, [2(ArgPt)+HCl]+ , observed at 914.993 Da/e and [(ArgPt)+Cl]+ 
observed at 474.982 Da/e. This spectrum was obtained by Dr. C. C. He at Dr. M.T. Rodgers’ lab. 
 
 
2.4.4 Preparation of aquated AAPt compounds 
For in vitro studies, cisPt or AAPt analogues converted into monoaquated species 
prior to reactions with nucleosides or oligonucleotides. Aquation of AlaPt, OrnPt, and 
ArgPt to generate the corresponding monoaquated AAPt species, involves replacement 
of one chlorido with an aqua ligand (Scheme 2.1). The AAPt compound (1.8 µmoles) and 
AgNO3 (1.3 µmoles, ratio of 1:0.7) were dissolved in 300 µL double deionized water 
(ddH2O) and agitated (using a vortex shaker) in the dark at room temperature for 15 h. 
The resulting white precipitate (AgCl) was removed through two centrifugation steps at 
14,000 rpm for 10 min each. The supernatant contained the corresponding monoaquated 










Scheme 2.1. Aquation of platinum compounds 
 
2.4.5 Preparation of nucleosides and oligonucleotides 
To prepare stock solutions, individual nucleosides were dissolved in ddH2O and filtered 
through centrifugation. Supernatants were collected and concentrations of the nucleosides were 
determined by measuring absorption on a DU730 UV/Vis spectrophotometer (Beckman Coulter) 
at the maximum wavelength and using molar extinction coefficient of the respective nucleoside. 
The extinction coefficients and wavelengths used were 14,900 M-1 cm-1 at 260 nm for Ado, 13,600 
M-1 cm-1 at 253 nm for Guo, 15,700 M -1 cm-1 at 260 nm for dAdo, and 13,000 M-1 cm-1 at 254 nm 
for dGuo [137].  
HPLC analysis and matrix assisted laser desorption ionization mass spectrometry 
(MALDI-MS) characterization of 5′-d(TTATT)-3′ (Figs. 2.20 and 2.21) and 5′-UUAUU-3′ (Figs. 
2.22 and 2.23) show that the oligonucleotides were pure and had the expected calculated 
masses. Concentrations of each strand were determined by measuring absorbance at 260 nm. 
At this wavelength, the extinction coefficients are 47,000 M-1 cm-1 for 5′-d(TTATT)-3′ and 52,600 







Figure 2.20. HPLC analysis of 5′-d(TTATT)-3′. A single peak for 5′-d(TTATT)-3′ is observed with 





Figure 2.21. MALDI-MS mass spectrum of 5′-d(TTATT)-3′. MALDI analysis (positive mode) of 
5′-d(TTATT)-3′ gave an observed m/z of 1548.6 Da/e (calculated exact mass of [d(TTATT)+H]+ is 
1548.3 Da). A peak corresponding to the oligonucleotide associated with a sodium ion is observed 










Figure 2.22. HPLC analysis of 5′-UUAUU-3′. A single peak for 5′-UUAUU-3′ is observed with 





Figure 2.23. MALDI-MS mass spectrum of the 5′-UUAUU-3′. MALDI analysis (positive mode) 
of 5′- UUAUU-3′ gave an observed m/z of 1571.7 Da/e (calculated exact mass of [UUAUU+H]+ is 
1572.1 Da). A peak corresponding to the oligonucleotide associated with one sodium ion is 
observed at m/z 1594.1 Da/e while an oligonucleotide associated with two sodium ions is 






2.4.6 Pseudo-first-order reaction kinetics  
The monoaquated AAPt compounds (or monoaquated cisPt) were used in 50-fold excess 
to produce pseudo-first-order reaction conditions. A 0.1 mM solution of the relevant nucleoside 
(Ado, Guo, dAdo, dGuo) or oligonucleotide was incubated with 5 mM of the aquated platinum 
complex in 25 mM Na2HPO4/NaH2PO4 buffer (pH 7) at 37 °C. For nucleoside reactions, six 
aliquots were collected from the sample at different time points (0, 0.5, 1, 2, 3, 4, and 6 h). For 
oligonucleotide reactions, six aliquots were collected from the sample at different time points (0, 
5, 15, 30, 60, 90, and 120 min). Each aliquot was quenched with NaCl (0.12 M final concentration) 
and then frozen at -80 °C until HPLC analysis. The HPLC was fitted with the Supelco Discovery 
C18 column (see instrumentation Section 2.4.5). For nucleoside elution, buffers A (40 mM 
NH4OAc, pH 6.5) and B (40% acetonitrile, 60% ddH2O) were employed using isocratic conditions 
with 5% B for 5 min followed by a linear gradient in which B was increased to 35% over 25 min. 
For oligonucleotide elution, the same buffers were employed using isocratic conditions with 10% 
B for 5 min followed by a linear gradient in which B was increased to 20% over 10 min, and further 
increased to 50% over the next 15 min.  The peak area of unreacted nucleoside/oligonucleotide 
was monitored over the six time points and their diminishing ratio to the product peaks was 
determined [138]. The unreacted nucleoside/oligonucleotide was monitored because its peak was 
dominant in area and could also be distinguished from other multiple product peaks based on the 
retention time of the control. The HPLC calibration curves show a linear relationship between the 
nucleoside concentration and normalized peak area (Fig. 2.24). Therefore, the peak area of the 






Figure 2.24. HPLC calibration curves for Ado and Guo. There is a linear 
relationship between the amount of a nucleoside injected and the area under 
curve. 
 
2.4.7 Fitting data into a kinetic equation 
The data were fit using an exponential equation assuming pseudo-first-order kinetics 
(Eqs. 2.1-2.5). The pseudo-first order kinetics equation is derived as follows, in which AAPtaq is 
the monoaquated compound and Nuo is the nucleoside or oligonucleotide [139]: 
Nuo + AAPtaq AAPt-Nuo adduct + H2O  (Eq. 2.1) 
Depending on the platinum-based compound, various charged species such as monoaquated 
or bisaquated species can be present in the solution and take part in the reaction [140]. The rate 
of reaction (V) is given by, 
V = kapp [AAPtaq] [Nuo]   (Eq. 2.2) 
in which, kapp is the apparent bimolecular rate constant. Under pseudo-first-order conditions, 
[AAPtaq] >> [Nuo] (50-fold excess of AAPtaq over Nuo) and remains approximately constant. Under 
these conditions, the rate constant, k, equals kapp[AAPtaq] and the rate (V) is given by,  
-d[Nuo]/dt = k [Nuo]  (Eq. 2.3) 





ln[Nuo]t = -kt + ln[Nuo]0     (Eq. 2.4) 
By rewriting the above equation in exponential form, 
 [Nuo]t = e-
kt + [Nuo]0   (Eq. 2.5)  
in which [Nuo]t is the concentration of unreacted nucleoside or oligonucleotide at time t, and [Nuo]0 
is the initial concentration of unreacted nucleoside or oligonucleotide. When [Nuo]t is plotted 
against t, the decay factor is k. The equation was input into KaleidaGraph software and used to 
fit the data. Experiments were performed in triplicate. The standard error was calculated by 
dividing the standard of the mean deviation by the square root of the number of replicates. 
2.4.8 Mass analysis of HPLC isolated AAPt-nucleoside adducts 
The HPLC fractions containing the AAPt-nucleoside adducts were collected and vacuum 
dried. The samples were redissolved in 50:50 MeOH:ddH2O (v/v) and ions were generated with 
an ESI source. The MS analyses were performed using a 7T Fourier transform ion cyclotron mass 
spectrometer (FT-ICR MS, solariX, Bruker Daltonics). Major ions were identified for each fraction. 
The dominant AAPt-nucleoside adduct in each fraction was isolated and subjected to CID-tandem 
mass spectrometry analysis. Fragments were observed and assigned based on their measured 
m/z values. 
 
2.4.9 NMR spectroscopy of AAPt-nucleoside adducts  
The 1H and 13C NMR (700 MHz) spectra of the AAPt-nucleoside adducts were recorded 
on a Bruker Avance 700 MHz spectrometer equipped with a TXI cryoprobe. The H2 and H8 
signals in Ado were assigned by identifying the C2 and C8 chemical shifts in 13C NMR [141] 
followed by two-dimensional heteronuclear single quantum coherence (HSQC) spectroscopy to 
correlate C2-H2 and C8-H8. To each sample, 10 μM trimethylsilyl propionate (TSP) was added 
as an internal standard. The 1H chemical shifts were referenced to the residual HDO (semi-heavy 
water) signal, which was calibrated against TSP. D2O (with no buffer) was also chosen as the 





2.4.10 Mass analysis of HPLC isolated AAPt-oligonucleotide adducts 
The HPLC fractions containing the AAPt-oligonucleotide adducts were collected and 
vacuum dried. For MALDI analyses, the dried samples were first redissolved in 10 µL ddH2O. A 
1.5 µL of each sample was mixed with 1.5 µL of saturated 3-HPA and spotted on a MALDI plate. 
The analyses were carried out on the Bruker UltrafleXtreme MALDI-TOF/TOF. For Orbitrap-ms 
analyses, the dried HPLC fractions containing the AAPt-nucleoside adducts were redissolved in 
100 µL ddH2O with 0.03% triethylamine. Ions were generated with an ESI source and spectra 
obtained on the ThermoScientific LTQ Orbitrap XL. 
2.4.11 Reactions of AAPt with poly(Ado) RNA, ethanol precipitation, and LC-MS 
characterization of adducts 
For platination reactions with poly(Ado) RNA, monoaquated AAPt was used in 4-fold 
excess to the RNA molecule. The sample was incubated in 25 mM Na2HPO4/NaH2PO4 buffer (pH 
7) at 37 °C overnight. Afterwards, the RNA was desalted using ethanol precipitation. To carry out 
ethanol precipitation, the platinum nucleic acid solution (of volume V) was mixed with 2.5 V of 
100% ethanol and 0.1 V of 3 M NH4OAc. The sample mixture was placed on dry ice for 45 min 
and then centrifuged at 14,000 rpm for 30 min at 4 °C. The supernatant was removed and 100 µL 
of 70% ethanol was added to the remaining pellet. The sample was centrifuged again at 14,000 
rpm for 30 min at 4 °C. The supernatant was removed followed by vacuum drying of the remaining 
pellet. The dried pellet was redissolved in 50 µL ddH2O and digested with P1 nuclease (1 unit) for 
5 h at 37 °C. This step was followed by calf intestine phosphatase (CIP, 2 units) treatment for 
another 5 h at 37 °C. The sample was then filtered with centrifugation (Millipore 10 kDa centrifugal 
filter) at 10,000 rpm for 30 min. The collected sample was vacuum-dried and redissolved in 50:50 
MeOH:ddH2O (v/v).  
LC-MS (Shimadzu 8040 triple quadrupole) was used to separate and identify the platinum 
adducts and corresponding unplatinated material. The LC-MS was equipped with ESI and fitted 





buffer B (9% acetonitrile with 10 mM NH4OAc in ddH2O) were employed under isocratic conditions 
with 0% B for 5 min followed by a linear gradient in which B was increased from 0 to 33% over 20 
min. 
2.4.12 Energy-resolved collision-induced dissociation (ER-CID) experiments and survival 
yield analyses 
ER-CID experiments of the HPLC fractions containing the AlaPt-Ado, OrnPt-Ado, and 
ArgPt-Ado adducts were performed on a quadrupole ion trap mass spectrometer (QIT MS, 
amaZon ETD, Bruker Daltonics). The method has been described in detail in previous work [116, 
124-125]. Briefly, HPLC fractions were vacuum dried and then redissolved in a MeOH:ddH2O 
(50:50 v/v) mixture. Each HPLC fraction (10 μM) was introduced to the ESI source to generate 
ions, which were then guided into the ion trap. In the trap, ions were accumulated and mass 
selected for tandem ER-CID experiments. Helium (1 mtorr) served as both the buffer and collision 
gas to provide efficient trapping and cooling of the ions as well as to achieve fragmentation of the 
precursor AAPt-nucleoside complex. The qz value was set to 0.25 for the ER-CID experiments, 
which leads to low mass cutoff of 27% of the precursor ion m/z. The rf excitation amplitude was 
increased from 0 V to the rf excitation amplitude required to produce complete dissociation of the 
precursor ion at a stepsize of 0.01 V. Experiments were performed in triplicate to assess 
reproducibility. All data were processed using Data Analysis 4.0 (Bruker Daltonics). 
The glycosidic bond cleavage (GBC) survival yield was calculated from the intensities of 
the precursor and fragment ions, and the ratio of the precursor ion intensity to the total ion intensity 
was determined using Eq. 2.6 [142],  
                        Survival Yield (GBC) =  (∑ 𝐼𝑓𝑖 + 𝐼𝑝)
𝑛−𝑥
𝑥 (⁄ ∑ 𝐼𝑓𝑖𝑖 + 𝐼𝑝)                  (2.6) 
in which 𝐼𝑓𝑖 and 𝐼𝑝 are the ion intensities of the fragment and precursor ions, respectively; x 
represents fragments in which the glycosidic bond remains intact. Data analyses were performed 





the Rodgers laboratory and reported previously [116, 122-125]. The GBC survival yield was 
plotted as a function of the rf excitation amplitude. The rf excitation amplitude required to produce 
50% glycosidic bond cleavage (GBC50%) was extracted by fitting of the survival yield curve using 
the four-parameter logistic dynamic equation (Eq. 2.7) [116, 124-125]. 
Survival Yield (GBC50%) = min + (max − min) [1 + (rfEA/GBC50%]
GBCslope⁄          (2.7)    
In this equation, max and min are defined as the maximum (1) and minimum (0) values of the 
survival yield, rfEA is the rf excitation amplitude applied to induce fragmentation, and GBCslope is 
the slope of the declining region of the survival yield curve. 
2.4.13 MTT cytotoxicity assays in human cell lines 
The number of cells was first determined using a hemocytometer. The cells (and media) 
were seeded in a transparent flat-bottom, 96-well plate with each well having 10,000 cells. The 
seeded plate was placed in an incubator (37 °C, 5% CO2) for 24 h to allow the cells to attach to 
the wells. Afterwards, the media was removed and fresh media with varying concentrations of the 
AAPt compound (or cisPt) added to the wells. In each plate, two types of controls were included. 
The first, referred to as the growth control, contained cells and media but no platinum compounds. 
The second, referred to as the blank control, had media only. The plates were incubated for 72 h 
after which 10 µL of MTT stock (5 mg/mL) was added to each of the wells. The plates were 
incubated for another 4 h during which time insoluble formazan is produced by viable cells. DMSO 
(100 µL) was added to the wells and incubated for 10 min to dissolve the formazan. The optical 
density (OD) of each well was measured at 520 nm using a microplate reader, BioTek synergy 
H1 hybrid reader in Dr. Y. H. Ahn’s lab. The percentage of viable cells for each concentration of 
platinum compound was determined using Eq. 2.8. 
% of viable cells =
OD for platinum compound concentration−OD for blank control
OD for growth control−OD for blank control





The IC50 plots were generated using GraphPad PRISM®, which fits the concentration of 
platinum compound (X) and normalized response (percentage of viable cells, Y) into a model 
equation, Eq. 2.9. 
Y=100/(1+(XhillSlope)/(IC50hillSlope)), in which hillslope is -1.  (2.9) 
The protocol for cell culture and maintenance of human cell lines is described in Appendix 
A. 
2.4.14 Quantification of cellular accumulation of platinum compounds 
The human prostate cancer cell line, DU145, and normal prostate cell line, RWPE-1, were 
grown in 100 x 20 mm tissue culture dishes until confluency. The cells were then detached from 
bottom of dishes by treating with trypsin. The suspension was homogenized and the cell number 
was determined using a hemocytometer. From the stock suspension, 460,000 cells were seeded 
on 60 x 15 mm culture dishes each and grown in an incubator (37 °C, 5% CO2) for 18 h. The 
media was removed and the dishes were washed with 3 mL PBS. In each dish, 3 mL of 
keratinocyte media with 50 µM of platinum compound was added. The dishes were incubated for 
another 2 h to allow uptake of the compounds by the attached cells. The media was removed and 
dishes washed again with 3 mL of PBS. The cells on the dishes were resuspended using 500 µL 
of trypsin and collected into centrifuge tubes. The cell number in each tube was counted using a 
hemocytometer. The cells were chemically digested using 300 µL of concentrated HNO3. The 
samples were left to further digest at room temperature for 16 h after which they were diluted by 
adding 2.7 mL of 2% HNO3 and 0.5% HCl (in ddH2O) solution prior to ICP-MS quantification. 
For ICP-MS calibration, a platinum standard series with 0.5, 1, 5, 10, 25, 50, 100, 200 ppb 
concentrations was prepared in 2% HNO3 and 0.5% HCl (in ddH2O). Aside from the standards 
and the digested cell samples, solvent blanks and blanks without platinum compounds were also 
included in the analysis. Quantification was carried out using an Agilent Technologies 7700 series 
ICP-MS instrument (plasma gas flow 15 L/min, nebulizer pump speed 0.3 rps, spectrum 





mode). A 10 ppb concentration of 209Bi solution was used as the instrument internal standard. The 
195Pt isotope was used for detection since has minimal polyatomic interference [143]. Data were 
collected under high energy He tune mode in which the internal standard signal was stable and 
the R value for the calibration curve was closest to 1. For quality control, a 10 ppm standard was 



























CHARACTERIZATION OF NON-CANONICAL ADDUCTS FORMED BY AMINO ACID-
LINKED PLATINUM(II) COMPOUNDSǂ 
ǂNucleoside level studies are adapted from Kimutai B, He CC, Roberts A, Jones ML, Bao X, 
Jiang J, Yang Z, Rodgers MT, Chow CS (2019) J Biol Inorg Chem 24:985-997. 
3.1 Abstract 
Cisplatin (cisPt) is an antitumor drug that preferentially coordinates and forms adducts 
with deoxyguanosine (dGuo) residues within DNA. These adducts inhibit important cellular 
functions and ultimately cause cancer cell death. Despite its success as an anticancer drug, cisPt 
has a number of drawbacks that reduce its efficacy, including repair of adducts and drug 
resistance. To overcome these problems, other approaches such as development of compounds 
that form non-canonical adducts by coordinating to other purine nucleobases, including those 
found in RNA can be pursued. The synthesized amino acid-linked platinum(II) (AAPt) compounds 
of alanine, ornithine, and arginine (AlaPt, OrnPt, and ArgPt, respectively) have unique reactivities 
that result in formation of non-canonical adducts with adenosine or deoxyadenosine (Ado or 
dAdo) residues.  In this chapter, the non-canonical adducts formed by the AAPt compounds with 
nucleosides/oligonucleotides were characterized. Nucleoside-level adducts were separated by 
HPLC on C18, then characterized by NMR spectroscopy and mass spectrometry (in collaboration 
with Dr. M. T. Rodgers’ lab). The chosen AAPt compounds form predominantly monofunctional 
adducts by reacting at the N1/N3, or N7 positions of purine nucleobases. The AAPt adducts with 
oligonucleotides were also isolated by HPLC and characterized by matrix-assisted laser 
desorption ionization mass spectrometry (MALDI-MS) and liquid chromatography mass 
spectrometry (LC-MS). The AAPt compounds were observed to form a variety of adduct types 








The antitumor drug cisPt platinates neighboring deoxyguanosine (dGuo) residues of DNA 
by coordinating at their N7 positions and forming bifunctional adducts [18, 37-38]. These adducts 
alter the DNA helical structure and inhibit important biological processes such as replication and 
transcription [11]. The adducts trigger a number of cellular responses, including cell cycle arrest, 
DNA repair, and apoptosis [1]. Despite its success, the application of cisPt as an anticancer drug 
is limited by cellular resistance and adverse side effects such as nephrotoxicity [69-71]. 
Resistance, which is caused by factors such as DNA repair and reduced accumulation of drug, 
enables cancer cells to survive cisPt treatment [71]. Resistance and adverse toxicity can be 
circumvented by developing other platinum-based compounds that have altered reaction profiles. 
Platinum analogues may coordinate with DNA sites that are not platinated by cisPt or target other 
biomolecules such as RNA. These analogues may therefore exhibit unique mechanisms of action 
that avert resistance, especially when the adducts cause irreparable damage [55-56, 29]. 
Therefore, the types of adducts formed by platinum-based compounds are important in their 
cytotoxic mechanism, as exhibited by cisPt-DNA bifunctional adducts that bend the DNA helix 
and trigger a cascade of events leading to apoptosis [37]. The adducts formed by cisPt or its 
analogues can be analyzed by using various chemical and analytical methods. 
As introduced previously in Chapter 1, there are several potential sites in the DNA where 
cisPt can platinate with varying degrees of preference (Fig. 3.1). At these nucleoside residues, 
cisPt coordinates with nitrogen atoms. The preferred site for cisPt coordination is the N7 position 
of dGuo [37-38, 10]. This site is situated in the major groove of the DNA, which is highly accessible 
compared to sites in the minor groove such as N3 [18, 39]. CisPt may form intrastrand or 
interstrand adducts, depending on whether coordination occurs on the same strand or separate 
strands, respectively [18, 41]. Adducts can also be defined as monofunctional, bifunctional, or 





It has been reported that 90–95% of cisPt-DNA adducts are intrastrand cross-links. whereas the 
rest are a combination of interstrand cross-links and monofunctional adducts [37, 41]. 
 
Figure 3.1. Possible coordination sites for cisPt in DNA. The preferred coordination site is 
dictated by accessibility and nucleophilicity. Arrows point at potential atoms that coordinate with 
cisPt. The N7 atom of dGuo is preferred since it is in the major groove and more nucleophilic than 
other DNA sites. 
 
Formation of cisPt adducts with DNA/RNA is influenced by a number of factors (e.g., 
coordination type and hydrogen-bonding properties) associated with the non-leaving group ligand 
[35-36]. These factors influence the target preferences and the types of platinum adducts formed 
with DNA or RNA. For example, hydrogen-bonding interactions are implicated in the preferential 
coordination of cisPt to dGuo [27]. This preference is because during the transition state, cisPt 
forms a strong hydrogen bond between its ammine ligand and the oxo at the 6 position of dGuo 





the 6 position, which cannot hydrogen bond with cisPt [27]. The type of ligands associated with 
cisPt (or other platinum-based compounds) may also affect several factors associated with the 
adduct structures due to unique interactions with the nucleobase functional groups. These factors 
include nucleoside platination sites (such as N1, N3, or N7) and geometric or constitutional 
isomers [105].  
 
 
Figure 3.2. The structures of cisPt and amino acid-linked platinum(II) (AAPt) compounds. 
The structures of AAPt compounds consist of a chelated amino acid and two chlorido ligands 
coordinated to the platinum center.  
 
Previous studies in our lab showed that AAPt compounds such as OrnPt and ArgPt form 
adducts at Ado residues in RNA [106]. In this chapter, the non-canonical adducts formed by AlaPt, 
OrnPt, and ArgPt (Fig. 3.2) with nucleosides and oligonucleotides were characterized to 
determine their adduct types and sites of platination. AAPt (or cisPt) compounds were first 
activated to form the monoaquated species, and then reacted with target 
nucleosides/oligonucleotides (Scheme 3.1). The reactions could in formation of different types of 
products that potentially vary in composition, platination site (N1, N3, or N7), and geometry. These 
reactions and products formed were monitored using HPLC. The HPLC fractions corresponding 
to adducts were isolated and characterized using mass spectrometry and NMR spectroscopy. 
These characterizations are crucial for understanding how functional groups of the amino acid 









Scheme 3.1. Aquation of platinum compounds and subsequent platination of purine residues. 
Possible coordination sites are highlighted in blue (N7) and red (N1 and N3). 
 
 
3.3 Results and discussion 
3.3.1 Characterization of AAPt-nucleoside adducts  
When cisPt coordinates with DNA, it predominantly platinates the N7 position of dGuo 
[101-102]. In this thesis work, we sought to characterize the non-canonical adducts formed by 
AAPt compounds and determine their binding site preferences. The structures and corresponding 
chemical properties of various AAPt compounds may alter the preferred sites of reactivity versus 
those targeted by cisPt. Mass spectrometry was used to determine the composition and type 





compounds, and 1H-NMR spectroscopy was used for characterization of the platination sites (e.g., 
N1, N3, or N7) on the nucleoside. 
The reactions of nucleosides with the monoaquated AAPt compounds result in the 
formation of one or more adducts with longer (AlaPt and ArgPt adducts) or shorter (OrnPt adducts) 
retention times on a C18 column relative to the unreacted nucleosides (Fig. 3.3A). Only one AAPt-
Guo adduct was expected based on the known preference for coordination of the aquated cisPt 
at the dGuo N7 position [101, 144]. Previously in our lab, Dr. Xun Bao characterized the products 
formed by platination of the Guo nucleoside [145]. HPLC and mass spectrometric analysis 
showed that platination (by cisPt or OrnPt) led to formation of one major product. NMR 
spectroscopy was used to determine that platination occurs at the N7 position of Guo [145]. 
The reactions of Ado with the monoaquated AAPt compounds result in the formation of 
one or more adducts with longer (AlaPt and ArgPt adducts) or shorter (OrnPt adducts) retention 
times on a C18 column relative to the unreacted nucleosides (Fig. 3.3B). Monoaquated AlaPt 
reacts with Ado to form two main products (distinct HPLC peaks), referred to as AlaPt-AdoN1/N3 
and AlaPt-AdoN7 (Fig. 3.3B). These adducts have longer retention times compared to Ado due to 
decreased polarity associated with the alanine ligand. Monoaquated OrnPt reacts with Ado to 
form two major products, OrnPt-AdoN1/N3 and OrnPt-AdoN7, which have shorter retention times 
than Ado on C18. Monoaquated ArgPt also reacts with Ado to form three major products, ArgPt-
AdoN1/N3, ArgPt-AdoN7, and ArgPt-Adomix, which have longer retention times than Ado. Although 
L-ornithine and L-arginine amino acids both have polar side chains (amine and guanidinium, 
respectively), the adducts formed by their respective AAPt derivatives have different behaviors 
on the C18 column. The adducts of OrnPt have shorter retention times compared to the adducts 
of ArgPt. This observation suggests that OrnPt and ArgPt may have different types of structures 
(N,O vs. N,N) as discussed in Section 2.4.2. Furthermore, the two compounds may form adducts 
that adopt different structural conformations that position their functional groups for favorable 





separation of the AlaPt-Ado, OrnPt-Ado, and ArgPt-Ado adducts was carried out in collaboration 
with the Rodgers’ laboratory using FT-ICR MS equipped with an ESI source. 
 
 
Figure 3.3. HPLC analysis (C18) of platination products. The AAPt-Guo (A) or AAPt-Ado (B) 
adduct profiles following reactions with monoaquated AlaPt, OrnPt, or ArgPt are shown. The 
peaks are labeled as follows; black asterisks for the free nucleosides, blue circles for N7 
platination adducts, and red triangles for N1/N3 platination adducts. The controls (unreacted Guo 
or Ado) are shown as the top traces in (A) and (B). 
 
Mass analysis of the compounds in the two fractions obtained from HPLC C18 separation 
of the AlaPt adducts (Fig. 3.3B), referred to as AlaPt-AdoN1/N3 and AlaPt-AdoN7, reveals that they 
have the same mass, charge, and isotopic distribution, corresponding to a monofunctional adduct, 
[Pt(Ado)(Ala)(Cl)+H]+ (Fig. 3.4). Because they have the same mass, the two adducts are 
constitutional isomers that may vary at the site of platination (N1, N3, or N7). For the geometric 
isomers, we expect that the structures shown in Scheme 3.1 are preferred because of the trans 
effect [146], but these structures still need to be confirmed experimentally. In addition, it would be 
of interest to understand how the binding types of platinum-based compounds (i.e., (N,N) vs. 
(N,O)) impact the adduct identities. Other species formed by the loss and addition of neutral 





[Pt(Ado)(Ala)(CH3CO2H)]+, and [Pt(Ado)(Ala)(CH3CN)(NH3)]+, which form as a result of the 
monofunctional adduct losing HCl and generating a complex with NH3, CH3CO2H, or CH3CN from 
the HPLC buffer, respectively. Due to the soft ionization conditions offered by ESI, it is not 
surprising to observe adduction of NH3 [147]. 
 
 
Figure 3.4. Mass spectra of the AlaPt-AdoN1/N3 and AlaPt-AdoN7 fractions. For both fractions, 
the monofunctional adduct species [Pt(Ado)(Ala)(Cl)+H]+ is observed with the predicted isotopic 







Figure 3.5. Wide range mass spectra of the AlaPt-Ado fractions. Both of the mass spectra for 
AlaPt-AdoN1/N3 (red) and AlaPt-AdoN7 (blue) contain the monofunctional adduct species, 
[Pt(Ado)(Ala)(Cl)+H]+. Other adducts are formed by the loss or addition of neutral molecules to 
the monofunctional adduct. The spectra were obtained by Dr. C. C. He in Dr. M. T. Rodgers’ lab. 
 
Similar to that found for the reactions of AlaPt with Ado, compounds in the OrnPt-Ado 
HPLC fractions (Fig. 3.3), referred to as OrnPt-AdoN1/N3 and OrnPt-AdoN7, have the same mass, 
charge, and isotopic distribution corresponding to a monofunctional adduct [Pt(Ado)(Orn)(Cl)]+ 
(Fig. 3.6), i.e., the two adducts are constitutional isomers with variation at the site of coordination 
(e.g., N1, N3, or N7) or varying geometries as discussed for AlaPt. Species assigned as 
[Pt(Ado)(Orn)(NH3)–H]+ and [Pt(Ado)(Orn)(CH3CN)(NH3)–H]+ are also observed, suggesting that 







Figure 3.6. Mass spectra of the OrnPt-AdoN1/N3 and OrnPt-AdoN7 fractions. For both fractions, 
the monofunctional adduct species [Pt(Ado)(Orn)(Cl)]+ is observed with the predicted isotopic 
distribution. The spectra were obtained by Dr. C. C. He in Dr. M. T. Rodgers’ lab. 
 
 
Figure 3.7. Wide range mass spectra of the OrnPt-Ado fractions. Both of the mass spectra 
for OrnPt-AdoN1/N3 (red) and OrnPt-AdoN7 (blue) contain the monofunctional adduct species, 
[Pt(Ado)(Orn)(Cl)]+. Other adducts are formed by the loss or addition of neutral molecules to the 






The ArgPt reaction with Ado results in three product HPLC fractions (Fig. 3.3). The first 
two product fractions, referred to as ArgPt-AdoN1/N3 and ArgPt-AdoN7, have the same mass, 
charge, and isotopic distribution corresponding to a monofunctional adduct [Pt(Ado)(Arg)(Cl)]+ 
(Fig. 3.8), i.e., the two adducts are constitutional isomers with variation at the site of coordination 
(e.g., N1, N3, or N7) or varying geometries as discussed for the AlaPt-Ado and OrnPt-Ado 
adducts. Species assigned as [Pt(Ado)(Arg)(H2O)–H]+ are also observed, suggesting that ligand 
substitution of one of the chlorido ligands with H2O is facile in solution (Fig. 3.9). The third fraction, 
referred to as ArgPt-Adomix, is a mixture of bifunctional ([Pt(Ado)2(Arg)]2+) and doubly platinated 
([Ado(Pt(Arg)Cl)2]2+) adducts (Fig. 3.10). 
 
 
Figure 3.8. Mass spectra of the ArgPt-AdoN1/N3 and ArgPt-AdoN7 fractions. For both fractions, 
the monofunctional adduct species [Pt(Ado)(Arg)(Cl)+H]+ is observed with the predicted isotopic 






Figure 3.9. Wide range mass spectra of the ArgPt-Ado fractions. Both of the mass spectra 
for ArgPt-AdoN1/N3 (red) and ArgPt-AdoN7 (blue) contain the monofunctional adduct species, 
[Pt(Ado)(Arg)(Cl)+H]+. An adduct, [Pt(Ado)(Arg)(H2O)-H]+, is also formed through ligand 
substitution of one of the chlorido ligands with H2O. The spectra were obtained by Dr. C. C. He in 




Figure 3.10. Mass spectrum of ArgPt-Adomix fraction. ArgPt-Adomix consists of a mixture of 
bifunctional ([Pt(Ado)2(Arg)]2+) and doubly platinated ([Ado(Pt(Arg)Cl)2]2+) adducts.  A fragment of 
the bifunctional adduct ([Pt(Ado)2(Arg)-ribose]2+)  is also observed, and formed due to the loss of 
one ribose sugar. All of the adducts are multiply charged and observed in the 2+ states. The 






Figure 3.11. The 2D heteronuclear single quantum correlation (HSQC) of OrnPt-AdoN7 (top) 
and OrnPt-AdoN1/N3 (bottom). In reference to the signal for Ado C2-H2 (top) [141], the major 
signal for OrnPt-AdoN1/N3 exhibits platination at the N1 (or N3) position. On the other hand, in 
reference to the Ado C8-H8 (bottom) [141], the major peak for OrnPt-AdoN7 exhibits platination at 
the N7 position. The minor signals observed are for doubly platinated or bifunctional adducts that 
elute with the major peaks during HPLC separation of the adducts (experiment performed by Dr. 
Jun Jiang and Dr. Xun Bao). 
 
NMR analysis was used to assign the platination sites of the adducts [138]. Two-
dimensional (2D) heteronuclear single quantum correlation (HSQC) spectroscopy was employed 
to assign the peaks for the H8 and H2 protons of OrnPt-AdoN1/N3 and OrnPt-AdoN7 (Fig. 3.11). 1H-
NMR spectroscopy was then employed to determine the specific platination sites of the AlaPt-
Ado, OrnPt-Ado, and ArgPt-Ado adducts by comparison of the chemical shifts of the H2 and H8 
protons of Ado (Figs. 3.12, 3.13, and 3.14). Compared to the chemical shifts of the H2 and H8 
protons of Ado, the corresponding peaks for the species assigned as AlaPt-AdoN1/N3 are shifted 





H2 compared to H8 suggests platination at the N1 position in AlaPt-AdoN1/N3 because of its 
proximity to H2 [144, 148]. However, platination at N3 of Ado cannot be ruled out because that 
adduct would also cause a downfield shift of H2. 1H-NMR analysis of AlaPt-AdoN7 shows the 
peaks assigned as H2 and H8 shifting downfield by 0.1 and 0.5 ppm, respectively (Table 3.1), 
suggesting that platination occurs at the N7 position for this adduct. 
 
 
Figure 3.12. Aromatic region of 1H-NMR spectra of AlaPt-Ado HPLC fractions. Ado (top), 
AlaPt-AdoN1/N3 (middle) and AlaPt-AdoN7 (bottom); proton signals assigned as H8 and H2 are 
noted with triangles and circles, respectively. The open circles and triangles are assigned as 
protons likely from bisaquated AlaPt-Ado species. The extent of proton signal shift is dependent 
on proximity of the platination site. The data were collected with assistance from Evan Jones in 
the Lumigen Instrument Center. 
 
Table 3.1. Downfield shifts of protons (in ppm) of AlaPt-Ado adducts relative to Ado protons 
  H2 H8 
AlaPt-AdoN1/N3a 0.4 0.1 
AlaPt-AdoN7b 0.1 0.5 
                                 amonofunctional [Pt(Ado)(Ala)(Cl)] with N1/N3 platination 






Figure 3.13. Aromatic region of 1H-NMR spectra of OrnPt-Ado HPLC fractions. Ado (top), 
OrnPt-AdoN1/N3 (middle) and OrnPt-AdoN7 (bottom);  proton signals for H8 and H2 are noted with 
triangles and circles, respectively. The open circles and triangles are assigned as protons from 
doubly platinated and bifuctional species that have also been confirmed by mass spectrometry. 
The extent of proton signal shift is dependent on proximity to the platination site (experiment 
performed by Dr. Jun Jiang and Dr. Xun Bao). 
 
 
Table 3.2. Downfield shifts of protons (in ppm) of OrnPt-Ado adducts relative to Ado protons 
  H2 H8 
OrnPt-AdoN1/N3a 0.5 0.1 
OrnPt-AdoN7b 0.1 0.5 
              amonofunctional [Pt(Ado)(Orn)(Cl)] with N1/N3 platination 
              bmonofunctional [Pt(Ado)(Orn)(Cl)] with N7 platination 
 
The analysis of platination sites on the monoaquated OrnPt adducts is similar to that of 
the AlaPt adducts (Fig. 3.13). In the 1H-NMR spectrum of OrnPt-AdoN1/N3, the major peak 
corresponding to H8 (closed triangle) shows a small chemical shift change (0.1 ppm), whereas 





3.2), which suggests that the metal center is most likely coordinated to the N1 (or N3) position of 
Ado [149]. For OrnPt-AdoN7, both peaks for H8 (triangles, open and closed for major products) 
are shifted downfield by approximately 0.5 ppm, while the corresponding changes in the H2 
chemical shifts are only 0.1 ppm (Fig. 3.13 and Table 3.2). The stronger downfield shift observed 
for the two H8 signals suggests that platination occurs on the neighboring N7 for both products. 
Therefore, the larger chemical shift change of the H2 peak is consistent with N1/N3 platination of 
the HPLC fraction assigned as OrnPt-AdoN1/N3, whereas OrnPt-AdoN7 is assigned as having N7 
platination due to the larger chemical shift change of the H8 peak. 
 
Figure 3.14. Aromatic region of 1H-NMR spectra of ArgPt-Ado HPLC fractions. Ado (top), 
ArgPt-AdoN1/N3 (middle) and ArgPt-AdoN7 (bottom); proton signals assigned as H8 and H2 are 
noted with triangles and circles, respectively. The extent of proton signal shift is dependent on 
proximity to the platination site. 
 
Table 3.3. Downfield shifts of protons (in ppm) of ArgPt-Ado adducts relative to Ado protons 
  H2 H8 
ArgPt-AdoN1/N3a 0.5 0.1 
ArgPt-AdoN7b 0.2 0.6 
               amonofunctional [Pt(Ado)(Arg)(Cl)] with N1/N3 platination 





The platination sites on the first two adducts of monoaquated ArgPt are also similar to that 
of the AlaPt and OrnPt adducts (Fig. 3.14). Compared to the chemical shifts of H2 and H8 protons 
of Ado, the corresponding peaks for the species assigned as ArgPt-AdoN1/N3 are shifted downfield 
by 0.5 and 0.1 ppm, respectively (Table 3.3). The greater change in chemical shift of H2 
compared to H8 suggests that platination occurs at the N1 or N3 position in ArgPt-AdoN1/N3 
because of its proximity to H2. The 1H-NMR spectrum of ArgPt-AdoN7 shows that the peaks 
assigned as H2 and H8 are shifted downfield by 0.2 and 0.6 ppm, respectively (Table 3.3). This 
change in chemical shift suggests that for the ArgPt-AdoN7 product, platination occurs at the N7 
position. 
 
3.3.2 Characterization of AAPt-RNA adducts 
The local environment of an oligonucleotide may affect the coordination of a platinum-
based compound. Elucidation of nucleoside-level adducts provides information about 
coordination sites, adduct types, and influence of ligands in binding kinetics. However, the 
nucleotides surrounding the target nucleotide within the context of RNA or DNA oligonucleotides 
may also modulate the coordination and lead to different platination profiles. The interaction of 
AAPt compounds with non-canonical targets of cisPt was investigated using the oligonucleotide 
sequence 5′-UUAUU-3′. This sequence was selected because cisPt and AAPt compounds have 
low reactivity with Thd (dT) and Urd (U) residues [106, 138]. Therefore, the presence of only one 
preferred residue (Ado (A)) directs the platination to a single site. 
MALDI-MS and ESI-MS were used to determine the composition and type (e.g., mono-, 
bifunctional, or doubly platinated) of non-canonical adducts formed by AAPt compounds with the 
5′-UUAUU-3′ oligonucleotide. The purity of 5′-UUAUU-3′ was first determined by HPLC (C18) as 
shown in Chapter 2 (Fig. 2.22), where the oligonucleotide was observed with only minor impurity 





(Chapter 2, Fig. 2.23). A peak was observed at m/z of 1571.7 Da/e, consistent with a calculated 
mass of 1571.2 Da for 5′-UUAUU-3′. 
Reactions of monoaquated AAPt compounds with 5′-UUAUU-3′ result in formation of 
adducts with longer retention times on a C18 column relative to the unreacted oligonucleotide. 
Several reactions were carried out followed by HPLC isolation of the fractions to obtain enough 
of the products for mass analysis. The fractions obtained were characterized using MALDI-MS or 
ESI-MS. For the AlaPt reaction, a product peak (AlaPt-UUAUU-1) with a longer retention time 
than the unreacted 5′-UUAUU-3′ oligonucleotide was formed (Fig. 3.15). The HPLC isolated 
fraction was analyzed by MALDI-MS. However, platinum associated peaks were not observed in 
the spectrum, likely because of low sample concentration. The sample was reanalyzed an 
Orbitrap-MS equipped with an ESI source. A triply charged species with the predicted platinum 
isotopic distribution was observed at 594.073 Da/e (Fig. 3.16). This species is assigned as a 
monofunctional adduct in which one of the uridines is fragmented (base loss) during ionization 
(calculated exact mass is 1782.150 Da or 594.050 Da/e for the triply charged state).  The 
calculated exact mass of triply charged adduct with all the bases is 1892.161 Da. Since platinum 
compounds have low reactivity with Urd residues, it is most likely that this adduct involves RNA 
platination at the Ado residue (Fig. 3.17). 
 
Figure 3.15. HPLC analysis (C18) of AlaPt-UUAUU platination products. The AlaPt-UUAUU 
adduct profile following reaction with monoaquated OrnPt is shown. A product, AlaPt-UUAUU-1, 







Figure 3.16. ESI mass spectrum of isolated AlaPt-UUAUU-1 product.  A triply charged 
species, [(M-uracil)+Pt(Ala)Cl+3H]3+, with the predicted platinum isotopic distribution observed at 
594.073 Da/e is assigned as a monofunctional adduct, with a loss of one uracil base. The 
calculated exact mass of the fragmented adduct is 1782.150 Da (594.050 Da/e for triply charged 
state), while the unfragmented adduct is 1892.161 Da. 
 
 
Figure 3.17. Adducts formed by AAPt compounds with 5′-UUAUU-3′ RNA. (A) A 
monofunctional adduct in which one AAPt molecule coordinates with the oligonucleotide at the 
Ado residue is shown. (B) A doubly platinated adduct in which two AAPt molecules coordinate 
with the oligonucleotide at the Ado residue is shown. Nitrogen atoms are color coded with red at 







The reaction of OrnPt with 5′-UUAUU-3′ results in formation of three distinct HPLC product 
peaks (OrnPt-UUAUU-1, OrnPt-UUAUU-2, and OrnPt-UUAUU-3) that have longer retention times 
(21.1, 23.0, and 24.0 min, respectively) than the unreacted 5′-UUAUU-3′ oligonucleotide (Fig. 
3.18). HPLC fractions of the adducts were concentrated and mass analysis was carried out using 
MALDI-MS. The OrnPt-UUAUU-1 fraction has an observed m/z of 1933.8 Da/e, which is assigned 
as a monofunctional adduct (calculated exact mass is 1933.2 Da) (Fig. 3.19). An unplatinated 5′-
UUAUU-3′ is also observed in the mass spectrum and could be formed if fragmentation of the 
adduct during ionization occurs. Unreacted 5′-UUAUU-3′ could also be present in the sample if 
there is incomplete HPLC peak separation (especially near the baseline) and residual unreacted 
5′-UUAUU-3′ is collected together with the OrnPt-UUAUU-1 fraction.  
 
 
Figure 3.18. HPLC analysis (C18) of OrnPt-UUAUU platination products. The OrnPt-UUAUU 
adduct profile following reaction of 5′-UUAUU-3′ with monoaquated OrnPt is shown. Three 
products, OrnPt-UUAUU-1, OrnPt-UUAUU-2, and OrnPt-UUAUU-3, are formed with retention 










Figure 3.19. MALDI mass spectrum of HPLC isolated OrnPt-UUAUU-1 product. Analysis of 
HPLC isolated OrnPt-UUAUU-1 indicates an m/z of 1933.8 Da/e, consistent with a 
monofunctional adduct (calculated exact mass is 1933.2 Da). The unplatinated oligonucleotide 
(m/z 1572.4 Da/e) is also observed in the spectrum. Adducts of unplatinated oligonucleotide with 
Na+ (m/z 1595.9 Da/e), Na++ NH3 (m/z 1610.3 Da/e), and Na++ K+(m/z 1633.7 Da/e) are observed 
as well. 
 
HPLC fractions for OrnPt-UUAUU-2 and OrnPt-UUAUU-3 peaks were combined during 
mass analysis due to incomplete separation of the two fractions in some of the HPLC isolations. 
MALDI-MS data show that the two fractions consist of multiple adducts including a monofunctional 
adduct observed at m/z 1933.4 Da/e (calculated mass is 1933.2 Da) and a doubly platinated 
adduct observed at m/z 2295.7 Da/e (calculated exact mass is 2295.2 Da) (Fig. 3.20). This result 
reveals that either the fraction of OrnPt-UUAUU-2 or OrnPt-UUAUU-3 contains a monofunctional 
adduct while the other contains the doubly platinated adduct. For the doubly platinated adduct 
structure, it is likely that both OrnPt molecules coordinate to different sites (N1, N3, or N7) of the 
Ado residue of the oligonucleotide (Fig. 3.17). Other minor peaks corresponding to a bisaquated 









Figure 3.20. MALDI mass spectrum of isolated OrnPt-UUAUU-2 and OrnPt-UUAUU-3 HPLC 
fractions. Analysis of isolated OrnPt-UUAUU-2, and OrnPt-UUAUU-3 indicate presence of a 
monofunctional adduct (m/z of 1933.4 Da/e) and doubly platinated adduct (m/z 2295.7 Da). Minor 
peaks observed (m/z 1898.9, 1916.4, 1956.6, 1992.2, and 2260.1 Da/e) are assigned on 
bisaquated OrnPt, loss of Cl-, and association with sodium ions. 
 
The reaction of ArgPt with 5′-UUAUU-3′ was analyzed and three HPLC product peaks 
(ArgPt-UUAUU-1, ArgPt-UUAUU-2, and ArgPt-UUAUU-3) were observed, which all have longer 
retention times (22.5, 23.8, and 25.5 min, respectively) than the unreacted 5′-UUAUU-3′ 
oligonucleotide (Fig. 3.21). Fractions were collected and analyzed by MALDI-MS. However, no 
peaks associated with ArgPt or RNA were observed, likely due to low sample concentration. The 
MALDI-MS characterization was repeated on a ArgPt-UUAUU reaction mixture that was first 
desalted through ethanol precipitation. Multiple platinum adducts were observed (Fig. 3.22). 
These include a monofunctional adduct observed at m/z 1979.4 Da/e (calculated mass is 1979.5 
Da), a doubly platinated adduct observed at m/z 2405.3 Da/e (calculated exact mass is 2405.5 
Da), and an aquated doubly platinated adduct observed at m/z 2366.1 Da/e (calculated exact 





platinated adduct associated with CH3COOH (from desalting buffers) (calculated exact mass is 
2510.7 Da). 
 
Figure 3.21. HPLC analysis (C18) of ArgPt-UUAUU platination products. The ArgPt-UUAUU 
adduct profile following reaction of 5′-UUAUU-3′ with monoaquated ArgPt is shown. Three 
products, ArgPt-UUAUU-1, ArgPt-UUAUU-2, and ArgPt-UUAUU-3, are observed with retention 
times of 22.5, 23.8, and 25.5 min, respectively. The control (unreacted 5′-UUAUU-3′) is shown as 




Figure 3.22. MALDI mass spectrum of isolated ArgPt-UUAUU reaction mixtures. 
Characterization indicates presence of a monofunctional adduct (m/z 1979.4 Da/e), doubly 
platinated adduct (m/z 2405.3 Da/e), and doubly platinated adduct with bisaquated ArgPt (m/z 
2366.1 Da/e). An adduct formed by addition of neutral molecules of CH3COOH is also observed 
at 2511.4 Da/e. 
 
In a separate experiment to investigate the formation of ArgPt adducts with RNA, a 





LC-MS as described in Section 2.4.11. ArgPt reacts with poly(Ado) RNA and forms three product 
peaks that were resolved on the liquid chromatograph (LC) (Fig. 3.23). The three product peaks 
(ArgPt-poly-1, ArgPt-poly-2, and ArgPt-poly-3) were subjected to mass analysis (Fig. 3.24). The 
first product peak (ArgPt-poly-1) has an observed m/z 482 Da/e, which is assigned as a 
bifunctional adduct. This adduct is doubly charged (2+) and consistent with ArgPt coordinated 
with two adjacent residues (Ado-p-Ado) (calculated mass is 964 Da). The second product peak 
(ArgPt-poly-2) has an observed m/z 672 Da/e, which is assigned as a singly charged (+) 
monofunctional adduct. This adduct consists of one ArgPt coordinated to a single Ado residue 
(calculated mass is 671 Da). The third product peak (ArgPt-poly-3) has an observed m/z 647 
Da/e. This is another doubly charged (2+) bifunctional adduct, which is consistent with three Ado 
residues (Ado-p-Ado-p-Ado) coordinated with one ArgPt molecule (calculated exact mass is 1294 
Da). The third Ado residue that is part of this adduct may be present because of incomplete 
digestion by P1 nuclease. 
 
 
Figure 3.23. LC spectrum of ArgPt-poly(Ado) reaction products. Three peaks referred to as 







Figure 3.24. LC-MS spectra of ArgPt-poly(Ado) reaction products. Mass spectra (positive 
mode) of the LC product peaks of ArgPt-poly-1, ArgPt-poly-2, and ArgPt-poly-3 are shown. ArgPt-
poly-1 contains a species assigned as a doubly charged bifunctional adduct (m/z 482 Da/e). 
ArgPt-poly-2 contains a species assigned as the singly charged monofunctional adduct (m/z 672 
Da/e), and ArgPt-poly-3 is assigned as a doubly charged bifuntional adduct with an additional Ado 
residue (m/z 647 Da/e). Representative structures of the adducts are given (p indicates the 
phosphate ester bond). 
 
3.3.2 Structural isomers of AAPt adducts 
In addition to the NMR data, the kinetic trans effect and previously reported theoretical 
calculations were used to propose the structures of the adducts [150]. The adducts likely have 
several structural orientations that allow maximum stability. We propose that AlaPt-Ado, OrnPt-
Ado, and ArgPt-Ado adducts have the trans orientation in which the α-NH2 is trans to the Ado 
platination site (N1, N3, or N7) (Fig. 3.25). In the trans geometry, the AAPt compounds coordinate 





trans to each other. These structures can be used to explain the nucleoside preferences of the 
platinum-based compounds. The selectivity of cisPt for dGuo has been attributed predominantly 
to a strong hydrogen bond between the cisPt ammine ligand and the 6-oxo group of dGuo [27]. 
In contrast, the selectivity of AlaPt, OrnPt, and ArgPt for Ado/dAdo can be explained by a 
hydrogen-bonding interaction unique to the AAPt compounds. The trans adduct structures (e.g., 
trans-Ado-N1 or trans-Ado-N7 in Fig. 3.26) would position the 6-amine of Ado/dAdo to form a 
hydrogen bond with the carboxylate ligand of the AAPt compound. Such interactions would 
stabilize the Ado/dAdo adduct, but are not available for Guo/dGuo, and possibly lead to higher 
reactivities of Ado/dAdo with the three AAPt compounds studied here. Formation of N3 platination 
products are less likely due to lack of a stabilizing hydrogen bond with the position 6 functional 
group of the purine (Fig. 3.26). 
 
Figure 3.25. Representative geometric and constitutional isomers of AAPt-Ado adducts. 
Platination occurs at the N1 or N7 positions (N3 platination is also possible). The platinating 
moiety may have different orientations to position the ligands for favorable interactions with the 






Figure 3.26. Possible adduct structures formed by AAPt with purines. AAPt compounds 
could coordinate at different sites of purine nucleosides forming various isomers and orientations 






Platination by cisPt occurs predominantly at the N7 position of dGuo residues and results 
in formation of bifunctional and monofunctional adducts. In contrast, the AAPt compounds (AlaPt, 
OrnPt, and ArgPt) were observed to form non-canonical adducts by coordinating to multiple sites 
on Ado/dAdo residues, specifically the N1/N3 and N7 positions of the nucleobases. Various 
techniques were employed to identify and characterize these adducts. HPLC was used to identify 
the products formed following the reaction of AAPt compounds with nucleosides or 
oligonucleotides. The products have different retention times on a C18 column compared to free 
nucleoside/oligonucleosides and could be isolated for further analysis. ESI-MS characterization 
was used to identify the composition (i.e., Ado vs. Guo) and types of adducts formed. Each of the 
AAPt compounds reacts with Ado residues and predominantly forms isomeric monofunctional 
adducts with the same m/z and platinum isotopic distribution pattern. Additionally, bifunctional 
and doubly platinated adducts are observed. MALDI-MS and ESI-MS were used to identify the 
types of adducts formed when AAPt compounds platinate short oligonucleotides with single Ado 
residues. Monofunctional and doubly platinated adducts are formed by AAPt compounds with 
these oligonucleotides. NMR spectroscopy was employed in differentiating the isomeric adducts 
formed by AAPt with Ado nucleosides. These isomers vary at their platination sites and could be 
identified based on the chemical shifts of neighboring protons.  
The three compounds coordinate at N1/N3 and N7 positions of Ado residues and the 
resultant adducts adopt several structural orientations. Although methods such as mass 
spectrometry and 1D-NMR spectroscopy were used for identifying the types of adducts formed, 
they give limited information on the structural orientations of the adducts. These orientations can 
be modulated by factors such as steric hindrance and hydrogen-bonding properties. 
Differentiating between N1 and N3 platination was also challenging because these sites have 
similar proximity to H2 proton. However, future studies could employ X-ray crystallography to 






REACTION KINETICS OF AMINO ACID-LINKED PLATINUM(II) COMPOUNDS WITH 
DNA/RNA NUCLEOSIDESǂ AND OLIGONUCLEOTIDES 
ǂNucleoside level kinetic studies are adapted from Kimutai B, He CC, Roberts A, Jones ML, Bao 
X, Jiang J, Yang Z, Rodgers MT, Chow CS (2019) J Biol Inorg Chem 24:985-997.
Abstract 
The diversity of the side chain functional groups together with the contribution of backbone 
atoms of amino acid-linked platinum(II) (AAPt) compounds can modulate their reactivities and 
targets. In this thesis work, the reaction kinetics of alanine-, ornithine-, and arginine-linked 
platinum(II) compounds (AlaPt, OrnPt, and ArgPt, respectively) were determined. Their reactivity 
preferences for DNA/RNA nucleosides and oligonucleotides were examined using pseudo-first-
order kinetics and HPLC analysis. The rate constants reflect the role of chemical structures and 
physical properties of the amino acid functional groups in target residue preferences. The 
oligonucleotide local environment also has an effect on the reactivity of the AAPt compounds. 
4.2 Introduction 
Platination kinetics have been shown to correlate with cellular activity of cisPt and second-
generation analogues [33-36]. For example, cis-diammine-1,1-cyclobutane dicarboxylate 
platinum(II) (carboplatin) is less potent and toxic than cisPt, which is partly attributed to its 100-
fold slower adduct formation with DNA [34]. As noted in Section 1.2.3, the coordination of 
platinum-based compounds with DNA involves a number of steps that contribute to the overall 
reaction rates. Before cisPt reacts with DNA in a cellular setting, it is first aquated to generate cis-
[PtCl(NH3)2(H2O)]+, whereby a chlorido is replaced with H2O [32, 151]. Reactions of the aquated 
cisPt species with DNA then occur under kinetic control, leading to stable adduct formation at the 
preferred dGuo sites [32, 40]. Therefore, kinetic studies can be used to compare the reactivities 
of aquated cisPt and AAPt compounds (Fig. 4.1). For in vitro studies, cisPt or AAPt analogues 





nucleosides or nucleic acids (Scheme 4.1) [32]. A number of AAPt-nucleoside adducts form by 
coordination at the N7 of dGuo/Guo or N1, N3, or N7 positions of dAdo/Ado. By comparing the 
kinetic rate constants (k values) for disappearance of the nucleoside/oligonucleotide over time, 
the target preferences of aquated cisPt and AAPt (i.e., AlaPt, OrnPt, or ArgPt, Fig. 4.1) can be 
determined [152-153, 58]. 
 
Figure 4.1. The structures of cisPt (cisPt) and amino acid-linked platinum(II) compounds, 
AlaPt, OrnPt, and ArgPt. 
 
 
Scheme 4.1. Aquation of platinum compounds and subsequent platination of 







The overall process of cisPt adduct formation such as aquation and DNA platination [34, 
36] is influenced by a number of factors associated with the non-leaving group ligand (typically an 
amine), including coordination type and hydrogen-bonding properties [35-36]. These factors play 
roles in target preferences and the types of adducts that are formed. CisPt reacts with dGuo of 
single- and double-stranded DNA leading to formation of kinetically inert adducts [35, 27, 44]. The 
adduct forms when the aqua ligand is substituted by a nucleobase atom via a trigonal-bipyramidal 
transition state [45] (Scheme. 4.2). Hydrogen bonding is implicated in the kinetic control of 
platination [36, 46] and can stabilize the transition state of the aquated cisPt-dGuo reaction [27]. 
More specifically, computational analysis showed that in the transition state, cisPt forms a strong 
hydrogen bond between its ammine ligand and the oxo at the 6 position of dGuo [27]. As such, 
this hydrogen-bonding interaction together with charge-charge interactions results in preferential 
coordination of cisPt to dGuo [27]. In contrast, formation of the cisPt-Ado adduct is less favored 
because Ado has an amine at the 6 position, which cannot hydrogen bond with cisPt [27]. 
 
Scheme 4.2. Associative substitution mechanism of cisPt coordination with dGuo. 




In this thesis work, the reaction kinetics of three AAPt compounds were examined to 





amino acid relate to reactivity and nucleoside preference. Pseudo-first-order kinetics were used 
to compare the reactivity of the three AAPt compounds with purine nucleosides. The hypothesis 
is that modification of cisPt with amino acid ligands of varying sizes and charges would alter the 
reaction kinetics and nucleic acid target preferences. Influence of the oligonucleotide local 
environment was also investigated since the nucleotides surrounding the target nucleotide may 
modulate the binding kinetics of cisPt and AAPt and lead to different platination rates and profiles. 
The impact of this local environment was determined by comparing the reactivities and 
preferences of AAPt compounds with oligonucleotides and nucleosides. The oligonucleotide 
sequences chosen were 5′-UUAUU-3′ for RNA and 5′-d(TTATT)-3′ for DNA. These sequences 
were selected because cisPt and AAPt compounds have low reactivity with Thd (dT) or Urd (U) 
residues [106, 138]. Therefore, the presence of only one preferred residue (Ado (A) or dAdo (dA)) 
directs the platination to a single site. By excluding competing reactivity with the flanking residues, 
the influence of the oligonucleotide local environment on platination at the preferred residue can 
be analyzed. Understanding reactivity and selectivity of platinum-based compounds at both the 
nucleoside and oligonucleotide level is needed to drive the development of new compounds that 
target alternative biological residues or molecules such as RNA [55, 29, 154]. This approach could 
potentially be important in achieving improved cellular activities and effectiveness. 
 
4.3 Results and discussion 
4.3.1 Kinetics of platination reactions with DNA/RNA purine nucleosides 
The reactions of (deoxy)nucleosides with the monoaquated AAPt compounds result in the 
formation of one or more adducts with longer (AlaPt and ArgPt adducts) or shorter (OrnPt adducts) 
retention times on a C18 column relative to the unreacted (deoxy)nucleosides (Fig. 3.3, Section 
3.3.1). The adduct characterization was described in previous chapter (Section 3.3.1). In 
summary, monoaquated AlaPt, OrnPt, and ArgPt each reacts with Guo to form one major product 





contrast, platination of Ado leads to formation of multiple adducts. Monoaquated AlaPt reacts with 
Ado to form two main products, AlaPt-AdoN1/N3 and AlaPt-AdoN7. Monoaquated OrnPt also reacts 
with Ado to form two major products, OrnPt-AdoN1/N3 and OrnPt-AdoN7. Monoaquated ArgPt reacts 
with Ado to form three major products, ArgPt-AdoN1/N3, ArgPt-AdoN7, and ArgPt-Adomix, which have 
longer retention times than Ado. The subscripts refer to coordination sites at the adducts. The 
rate of formation of products varies depending on the identity of the AAPt compound and the 
target nucleoside. By monitoring the rates of formation of products, the rate constants (k values) 
and reactivity preference of each platinum compound can be determined. 
Kinetic rate constants (k values) were used to reveal the preferred target nucleoside of 
each AAPt compound relative to cisPt. Under pseudo-first-order reaction conditions for the 
monoaquated AAPt (or cisPt) and purine nucleosides, the peak areas of the unreacted 
nucleosides were monitored by HPLC and observed to decrease with time (Fig. 4.2). The rate of 
decrease of the peak area corresponding to the unreacted nucleoside (Ado, Guo, dAdo, or dGuo) 
varies, depending on the identity of the platinum compound (monoaquated AlaPt, OrnPt, or 
ArgPt). As described in Section 2.4.7, the peak area of the nucleoside at each time point can be 
integrated quantitatively, plotted, and fitted to an exponential decay equation (Eq. 4.1) to extract 
the pseudo-first-order rate constant (k). 
[Nuo]t = e-
kt + [Nuo]0   (Eq. 4.1) 
From Eq. 4.1, [Nuo]t is the concentration of unreacted nucleoside or oligonucleotide at time t, and 
[Nuo]0 is the initial concentration of unreacted nucleoside or oligonucleotide. When [Nuo]t is 
plotted against t, the decay factor is k. The k values for each AAPt analogue with DNA/RNA 






Figure 4.2. Reaction rates of monoaquated AlaPt, OrnPt, and ArgPt with purine 
nucleosides. Representative kinetic traces of reactions of monoaquated AlaPt, OrnPt, or ArgPt 
with the purine nucleosides showing the fraction of the unreacted nucleoside diminishing over 






Table 4.1. Pseudo-first-order rate constants, k (μs-1)a 
  dGuo Guo dAdo Ado 
cisPt
b
 49±1 25±2 6±1 6±2 
AlaPt
b
 19±7 9±4 176±9 9±4 
OrnPt
b
 20±1 24±1 125±1 100±1 
ArgPt
b
 23±2 25±1 115±15 108±1 
           a triplicate runs in 25 mM Na2HPO4/NaH2PO4 buffer (pH 7) at 37 °C; 




Figure 4.3. Comparisons of rate constants (k) for reaction of monoaquated cisPt (grey) and AAPt 
compounds (monoaquated AlaPt, green; monoaquated OrnPt, orange; monoaquated ArgPt, 
violet) with DNA/RNA purine nucleosides (dGuo, Guo, dAdo, and Ado) are shown. 
 
CisPt is known to preferentially target dGuo over other residues of DNA [38, 33, 101, 41]. 
This selectivity was confirmed here with the nucleoside-level kinetic studies, in which the highest 
reaction rate constant (k) of aquated cisPt is with dGuo (49 × 10-6 s-1) (Table 4.1). The reactivity 
of monoaquated cisPt with Guo, dAdo, and Ado is lower than dGuo by two- to eight-fold. The 
AAPt compounds display a wide range of reactivities as shown in Fig. 4.3. The highest reactivity 
of monoaquated AlaPt is with dAdo (176 × 10-6 s-1), which is nine to twenty-fold higher than that 




reactivity of monoaquated AlaPt is strongly influenced by both the identity of the purine base as 
well the functional group at the 2′ position (e.g., H or OH), with a preference for dAdo over Ado. 
The highest reaction rates for OrnPt are with dAdo and Ado (125 × 10-6 s-1 and 100 × 10-6 s-1, 
respectively). These rates of reactions for monoaquated OrnPt with Ado/dAdo are four- to six-fold 
higher than reactions with Guo/dGuo (Table 4.1 and Fig. 4.3), demonstrating its preference for 
the adenine moiety. The highest reactivity of monoaquated ArgPt is with dAdo and Ado (115 × 
10-6 s-1 and 108 × 10-6 s-1), which is four- to five-fold higher than its reactivity with Guo/dGuo, and 
demonstrates that monoaquated ArgPt also has a preference for the adenine moiety (Table 4.1 
and Fig. 4.3). 
 
4.3.2 Kinetics of platination reactions with DNA/RNA oligonucleotides 
CisPt reacts with DNA and RNA constructs by preferentially targeting the Guo/dGuo 
residues. The reactivity of cisPt is modulated by the local conditions such as salt concentrations 
and pH [155-156, 49]. Previous literature reports and work from our lab focused on the reaction 
kinetics of cisPt with various DNA and RNA constructs. Representative k values are shown in 
Table 4.2. These values vary depending on the type of DNA/RNA construct and the conditions 
(i.e., salt concentration, buffer type, etc.) of the experiments. Kinetic experiments with cisPt often 
employ sequences with dGuo/Guo residues due to its preference for such residues. In this thesis 
work, the reaction of cisPt (and AAPt compounds) with DNA/RNA constructs that do not have 
dGuo/Guo residues, but instead have dAdo/Ado as the target sites were investigated. 
The monoaquated cisPt or AAPt compounds react with DNA and RNA oligonucleotides 
(5′-d(TTATT)-3′ and 5′-UUAUU-3′, respectively), resulting in formation of multiple product peaks 
with longer retention times on a C18 column relative to the unreacted oligonucleotides (Fig. 4.4). 
Multiple peaks result from formation of different types of adducts (e.g., monofunctional and doubly 
platinated). Monoaquated cisPt reacts with the RNA oligonucleotide to form one major product, 




with the RNA oligonucleotide to form two major products, that have longer retention times than 
the free RNA on C18 (Fig. 4.4B). These AlaPt-UUAUU products likely have decreased polarity 
due to the associated alanine ligand, leading to longer retention times compared to those of 
unreacted oligonucleotide. Monoaquated OrnPt reacts with 5′-UUAUU-3′ to form three products, 
which also have longer retention times on a C18 column relative to the unreacted oligonucleotides 
(Fig. 4.4C). Similarly, monoaquated ArgPt reacts with the RNA oligo to form three products that 
also have longer retention times on a C18 column relative to the free oligonucleotides (Fig. 4.4D). 
Factors that could increase the retention time of platinated oligonucleotides relative to the free 
oligonucleotides include neutralization of the oligonucleotide local charge by platinum 
compounds, structural changes, and increased size of the oligonucleotide after platination. 
 
Table 4.2. Rate constants of cisPt reactions with various DNA/RNA constructs 
  sequence  
k values  
(x10-4 s-1) [ref]   conditions   
RNA 5′-CGCGUUGUUCGCG-3′ 4.4 ± 0.4 [49] 35 mM Na+, pH 6.0, 37 °C 
     
DNA 5′- (T)10-GG-(T)10-3′ 7.4 ± 0.8 [156] 
10 mM K+, 5 mM Na+, 
pH 6.2, 37 °C 
    
RNA 5′- (U)10-GG-(U)10-3′ 3.3 ± 0.7 [156] 
10 mM K+, 5 mM Na+, 
pH 6.2, 37 °C 
     
DNA 5′- (T)10-GG-(T)10-3′ 24 ± 5 [156] 
10 mM K+, 20 mM Na+, 
pH 6.2, 37 °C 
    
RNA 5′- (U)10-GG-(U)10-3′ 33 ± 10 [156] 
10 mM K+, 20 mM Na+, 
pH 6.2, 37 °C 
     
RNA 5′-GGCCGΨAACΨAΨAACGGUC-3′ 13.3 ± 0.9 [155] 
10 mM K+, 20 mM Na+, 
pH 6.2, 37 °C 
     
RNA 5′-GCAGGAUUAGAUACCCUGC-3′ 16.2 ± 1.1 [155] 
10 mM K+, 20 mM Na+, 






Figure 4.4. HPLC analysis (C18) of platinated RNA products. The adduct profiles following 
reactions of 5′-UUAUU-3′ with monoaquated cisPt (A), AlaPt (B), OrnPt (C), and ArgPt (D) are 
given. Multilple product peaks (indicated in the figure) are formed during the reactions. The 
reaction times are indicated and the controls (unreacted oligonucleotides with buffer, black 






Figure 4.5. HPLC analysis (C18) of platinated DNA products. The adduct profiles following 
reactions of 5′-d(TTATT)-3′ with monoaquated cisPt (A), AlaPt (B), OrnPt (C), and ArgPt (D) are 
given. Multilple product peaks (indicated in the figure) are formed during the reactions. The 
reaction times are indicated and the controls (unreacted oligonucleotides with buffer, black 
asterisks) are shown as the top traces. Some minor peaks with short retention time were also 





Figure 4.6. Reaction rates of AlaPt, OrnPt, and ArgPt with RNA and DNA oligonucleotides. 
Kinetic traces of reactions of monoaquated cisPt, AlaPt, OrnPt, or ArgPt with RNA and DNA 
oligonucleotides showing the fraction of unreacted oligonucleotide diminishing over time. 5′-
UUAUU-3′ is represented by a solid line and 5′-d(TTATT)-3′ is represented by a dashed line. 
 
Similarly, AAPt compounds (and cisPt) react and form products with DNA oligos (Fig. 4.5). 
The number of products and their retention time in relation to free oligonucleotides are similar to 
reactions with RNA oligonucleotides. AlaPt reacts with 5′-d(TTATT)-3′ to form one main product, 




with 5′-d(TTATT)-3′ to form three major products, which have longer retention times than the free 
DNA oligo on the C18 column (Fig. 4.5C). Monoaquated ArgPt also reacts with 5′-d(TTATT)-3′ to 
form three major products that have longer retention times than the unreacted DNA oligo (Fig. 
4.5D). 
The k values were used to compare the reactivities of cisPt and each AAPt compound 
with the oligonucleotides. Similar to the nucleoside level analysis, the peak areas of the 
oligonucleotides at each time point can be integrated quantitatively, plotted, and fitted to an 
exponential decay equation (Eq. 4.1) to extract the pseudo-first-order rate constants (k values). 
The HPLC peak areas of the unreacted oligonucleotides (5′-UUAUU-3′ or 5′-d(TTATT)-3′) were 
monitored and observed to decrease at different rates depending on the identity of the platinum 
compound (monoaquated cisPt, AlaPt, OrnPt, or ArgPt) (Fig. 4.6). The k values for each AAPt 
analogue with the oligonucleotides are summarized in Table 4.3 and shown graphically in Fig. 
4.7. 
 
Table 4.3. Pseudo-first-order rate constants, k (x10-4 s-1)a 
  5′-d(TTATT)-3′ 5′-UUAUU-3′ 
cisPt
b
 3.2 ± 0.1 5.0 ± 0.1 
AlaPt
b
 7.9 ± 0.1 7.5 ± 1.2 
OrnPt
b
 8.0 ± 0.5 17.7 ± 2.1 
ArgPt
b
 8.7 ± 0.2 7.4 ± 0.8 
           a triplicate runs in 25 mM Na2HPO4/NaH2PO4 buffer (pH 7) at 37 °C; 







Figure 4.7. Comparison of reactivity of platinum-based compounds with oligonucleotides. 
The rate constants (k) for reaction of monoaquated cisPt, AlaPt, OrnPt, and ArgPt with DNA 
oligonucleotides and RNA oligonucleotides are shown. 
 
A comparison of the k values for cisPt with the chosen RNA (5.0 × 10-4 s-1) and DNA (3.2 
× 10-4 s-1) oligonucleotides indicates that cisPt is moderately selective in its reactivity with the two 
nucleic acids (less than two-fold difference) under low salt conditions (25 mM 
Na2HPO4/NaH2PO4). The k values for reaction kinetics of cisPt with the chosen sequences are in 
the same range as other reported literature values and previous work in our lab, with variation 
that is consistent with the preferred targets of cisPt and salt conditions (Tables 4.2 and 4.3) [155-
156, 49]. Based on the k values, cisPt reactivity with 5′-UUAUU-3′ or 5′-d(TTATT)-3′ is relatively 
lower compared to its reactivity with constructs that have Guo/dGuo residues. This is not 
surprising due to the preference of cisPt for Guo residues [33, 38, 101, 41]. Compared to the three 
AAPt compounds, cisPt has the lowest k values when reacting with 5′-UUAUU-3′ and 5′-
d(TTATT)-3′ because of the lack of its preferred Guo/dGuo target in the sequences (Table 4.3). 
  The range of k values for the reactions of AAPt compounds with oligos are as shown in 
Fig. 4.7. The AAPt compounds are generally more reactive than cisPt with the chosen DNA/RNA 




also observed when the compounds react with nucleosides (Section 4.3.1). Monoaquated AlaPt 
has similar reactivity with both DNA and RNA oligonucleotides (7.9 × 10-4 s-1 and 7.5 × 10-4 s-1, 
respectively) (Table 4.3 and Fig. 4.7). Monoaquated OrnPt exhibits a two-fold preference for RNA 
over DNA with k values of 17.7 × 10-4 s-1 and 8.0 × 10-4 s-1, respectively (Table 4.3 and Fig. 4.7) 
demonstrating its preference for the ribose moiety. The functional group at the 2′ position (e.g., H 
or OH) of the nucleic acid appears to influence the OrnPt reactivity.  The k values of monoaquated 
ArgPt with DNA and RNA oligonucleotides are similar (8.7 × 10-4 s-1 and 7.4 × 10-4 s-1, 
respectively). 
There is generally higher reactivity between AAPt compounds with RNA/DNA 
oligonucleotides than with free nucleosides, as exhibited by the increased k values in the 
oligonucleotide level reactions (Tables 4.1 and 4.3). The oligonucleotide local environment 
enhances reactivity of the AAPt compounds, likely due to factors such as negatively charged 
phosphate groups that attract the positively charged side chains of OrnPt and ArgPt. The 
backbone phosphate group of the oligonucleotides could also provide hydrogen-bond acceptors 
that stabilize interactions with the AAPt compounds. AlaPt exhibits discrimination between Ado 
and dAdo at the nucleoside level (Table 4.1) likely because its reactivity is more strongly 
influenced by the functional group at the 2′ position (e.g., H or OH). This influence is minimized 
at the oligonucleotide level where the phosphate backbone may have a larger influence on 
reactivity. Similar reactivity is observed for AlaPt with 5′-UUAUU-3′ and 5′-d(TTATT)-3′ 
oligonucleotides. In contrast, OrnPt does not discriminate between Ado and dAdo nucleosides, 
but has a two-fold higher reactivity with 5′-UUAUU-3′ than with 5′-d(TTATT)-3′. This result implies 
that the presence of a backbone phosphate group, along with other factors (e.g., the functional 
group at the 2′ position), plays a role in either diminishing or amplifying the selectivity of AAPt 







CisPt preferentially coordinates with dGuo residues, which is correlated with its anticancer 
activity [33, 38, 101]. Finding platinum-based compounds that preferentially platinate alternative 
targets has been an attractive goal, but has yielded little success to date. In this thesis work, 
platinum-based compounds AlaPt, OrnPt, and ArgPt have been shown to exhibit kinetic 
preferences for Ado/dAdo residues. These monoaquated AAPt compounds exhibit altered 
reactivity and different nucleoside preferences compared to monoaquated cisPt. OrnPt exhibits a 
greater than five-fold increase in reactivity with Ado/dAdo nucleosides over Guo/dGuo, and AlaPt 
has over nine-fold higher selectivity for dAdo over all other purines. The AAPt compounds exhibit 
unique differences in their reactivity by having altered preferences with non-canonical targets of 
cisPt. These differences suggest that the mode of amino acid coordination (e.g., N vs. O) plays a 
role in modulating the rate of reactivity. While cisPt only has only (N,N) type of binding, the amino 
acid complexes can have (N,O) or (N,N) coordination. 
The AAPt compounds have generally an increased reactivity with oligonucleotides 
compared to nucleosides. The local environment flanking the target residues in a DNA or RNA 
oligonucleotide, such as phosphate groups with associated cations, likely enhances the binding 
kinetics of cisPt and AAPt. The negatively charged phosphate groups can interact favorably with 
positively charged AAPt compounds or provide hydrogen bond acceptors that stabilize the 
interactions of AAPt compounds with their targets. OrnPt has a two-fold higher preference for 
RNA oligonucleotides over DNA, demonstrating that certain features of platinum-based 
compounds could modulate selective targeting of one nucleic acid over another. This preference 
could also be important in the development of compounds that target either DNA or RNA with 
high selectivity. 
HPLC fitted with a C18 column has been used previously to monitor kinetic reactions of 
platinum-based compounds with their targets and to extract rate constants [138, 157].  In this 




nucleic acid targets. The rate constants were extracted after plotting the ratio of diminishing 
reactants as a function of time. Although the formation of individual AAPt-nucleoside or AAPt-
oligonucleotide products could also be monitored, the identification of their rate of formation was 
challenging since one adduct could be converted to another type of adduct during the course of 
reaction (e.g. a monofunctional adduct converting into a bifunctional adduct). In the future, this 
method could be modified to include an internal standard so as to ascertain and correct for 
variability between injections. There are other alternative methods such as NMR spectroscopy 
and mass spectrometry that could also be used to monitor kinetic reactions and extract rate 
constants [32, 34, 149, 158]. These methods could be used to confirm the reaction kinetics and 
selectivity of AAPt compounds with their targets. 
The AAPt compounds studied here have altered selectivity compared to cisPt and are 
therefore candidates for an alternative pathway of cytotoxicity that could involve non-canonical 
targets such as dAdo residues of DNA as well as Ado residues of RNA. Since platination of 
biomolecules such as proteins are often overlooked [30, 61-62], AAPt compounds may also have 
















IMPACT OF AMINO ACID-LINKED PLATINUM(II) COMPOUNDS ON GLYCOSIDIC BOND 
STABILITY OF ADDUCTSǂ 
ǂAdapted from Kimutai B, He CC, Roberts A, Jones ML, Bao X, Jiang J, Yang Z, Rodgers MT, 
Chow CS (2019) J Biol Inorg Chem 24:985-997 
 
5.1 Abstract 
Destabilization of glycosidic bonds accelerate depurination and formation of abasic sites 
in nucleic acids, which could ultimately contribute to cell cytotoxicity. Unstable glycosidic bonds 
can be caused by a change in chemical composition of the nucleoside due to modifications. 
Platination of deoxyguanosine (dGuo) residues by cisplatin (cisPt) has been reported to have no 
destabilizing effect on the adduct glycosidic bonds. However, changes in stabilization may occur 
in non-canonical target residues that are modified by other platinum-based analogues. Amino 
acid-linked platinum(II) (AAPt) compounds of alanine, ornithine, and arginine (AlaPt, OrnPt, and 
ArgPt, respectively) have unique reactivities that result in altered preferences for adenosine (Ado) 
or deoxyadenosine (dAdo) residues. The compounds predominantly form monofunctional 
adducts by reacting at the N1, N3, or N7 positions of purine nucleobases. Features of the AAPt 
compounds that impact glycosidic bond stability of Ado residues were explored in this chapter. 
The glycosidic bond cleavage of the adducts was investigated using energy-resolved collision-
induced dissociation (ER-CID) tandem mass spectrometry and survival yield analysis (in 
collaboration with Dr. M.T. Rodgers’ lab). Our results indicate that glycosidic bond cleavage is 
activated differentially for AlaPt-Ado and OrnPt-Ado isomers. Formation of unique adducts at non-
canonical residues and subsequent destabilization of the glycosidic bonds are important features 







Modification of nucleic acid residues may have unique influences on the chemical 
properties of nucleosides such as bond strengths. Alkylation or protonation of DNA residues have 
previously been reported to weaken the glycosidic bonds and accelerate the process of 
depurination [115-118]. Hydrolytic instability of purine glycosidic bonds may impact nucleoside 
integrity, particularly under varying pH and ionic strength conditions and modification states [116, 
119-121]. Stability of the glycosidic bonds is important for maintaining the integrity of nucleic acids 
and crucial for cell viability [159-160]. Previous experiments with N-glycosydases showed that 
hydrolytic cleavage of particular Ado glycosidic bonds in rRNA is toxic, as it causes inactivation 
of the ribosome [159].  
In a previous theoretical study, evaluation of the effects of cisPt modification indicated that 
platination at N7 does not impact stability of the dGuo glycosidic bond [26]. However, platination 
of nucleic acids by other cisPt analogues may have an impact on glycosidic bond strengths. To 
the best of our knowledge, the influence of platination on the glycosidic bonds of dAdo or Ado 
adducts has not been investigated, likely because cisPt and other platinum-based compounds 
coordinate preferentially with dGuo (or Guo) residues. AAPt compounds, including AlaPt, OrnPt, 
and ArgPt, have reactivity preferences for Ado and dAdo residues (discussed in Chapters 3 and 
4). A previous report from our lab also showed that OrnPt has the ability to modify Ado residues 
in folded RNA [106]. We therefore sought to evaluate the relative glycosidic bond strengths of 
these non-canonical structures. 
Structural and chemical features of platinum-based compounds could determine the 
extent of glycosidic bond stability once coordination with a nucleotide occurs. For AAPt 
compounds, the type of side chain and the backbone atoms may affect stability of the adduct. 
Glycosidic bond strength may also be affected differentially depending on the position of the 
nucleobase at which the AAPt compounds platinate. The reactions of monoaquated AAPt 




constitutional isomers vary at the sites at which platination occurs, including N1, N3, or N7 
positions (Fig. 5.1). Understanding the features that promote glycosidic bond destabilization in 
nucleic acids is important for development of analogues that trigger unique cytotoxic responses 
not exhibited by cisPt [55, 29, 154]. Possible destabilization that activates cleavage of the 
glycosidic bonds in AAPt-Ado adducts could also be exploited as a therapeutic pathway against 
cisPt resistant cancer cells. This is also potentially useful in understanding features of platinum-
based drug candidates that have improved cellular activities and effectiveness in cancer cells. 
 
 
Figure 5.1 Structure of monofunctional AAPt-Ado adduct. The AAPt compounds (AlaPt, 
OrnPt, or ArgPt) can coordinate at the N1, N3, or N7 position of nucleobase forming constitutional 
isomers. The glycosidic bond of the adduct is shown. 
 
In this collaborative project, I first carried out the synthesis of AAPt compounds followed 
by reactions with Ado nucleosides as described in Chapter 2. Using HPLC fitted with a C18 




spectroscopy characterization and subsequent tandem mass spectrometry analysis. Energy-
resolved collision-induced dissociation (ER-CID) tandem mass spectrometry and survival yield 
analysis was carried out by Dr. C. C. He in Dr. M. T. Rodgers’ lab. 
ER-CID tandem mass spectrometry and survival yield analysis have been used previously 
to investigate glycosidic bond stabilities [116, 122-125]. In this thesis work, the techniques were 
also applied to investigate the impact of AAPt coordination on relative glycosidic bond strengths. 
In ER-CID tandem mass spectrometry, isolated HPLC fractions containing the nucleoside-
platinum adducts are first ionized in the ESI source. The nucleoside-platinum precursor ions are 
mass selected and guided into the ion trap where cleavage of adduct ions is activated using ER-
CID. This step is followed by mass analysis and detection of the resultant fragments (Fig. 5.2). 
Survival yield analysis is a method that monitors the fragmentation patterns of ions as a function 
of excitation voltage [142]. The setup of ER-CID experiments and survival yield analysis was 




Figure 5.2. Schematic representation of the ER-CID experiment. HPLC 
isolated adduct fractions are ionized in the ESI source. Precursor ions are mass 
selected in MS1 and guided into the ion trap where they are fragmented by ER-








5.3 Results and discussion 
5.3.1 Non-canonical AAPt-Ado adduct isomers and their differential fragmentation patterns 
The reactions of Ado with the monoaquated AAPt compounds result in the formation of 
more than one product as discussed in Chapter 3. These products were separated by HPLC 
using a C18 column (Chapter 3, Fig. 3.3B). Characterization of the HPLC isolated products using 
mass spectrometry and NMR spectroscopy were discussed in Section 3.3.1.  
The fragmentation pattern of these adducts and the stability of their glycosidic bonds can 
be affected differentially depending on the type of amino acid ligand linked to the platinum center 
of the AAPt compound. Furthermore, isomers can also exhibit differences in stability dictated by 
the site of platination (N1, N3, or N7). Cleavage of AAPt-AdoN1/N3 and AAPt-AdoN7 isomers was 
activated through CID and composition of the fragments was determined by using tandem mass 
spectrometry in which several fragmentation products (both charged and neutral) could be 
formed, depending on the bond stability (Fig. 5.3). 
 
Figure 5.3. Activation of AAPt-Ado adduct towards cleavage. Activation by CID of the 
precursor ion results in cleavage of different bonds including the glycosidic bond. Charged and 
neutral fragments are formed, depending on which functional groups are lost. 
 
Despite having different platination sites, the N1/N3 and N7 adducts of AlaPt-Ado produce 
comparable fragmentation patterns with a major fragment (m/z: 454.036 Da) formed by loss of 




proton transfer of H2' to the nucleobase [120]. Minor neutral losses of HCl, H2O, and [Pt(Ala)(Cl)–
H] from AlaPt-AdoN1/N3 (m/z: 550.101, 532.091 and 268.104 Da, respectively) are also observed.  
In contrast to the AlaPt-Ado adducts, fragmentation patterns of the OrnPt-Ado adducts 
vary between the isomers, despite being subjected to similar fragmentation conditions (Fig. 5.5). 
Two groups of fragments are observed in each CID mass spectrum. The first group contains 
fragments formed by loss of neutral molecules of NH3, HCl, and (NH3 + HCl) from OrnPt-Ado (m/z: 
612.080, 593.130, and 576.103 Da, respectively); the second group corresponds to fragments 
involving glycosidic bond cleavage ions resulting in loss of the ribose sugar and the same neutral 
losses (m/z: 497.063, 480.036, 461.085, and 444.058 Da, respectively). For OrnPt-AdoN1/N3, both 
groups have approximately the same intensity, whereas for OrnPt-AdoN7, the second group of 
fragments dominate. This result indicates a difference in the overall stability of the glycosidic 
bonds of these two OrnPt-Ado isomers. 
 
Figure 5.4. CID fragmentation patterns of AlaPt-Ado adducts. AlaPt-AdoN1 (or AlaPt-AdoN3) 
and AlaPt-AdoN7 fragmentation patterns are shown. The spectra were obtained by Dr. C. C. He 






Figure 5.5. CID fragmentation patterns of OrnPt-Ado adducts. OrnPt-AdoN1 (or OrnPt-AdoN3) 
and OrnPt-AdoN7 fragmentation patterns are given. The spectra were obtained by Dr. C. C. He in 
Dr. M. T. Rodgers’ lab. 
 
Similar to the OrnPt-Ado adducts, fragmentation patterns of the ArgPt-Ado adducts also 
vary between the isomers, despite being subjected to similar fragmentation conditions (Fig. 5.6). 
Two groups of fragments are also observed in each CID mass spectrum. The first group contains 
fragments formed by loss of neutral molecules of H2O, HCl, and CH4N2O from ArgPt-Ado (m/z: 
653.131, 635.165, and 611.110 Da, respectively); the second group corresponds to fragments 
involving glycosidic bond cleavage ions resulting in loss of the ribose sugar and the same neutral 
losses (m/z: 539.099, 521.088, 503.123, and 479.067 Da, respectively). For ArgPt-AdoN1/N3, both 
groups have a wide range of intensities, with the loss of CH4N2O being the most intense. For 
ArgPt-AdoN7, both groups have a wide range of intensities, but the loss of the sugar is more 
dominant. This result indicates a difference in the overall stability of the glycosidic bonds of these 





Figure 5.6. CID fragmentation patterns of ArgPt-Ado adducts. ArgPt-AdoN1 (or ArgPt-AdoN3) 
and ArgPt-AdoN7 mass spectra are shown. The spectra were obtained by Dr. C. C. He in Dr. M. 
T. Rodgers’ lab. 
 
5.3.2 Differential activation of AAPt-Ado isomers towards glycosidic bond cleavage 
Glycosidic bond survival yield analysis employing ER-CID tandem mass spectrometry has 
been used previously to study relative stabilities of the glycosidic bonds in the context of 
cationization and protonation of purine (deoxy)nucleosides [120, 124, 161-162]. In this study, we 
aimed at investigating the glycosidic bond stabilities of AAPt-nucleoside adduct isomers. First, I 
carried out reactions of AAPt compounds with Ado and isolated the adducts by HPLC using a 
C18 column. This was followed by survival yield analysis carried out by Dr. C. C. He. Glycosidic 




platination site) were compared in order to determine their relative glycosidic bond stabilities. 
Because the adducts are isomers, they have an equal number of atoms and degrees of freedom, 
and thus internal energy and dissociation lifetime effects on the fragmentation should be very 
similar such that differences in the survival yield can be directly correlated to glycosidic bond 
stability. The two OrnPt-Ado adducts were compared in a similar fashion. 
 
Figure 5.7. Glycosidic bond survival yield curves of AlaPt adduct isomers. Glycosidic bond 
survival yield curves of AlaPt-AdoN1/N3 in red and AlaPt-AdoN7 in blue.  The spectrum was obtained 
by Dr. C. C. He in Dr. M. T. Rodgers’ lab.  
 
Fits to the survival yield curves of the AlaPt-Ado isomers produce GBC50% values for AlaPt-
AdoN1/N3 and AlaPt-AdoN7 of 0.099 V and 0.085 V, respectively (Fig. 5.7). Platination in both 
isomers activates dissociation primarily through cleavage of the glycosidic bond with 95% and 
100% of the fragmentation of AlaPt-AdoN1/N3 and AlaPt-AdoN7 occurring via glycosidic bond 
cleavage, respectively, i.e., neutral losses account for 5% or less of the dissociation behavior for 
both AlaPt-Ado isomers. Trends in the GBC50% values indicate that N7 platination is more 




The GBC50% values determined for OrnPt-AdoN1/N3 and OrnPt-AdoN7 are much larger, 
0.364 V and 0.351 V, respectively (Fig. 5.8). The trend in these values again indicates that N7 
platination activates the glycosidic bond more effectively than N1/N3 coordination of platinum. 
Furthermore, both OrnPt-Ado adducts exhibit significant competition between glycosidic bond 
cleavage and neutral loss pathways. Indeed, neutral loss pathways account for 60% and 10% of 
dissociation for OrnPt-AdoN1/N3 and OrnPt-AdoN7 adducts, respectively. Because AlaPt and OrnPt-
Ado differ in size, direct comparison of GBC50% values may be problematic, but the large shifts in 
these values determined for the AlaPt-Ado vs. OrnPt-Ado adducts strongly suggest that binding 
of AlaPt activates the glycosidic bond more effectively than OrnPt binding. The increased 
competition with the neutral loss pathways in OrnPt-Ado compared to AlaPt-Ado adducts also 
supports this conclusion.  
 
Figure 5.8. Glycosidic bond survival yield curves of OrnPt adduct isomers. Glycosidic bond 
survival yield curves of OrnPt-AdoN1/N3 in red and OrnPt-AdoN7 in blue. The spectrum was obtained 





The survival yield analysis of ArgPt-Ado isomers (ArgPt-AdoN1/N3 and ArgPt-AdoN7) will be 
performed in the future. Because of the observed difference in CID fragmentation pattern (Fig. 
5.6), they are predicted to have different behaviors in their glycosidic bond cleavage and neutral 
loss pathways. 
The difference in stability between the adduct isomers suggests that two factors can 
influence the glycosidic bond stability, the type of amino acid ligand linked to the platinum center, 
and the site at which the AAPt coordinates with the nucleoside. Platination by monoaquated AlaPt 
results in adduct isomers that have relatively lower glycosidic bond stabilities than adduct isomers 
formed by monoaquated OrnPt. The fact that N7 platination by AlaPt and OrnPt results in lower 
adduct glycosidic bond stability compared to N1 (or N3) platination suggests that the closer the 
proximity of the platination site to the ribose sugar, the greater the destabilization of the glycosidic 
bond. Protonation or platination modifications on the nucleoside can accelerate the depurination 
reaction by reducing the transition state energy [26]. The ligands of AlaPt or OrnPt may cause 
electron-density withdrawal at the N9 position in a manner that is dependent on proximity of the 
platinum atom. In the future, further tandem mass spectrometry and spectroscopic studies, 
including computational analysis, will be performed in an effort to elucidate detailed mechanisms 
for glycosidic bond cleavage of the N7 and N1/N3 AlaPt , OrnPt, and ArgPt adduct species, as 
done previously with both standard and modified nucleosides [116, 120, 163] . 
5.4 Conclusions 
Enzymatic cleavage of Ado glycosidic bonds in RNA and subsequent depurination are 
lethal to cells [159, 164]. Alternatively, cleavage through activation of glycosidic bonds could lead 
to fragmentation of nucleic acids [115-118]. In this collaborative work with Rodgers’ laboratory, 
glycosidic bond survival yield analysis was applied to determine the impact of AAPt coordination 
on the relative glycosidic bond strength of an RNA-based nucleoside, Ado. When either AlaPt or 
OrnPt coordinate to the N7 position of Ado, they destabilize the glycosidic bond to a greater extent 




the resulting AlaPt-Ado adduct via cleavage of the glycosidic bond. In contrast, OrnPt is less 
activating of the glycosidic bonds such that fragmentation of OrnPt-Ado also involves other neutral 
loss pathways. Such activation of AAPt-Ado adducts is particularly important considering that 
cisPt is reported to have no destabilizing effect on the glycosidic bonds of target dGuo residues 
[26]. Within a biological context, AlaPt and OrnPt could potentially exert destabilization of 
glycosidic bonds in nucleic acid residues and lead to abasic sites. Formation of abasic sites, 
especially in RNA, could possibly trigger apoptosis, as well as provide an alternative pathway of 
cytotoxicity that circumvents cisPt resistance. The variation in the influence of AlaPt and OrnPt 
on Ado also highlights the importance of structure for other classes of platinum-based drugs in 





















POTENCY AND ACCUMULATION OF AMINO ACID-LINKED PLATINUM COMPOUNDS IN 
HUMAN CANCER AND NORMAL CELLS 
 
6.1 Abstract 
Although cisplatin (cisPt) is widely used for treatment of a variety of cancer types, its 
therapeutic application has major drawbacks due to resistance, adverse toxicity, and reduced 
accumulation. Second generation analogues including carboplatin and oxaliplatin have reduced 
toxicity and resistance, but have low potency compared to cisPt. It is therefore important to 
develop more ideal platinum-based compounds that balance between potency, selectivity for 
cancer cells, and reduced toxicity in normal cells. Amino acid-linked platinum(II) (AAPt) 
compounds including AlaPt, OrnPt, and ArgPt provide another class of metal-based compounds 
with oral drug-like features that conform with Lipinski rules. At the molecular level, these 
compounds have been demonstrated to have altered reactivity preferences and form non-
canonical adducts compared to cisPt. The altered reactivity preference could translate to unique 
activity at the cellular level that triggers different cytotoxic responses in cancer and normal cells. 
In this thesis chapter, the half maximal inhibitory concentration (IC50) values of AAPt compounds 
with various cancer and normal cells are reported. The values were determined using the MTT 
(3-(4,5-dimethylthiaxol-2-yl)-2,5-diphenyltetrazolium bromide) assay. AlaPt, OrnPt, and ArgPt are 
observed to have a wide range of potencies in the chosen cell lines. Whereas cisPt does not 
exhibit selective potency with these cell lines, ArgPt exhibits selective potency in prostate cancer 
cells over normal cells. The uptake and accumulation of platinum-based compounds in cancer 
cells determines the extent of the cellular response that leads to apoptosis. Accumulation of the 
AAPt compounds in prostate cancer and other cancer cell lines was determined using inductively 
coupled plasma mass spectrometry (ICP-MS). Compared to cisPt, ArgPt has significantly higher 




uptake of platinum-based compounds with other factors such as structural features of the 
compound and DNA/RNA adducts. 
6.2 Introduction 
CisPt is a common metal-based anticancer drug used for the treatment of a variety of 
cancer types [18, 11]. It has a cure rate of up to 80% in some forms of cancer such as testicular 
cancer [18, 11]. However, cisplatin cancer applications have been hindered by drawbacks such 
as resistance and adverse side effects such as nephrotoxicity [165-166, 71]. Resistance occurs 
when cancerous cells do not undergo apoptosis within the clinically relevant drug doses. Factors 
that lead to resistance include reduced drug accumulation, increased thiol levels that inactivate 
cisPt, and increased DNA damage repair that removes cisPt adducts [71]. CisPt can also cause 
major toxic side effects including nephrotoxicity, which occurs when cisPt accumulates in the 
kidney and causes injury to renal epithelial cells, leading to undesirable death of healthy cells 
[167]. To mitigate these challenges, analogues of cisPt such as carboplatin and oxaliplatin have 
been developed with the goal of reducing toxicity and resistance [16]. The chemical 
characteristics of carboplatin gives it an advantage over cisPt, and toxicity can be circumvented 
due to its lower reactivity and adduct formation (discussed in Chapter 1, Section 1.4.3) [91]. 
Despite having reduced toxicity and lower cellular resistance, the activity of analogues such as 
carboplatin has been hampered by lower potency. As high as 90% of administered carboplatin 
does not react with the target and is excreted, meaning that a much higher dose is required in 
order to achieve the same effectiveness as cisPt [16]. It is therefore desirable to develop new 
platinum-based compounds that have the same or better efficacy than cisPt while being selective 
for cancer cells in order to reduce the toxic side effects. The compounds should also be able to 
circumvent cellular resistance so as to impart apoptosis of tumor cells even with long-term use. 
The potency of platinum-based compounds can be determined using their IC50 values. An 
IC50 value refers to the concentration of a compound that causes a reduction in cell viability by 




such as the MTT assay (discussed in Chapter 2, Section 2.4.13) [168]. This assay is used to 
quantify the number of viable cells based on the amount of metabolic activity that is detected. In 
this assay, the mitochondrial NAD(P)H-dependent reductase enzymes in viable cells reduce the 
MTT into the insoluble, purple compound known as formazan [169]. Formazan crystallizes on the 
cell surface and is then dissolved by solvents such as dimethyl sulfoxide (DMSO) [168-169]. 
Absorbance measurements of the resulting solutions are taken using a spectrophotometer. The 
absorbance readings are correlated with the percentage of viable cells and plotted as a function 
of compound concentration [170]. The fitted dose-response curves are used to extract the IC50 
values. 
The MTT assay has been modified in which tetrazolium is used to determine the IC50 
values of compounds in cells. The alternative reagents also include MTS (3-(4,5-dimethylthiazol 
2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium), XTT (2,3-bis-(2-methoxy-4-
nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide), and WST (2-(2-methoxy-4-nitrophenyl)-3-
(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium) [170]. These assays have been modified to 
eliminate the need for washing and solvent solubilization steps because they generate water-
soluble products [171]. However, the MTT assay is still preferred for investigating cell viability and 
proliferation [171] because of its higher sensitivity and validated use in miniaturized high-
throughput assays [171]. This technique is also preferred over alternatives such as the radioactive 
isotope-based thymidine incorporation assay, which is more time consuming and expensive [171-
172]. Other techniques such as counting total viable cells using a hemocytometer are 
cumbersome and require a large number of samples to be processed [172]. 
The IC50 values of FDA-approved platinum compounds varies depending on the 
compound, the type of cells being treated, and the length of time of treatment [173-182]. In Table 
6.1, examples of IC50 values of the FDA-approved platinum-based drugs in common cell lines are 
given. Generally, the IC50 values of cisPt are lower than carboplatin [33-36]. For example, cisPt 




carboplatin achieves a similar value after 5 days of treatment (Table 6.1) [174, 180]. In lung cell 
lines A549 and MCF7, oxaliplatin has similar or lower IC50 values than cisPt (Table 6.1) [178-179, 
182]. This may be attributed to the structural characteristics of oxaliplatin, which includes its 
relatively larger non-leaving ligand that triggers cell death by protruding into the major groove and 
effectively blocking DNA replication and transcription (discussed in Chapter 1, Section 1.4.3) 
[94, 96]. 
Table 6.1. IC50 (μM) values of cisPt, carboplatin, and oxaliplatin in human cancer cell lines 
tissue 
 
cell line  
[ref] 
cisPt 







lung H1299  
[129] 
21 ± 4  
(72 h) [180] 
19 ± 3  






2 ± 1 
(72 h) [181] 
5 ± 2  
(96 h) [175] 
12 ± 1 





1.4 ± 0.2 
 (5 h) [182] 
8 ± 1  
(5 d) [182] 
23 ± 1 





3 ± 1  
(5 d) [182] 
20 ± 1 
 (5 h) [182] 
0.9 ± 0.1 





16 ± 6 
 (24 h) [179] 
4 
 (48 h) [173] 
2 ± 1 






 (72 h) [177] 
10 ± 1 
 (48 h) [174] 
2.1 ± 0.2 
 (72 h) [178] 
 
The AAPt compounds could provide another class of metal-based compounds with oral 
drug-like features according to Lipinski rules [126]. The Lipinski rules are a set of requirements 




require that compounds should not violate more than one of the four rules, which include having: 
1) less than 500 Da in molecular weight, 2) less than five hydrogen-bond donors, 3)  less than ten 
hydrogen-bond acceptors, and 4) logP values of not greater than five [185]. The structural 
characteristics and molecular weights of AAPt compounds conform with the Lipinski rules (Fig. 
6.1). There has been limited previous attempts to investigate the activity and potency of AAPt 
compounds in cancer cell lines. The cytotoxicity of ArgPt, LysPt (lysine-linked platinum(II)), and 
several LysPt-related derivatives were previously investigated in HeLa and KM-12 cell lines using 
colony counting method  [112, 103]. In these studies, ArgPt and LysPt exhibited promising IC50 
values of 25 µM in a HeLa cell line following 24 h of treatment and further 7-10 days of cell growth 
[112]. There is still a need to investigate the potency of AAPt compounds (including AlaPt and 
OrnPt) in a larger variety of cancer cell lines including cisPt-resistant and cisPt-sensitive cells. 
The results would provide a deeper understanding of the features of platinum-based compounds 
that promote their activity, selectivity, and circumvention of resistance. 
 
Figure 6.1. The structures of cisPt and AAPt compounds. The structures and molecular 
weights of cisPt, AlaPt, OrnPt, and ArgPt are given. 
 
The drawbacks of cisPt therapy such as resistance due to DNA repair, non-selectivity, and 
toxicity limit its effectiveness, but could possibly be mitigated by compounds that form adducts at 
novel targets that are not preferentially platinated by cisPt. CisPt preferentially binds with DNA 
dGuo residues, which plays a role in its anticancer activity [18, 27, 40, 38]. Formation of adducts 
at non-canonical sites could be important in circumventing resistance and triggering alternative 




(AlaPt, OrnPt, and ArgPt) have altered reactivity compared to cisPt. AAPt compounds have 
reactivity preferences for dAdo and Ado residues of DNA and RNA [105-106]. These AAPt 
compounds could become candidates that induce alternative cytotoxic pathways by involving non-
canonical targets such as dAdo residues of DNA as well as Ado residues of RNA. The features 
of compounds that lead to tumor cell death can be investigated at both the molecular and cellular 
levels.  
In this thesis chapter, the anticancer potency of AAPt compounds at the cellular level is 
reported. The IC50 were determined in several human cancer cell lines by using MTT assay. The 
potency of the compounds was investigated in prostate, breast, and lung cancer cell lines. 
Prostate and lung cancers are the leading causes of cancer-related deaths among men in the 
United States, whereas breast and lung cancers are the leading causes of cancer-related deaths 
among women [186]. CisPt chemotherapy has been applied in the treatment of lung, breast, and 
prostate cancer [187-189], but has been hindered by adverse toxicity, side effects, and resistance 
[187-188]. Therefore, there is a need to develop other platinum-based compounds that have 
better activity and selectivity than cisPt in these forms of cancer. 
The accumulation of anticancer compounds inside cells is an important aspect that drives 
their pharmacological impacts. Low accumulation of cisPt in cells causes DNA damage, which 
potentially stimulates resistance rather than apoptosis [71]. Reduced cellular accumulation of 
cisPt is caused by factors such as disruption of drug uptake or increased efflux [71]. Higher cellular 
accumulation of cisPt (or other platinum-based compounds) is important for formation of a 
sufficient number of DNA adducts to trigger apoptosis. Therefore, accumulation of the compounds 
in cells can be correlated with their potency and IC50 values, in which higher accumulation 
corresponds to higher potency (and lower IC50 values). Previously, whole cell cisPt uptake in 
cisPt-sensitive and cisPt-resistant lung tumor cells was determined by using ICP-MS [190]. It was 
observed that cisPt-resistant cancer cells have four-fold lower uptake of cisPt compared to the 




of cisPt bound to biological targets such as DNA and RNA, has been quantified in other studies 
by using ICP-MS [59]. In the thesis work reported in this chapter, cellular accumulation of AAPt 
compounds in comparison to cisPt in both cancer and normal cells was determined using ICP-
MS. The structural characteristics of AAPt compounds could be important for efficient cellular 
uptake and accumulation. The positively charged ligand side chains of ArgPt and OrnPt could 
promote cell penetration due to electrostatic interactions with the anionic plasma membrane [191]. 
Cancer cells have a net negative charge on the surface on their cell membranes compared to 
normal cells [192-194]. This can be attributed to high levels of lactate anions secreted by cancer 
cells that minimize the presence of cations on the cell surface and promote a net negative charge 
[195]. This behavior is unique to cancer cells, which have an active metabolism that causes 
glycolysis to form high amounts of lactate anions compared to normal cells [196]. Furthermore, 
cancer cells have upregulation of negatively charged sulfated proteoglycans on the cell surface 
that further contribute to the negative charge [197-198]. Favorable interactions with the negative 
cell surface prior to uptake could favor selective targeting of cancer cells. 
6.3 Results and discussion 
6.3.1 Potency of AAPt compounds in human cancer and normal cells 
 The potency of AAPt compounds in prostate (DU145), lung (H1299), breast (MDA-MB-
453 and MDA-MB-231), and cervical (Hela) cancer cell lines was investigated by using the MTT 
assay. The activities of platinum-based compounds in prostate normal (RWPE-1) and prostate 
cancer (DU145) cell lines were also determined so as to understand their selective potency. The 
MTT assay, as described in Section 2.4.13, was used to investigate the viability of cells following 
treatment with the AAPt compounds and cisPt. The percentage of viable cells as a function of 
increasing concentration of platinum-based compounds was plotted and used to extract the IC50 
values.  
The DU145 cell line was treated with the AAPt compounds (and cisPt) for 72 h. The dose-




concentration of platinum-based compound (Fig. 6.2). The degree in which the number of viable 
cells decreases depends on the identity of the platinum compound (cisPt, AlaPt, OrnPt, and 
ArgPt). These results suggest that the different structural forms of the platinum-based compounds 
have different uptake levels and/or trigger different cytotoxic responses in the cells. 
 
Figure 6.2. Dose-response curves of AAPt compounds (and cisPt) in prostate cancer 
(DU145) cell line. The MTT assay was used to determine the percentage of viable cells as a 
function of increasing concentration of platinum-based compound. The type of cancer cell line 
and platinum-based compound used are indicated in the plots. All cells were treated for 72 h. 
Cells have varied responses to the different compounds used in the assay. GraphPad PRISM 
software was used for curve fitting using the model equation Y=100/(1+(XhillSlope)/(IC50hillSlope)), in 






From the dose-response curves, the AAPt concentrations that resulted in 50% reduction 
of viable cells (IC50 values) were extracted. The IC50 value of cisPt was compared to those of 
AAPt compounds (Table 6.2). Cispt has an IC50 value of 4 µM in prostate cancer cells following 
the 72 h treatment. This value is consistent with a reported IC50 value of 3 µM following treatment 
of the same cell line with cisPt over 72 h [177]. AlaPt has an IC50 value of 75 µM in the DU145 
cell line, which is 19-fold higher than cisPt value (Table 6.2). This result shows that in this cell 
line, AlaPt is less potent (or has lower uptake) and its chemical structure does not elicit cytotoxic 
responses comparable to cisPt. OrnPt has an IC50 value of 46 µM in the DU145 cell line which is 
11-fold higher than cisPt (Table 6.2). This result shows that OrnPt is also less potent in prostate 
cancer cells compared to cisPt. 
Table 6.2. Comparison of potency of AAPt compounds, cisPt, and carboplatin in DU145 cell line 
Compounds (ref) cell line (ref) IC50 value (μM)ǂ 
cisPt DU145 [133] 4 ± 1 
AlaPt DU145 [133] 75 ± 13 
OrnPt DU145 [133] 46 ± 12 
ArgPt DU145 [133] 12 ± 2 
carboplatin [174] DU145 [133] 10 ± 1 
     ǂerror is from at least two biological replicates 
 
ArgPt has an IC50 value of 12 µM in the DU145 cell line (Table 6.2). This value is three-
fold higher than that of cisPt, showing only a moderately lower potency.  Although the low IC50 
value of cisPt may translate to high potency, the high activity may also cause toxicity to rapidly 
dividing cells and other side effects [165-166, 71] and hence, a three-fold lower activity of ArgPt 
could be more ideal in cancer targeting. Carboplatin is reported to have an IC50 value of 10 µM in 
DU145 [174], which is similar to that of ArgPt in the same cell line (Table 6.2). Therefore, ArgPt 




potentially less toxic than cisPt in normal cell lines. The lower potency of carboplatin is 
advantageous in circumventing the adverse toxicity usually caused by high dosages of platinum 
compounds [91]. For ArgPt, having an IC50 value that is comparable to carboplatin could be 
important in balancing selective potency in cancer cells and toxicity in normal cells. ArgPt and 
carboplatin may have structural features that promote both potency and reduced toxicity. 
Because of the potency of ArgPt in prostate cancer cells, its activity in a prostate normal 
(RWPE-1) cell line was also investigated and compared to cisPt. In RWPE-1, cisPt has an IC50 
value of 4 µM after a 72 h treatment (Fig. 6.3 and Table 6.3). This low micromolar value is similar 
to its IC50 value in the DU145 cancer cell line, meaning that cisPt is highly potent and not selective 
for cancer over normal prostate cells. This result was expected because cisPt is known to be non-
selective and toxic to normal cells [199-200]. 
 
 
Figure 6.3. Dose-response curves of cisPt and ArgPt in normal prostate (RWPE-1) cell 
lines. An MTT assay was used to determine the percentage of viable cells as a function of 
increasing concentration of platinum-based compound. The type of cancer cell line and platinum-
based compound used are indicated in the plots. The cell lines were treated for 72 h.  Cells have 
varied responses to the different compounds used in the assay. GraphPad PRISM software was 
used for curve fitting using the model equation Y=100/(1+(XhillSlope)/(IC50hillSlope)), in which hillslope 







Table 6.3. Comparison of IC50 (μM) values of cisPt and ArgPt in normal and cancer cell lines 
tissue cell line (ref) disease cisPtǂ ArgPtǂ 
prostate DU145 [133] carcinoma 4 ± 1 12 ± 2 
prostate RWPE-1 [134] normal 4 ± 1 69 ± 5 
  fold change in 
IC50 values 
1 6 
        ǂerror is from at least two biological replicates 
 
ArgPt has a low IC50 value of 12 µM in prostate cancer cells and a moderately high IC50 
value of 69 µM in prostate normal cells (Fig. 6.3 and Table 6.3). The six-fold difference in the IC50 
values of ArgPt in prostate cancer and normal cells shows that ArgPt is moderately selective for 
the cancer cells. The selective potency of ArgPt in the cancer cell line compared to normal cells 
could be due to its ligand side chains. Cancer cells have been reported to have a higher net 
negative charge on their cell surface compared to normal cells [192-194] and also upregulation 
of negatively charged sulfated proteoglycans on the cell surface [197-198]. The negative surface 
and sulfated sugars may enable favorable electrostatic interactions with the positive guanidinium 
side chains [201, 195] leading to attraction of ArgPt towards cancer cells and promoting uptake 
by the same cells.  
Although OrnPt has a positive side chain, its four-fold lower potency could be related to 
its different amine side chain (compared to guanidinium). The positively charged amine may not 
possess favorable interactions with cancer cells compared to the guanidinium in ArgPt. This 
difference is observed in various cell penetrating peptides (CPP), in which the arginine moiety 
stimulates higher cellular uptake compared to lysine (which has similar amine moiety as ornithine) 
[202, 201, 203]. An example is where arginine-enriched peptides stimulates more cellular 
internalization through endocytosis than lysine-enriched peptides [202]. Efficient uptake of both 
arginine- and lysine-rich peptides is also attributed to their interactions with cell surface 




peptides meaning that the arginine moiety modulates cell penetration through several pathways 
that may not be available for the lysine moiety [201]. Furthermore, as mentioned in Section 2.4.2, 
it is possible that OrnPt may exist with an (N, N) type of structure. The (N, O) and (N, N) type of 
structures could elicit different cytotoxic responses in cells. Therefore, among the three AAPt 
compounds investigated, ArgPt has higher potency in cancer cells over normal cells, a feature 
that could be advantageous over cisPt. 
 
Figure 6.4. Dose-response curves of cisPt and ArgPt in breast cancer cell lines. An MTT 
assay was used to determine the percentage of viable cells as a function of increasing 
concentration of platinum-based compound. The type of cancer cell line and platinum-based 
compound used are indicated in the plots. All cells were treated for 48 h except MDA-MB-453 
which was treated for 64 h. GraphPad PRISM software was used for curve fitting using the model 
equation Y=100/(1+(XhillSlope)/(IC50hillSlope)), in which hillslope is -1. IC50 values were extracted from 





As mentioned before, breast and lung cancer are the leading causes of cancer-related 
deaths among women in the United States [186]. Because of the promising results of ArgPt with 
prostate cancer cell lines, its potency in breast (Fig. 6.4 and Table 6.4) and lung (Fig. 6.5 and 
Table 6.4) cancer cell lines was also investigated in comparison to cisPt using the MTT assay. 
The potency of the compounds in a cervical cancer cell line (HeLa) was also determined (Figs. 
6.4 and 6.5). The dose-response curves of all cell lines tested show that the percentage of viable 
cells is diminished with an increase in the concentration of platinum compounds depending on 
the type of cell line and identity of the platinum compound. ArgPt has an IC50 value of 35 µM in 
the breast cancer cell line MDA-MB-453 and 73 µM in breast cancer cell line MDA-MB-231 (Table 
6.4). The response to ArgPt treatment is therefore different in the two breast cancer cell lines 
under investigation, with a two-fold higher potency in MDA-MB-453 cells compared to MDA-MB-
231 cells. ArgPt has an IC50 value of 73 µM in the H1299 cell line and 78 µM in the HeLa cell line. 
The IC50 values in all four cell lines indicate that ArgPt has only moderate activity in these cell 
lines. Compared to cisPt, ArgPt has significantly less potency in the same cell lines (Table 6.4). 
To confirm that the cellular potent activity is only from the complexes of amino acids linked with a 
platinum center and not the free amino acids, future experiments will involve the use of respective 
amino acids as controls. 
Table 6.4. IC50 (μM) values ArgPt in comparison with cisPt 
tissue cell line (ref) treatment time cisPtǂ ArgPtǂ 
breast MDA-MB-231 [130] 48 h 17 ± 4 73 ± 10 
breast MDA-MB-453 [128] 64 h 10 ± 1 35 ± 3 
lung H1299 [129] 48 h 25 ± 2 73 ± 5 
cervical HeLa [132] 48 h 23 ± 2 78 ± 9 






Figure 6.5. Dose-response curves of ArgPt and cisPt in cervical and lung cancer cell lines. 
MTT assays were used to determine the percentage of viable cells as a function of increasing 
concentration of platinum-based compound. GraphPad PRISM software was used for curve fitting 
using the model equation Y=100/(1+(XhillSlope)/(IC50hillSlope)), in which hillslope is -1. IC50 values were 
extracted from the plots. Each plot is from at least two biological replicates. 
 
 
6.3.2 Quantification of platinum abundance in cells 
In this thesis work, the cellular accumulation of AAPt compounds and cisPt in DU145 and 
RWPE-1 cell lines was determined. Because of the selective potency of ArgPt in prostate cancer 
cells compared to normal cells, it was of interest in this thesis work to determine the possible 
difference in uptake and accumulation of the compound in both cell types. Cells were treated with 
either AAPt or cisPt compounds and their cellular platinum concentration determined 
quantitatively by using ICP-MS (Chapter 2, Section 2.4.14). The ICP-MS has four tune modes 




(HEHe) tune mode because the internal standard signal was stable and the R value of calibration 
was closest to 1. The calibration curves from the four tune modes are shown in the Appendix 
(Figs. 1A-4A). As shown in Table 6.5, accumulation of the platinum-based compounds varies 
depending on the cell line and the identity of compound. To confirm the consistency of the 
quantification, the samples were diluted 2X and 10X, followed by measurements on the ICP-MS 
and correction of dilution factors (Table 6.6). Readings for respective samples were consistent 
with each other with a low error percentage ranging from 0.1 to 7.8%. 
 
Table 6.5. Accumulation of platinum compounds in prostate cancer and normal cells 
disease cell line Pt compound amount (nmol/106 cells) 
normal RWPE-1 cisPt 0.9 ± 0.3 
carcinoma DU145 cisPt 15 ± 8 
normal RWPE-1 OrnPt 0.9 ± 0.2 
carcinoma DU145 OrnPt 28 ± 11 
normal RWPE-1 ArgPt 3.2 ± 0.1 




Table 6.6. ICP-MS analysis of diluted samples of cells treated with platinum-based compounds 







normal/cisPt 0.9 0.9 0.9 0.9 <0.1 
cancer/cisPt 15 16 16 16 1.9 
normal/OrnPt 0.9 1.1 1.1 1.0 <0.1 
cancer/OrnPt 28 30 28 29 2.4 
normal/ArgPt 3.2 4.2 4.1 3.8 7.8 




CisPt has an accumulation of 15.3 nmol per million cancer cells, which is 17-fold higher 
than its accumulation in normal cells (Table 6.5 and Fig. 6.6). OrnPt has an accumulation of 28 
nmol per million cancer cells, which is thirty-fold higher than its accumulation in normal cells. 
ArgPt has an accumulation of 96 nmol per million cancer cells, which also represents a 30-fold 
higher accumulation than in normal prostate cells. Therefore, OrnPt and ArgPt exhibit higher fold 
changes in their accumulation in cancer cells over normal cells compared to cisPt. The 
considerably higher accumulation in cancer cells than normal cells could be important in triggering 
selective potency. The 30-fold higher ArgPt accumulation in cancer cells translated to a six-fold 
selective potency in the same cells compared to normal cells (Tables 6.2 and 6.3). The presence 
of a positively charged guanidinium on the side chain of ArgPt may be important for its penetration 
and potency in cells. It has been reported that positively charged residues including arginine 
promote cell penetration due to strong electrostatic interactions with anionic plasma membranes 
[204] and through their interactions with the negative sulfated proteoglycans [201-202]. Cancer 
cells have a higher net negative surfaces on their cell membranes [192-194] and upregulated 
levels of proteoglycans [197-198], which would likely interact favorably with the positive ArgPt 
side chains. Therefore, it is plausible that ArgPt has favorable interactions with the surfaces of 
cancer cells and transit through the cell membrane followed by interactions with the negatively 
charged nucleic acids inside cells. Although OrnPt also has a positive amine on its ligand side 
chain, it has a four-fold lower potency and three-fold lower accumulation than ArgPt in DU145 cell 
line. This is likely because the guanidinium moiety of arginine is more efficient in promoting cell 
internalization compared to the amine moiety of ornithine (or lysine) [201-202]. This also means 
that other properties of ArgPt in addition to its positively charged guanidinium on the side chain 





Figure 6.6. Accumulation of platinum-based compounds in prostate normal (blue, DU145 cell 
line) and cancer (red, RWPE-1) cell lines. Error is calculated fom three repeats. 
 
 
While cellular uptake of the AAPt compounds (and cisPt) is crucial in adduct formation 
and triggering cell death, other factors associated with the cells could also play a role in mediating 
the extent of potency once uptake occurs. The difference in potency of ArgPt in all the cell lines 
investigated in this thesis work could be explained by their p53 status. It is suggested that 
antitumor agents including cisPt induce apoptosis through involvement of the tumor suppressor 
p53 protein [205-206]. Cell lines with downregulated or mutated p53 proteins are less 
chemosensitive to cisPt  [205-206]. The p53 status and cisPt sensitivity in the cell lines 
investigated in this thesis work are consistent. If ArgPt induces apoptosis through involvement of 
p53 proteins in a manner similar to cisPt, then cells with this tumor suppressor would be more 
chemosensitive to ArgPt. Breast cancer cell line MDA-MB-453 has full length p53 [207] while its 
related MDA-MB-231 has mutated p53 proteins [208]. The response to ArgPt by these two cell 
lines are consistent with their p53 status in which MDA-MB-453 is two-fold more sensitive to ArgPt 
than the MDA-MB-231 cell line. H1299 and HeLa cell lines are p53 null [209-210] and this may 




expresses p53 [211], and this could also contribute to the observed high sensitivity to ArgPt as 
indicated by the low IC50 value. 
6.4 Conclusions 
At the cellular level, ArgPt exhibits increased potency and accumulation compared to cisPt. 
While cisPt is potent in both cancer and normal prostate cells, ArgPt is selective in potency 
towards prostate cancer cells compared to normal cells. ArgPt also has higher accumulation in 
prostate cancer cells, which correlates with its lower IC50 value and higher potency. ArgPt is 
observed to have a 30-fold higher accumulation in prostate cancer cells than normal cells, which 
translates into a six-fold selective potency in cancer cells. Structural characteristics of AAPt 
compounds could enable the compounds to have unique cell penetration properties and potency 
compared to cisPt. The positively charged guanidinium on side chain of ArgPt could promote cell 
penetration due to electrostatic interaction with anionic plasma membrane. Unique features of 
cancer cells including the higher net negative charge on the surface of cell membranes or the 
presence of negatively charged sulfated proteoglycans could also recruit ArgPt towards cancer 
cells and promote selective uptake of the compounds. Although, OrnPt is also observed to have 
higher accumulation in prostate cancer cells than normal cells, its potency in prostate cancer cells 
is relatively low compared to ArgPt. The possible existence of OrnPt adducts with an (N, N) type 
of structure of metal complex could explain this difference, especially if the (N, N) type of 
structures do not have favorable interactions with cells compared to (N, O) type of structures. 
Future directions will involve using respective free amino acids during MTT assays as controls 
so as to ascertain if the complex of platinum center together with the amino acid ligand induce 
the potent activity of AAPt compound as opposed to free amino acid alone. Furthermore, 
competition studies of cellular uptake of free amino acids and AAPt compounds could be carried 
out by incubating cells with the compounds prior to ICP-MS quantification of platinum 
accumulation. These studies may give further information on possible cell receptors or 




Inherent cellular features including the status of tumor suppressors such as p53, could also 
modulate the extent of potency in a given cancer cell line. Cell lines with low p53 abundance or 
mutated p53 have lower sensitivity towards not only cisPt but also OrnPt and ArgPt. This tumor 
suppressor may play a role in mediating the cytotoxic pathway of ArgPt and OrnPt in a manner 
similar to cisPt, but this has to be tested with further experimentation. The high accumulation of 
AAPt compounds in cancer cells combined with selective potency and non-canonical targets 
(reported in previous chapters) could enable the compounds to have a robust and unique 























CONCLUSIONS AND FUTURE DIRECTIONS 
7.1 Overall conclusions 
Cisplatin (cisPt) was approved over 40 years ago for anticancer therapy and has since 
been used for treatment of several forms of cancer [9, 11]. CisPt preferentially form adducts with 
deoxyguanosine (dGuo) residues, which alters the DNA structure and inhibits biological 
processes such as replication and transcription [11, 38]. The adducts trigger other cellular 
responses, including cell cycle arrest, DNA repair, and apoptosis [1]. The clinical use of cisPt has 
been limited by cellular resistance and adverse side effects such as nephrotoxicity [69-71]. These 
drawbacks have provided the inspiration to explore other modified cisPt ligands and research 
their structure-activity relationships. The parent cisPt has two ammine and two chlorido ligands 
that modulate its various chemical properties ranging from reaction kinetics to preferred biological 
targets of the compound [16-18]. 
The ligands of second generation cisPt analogues possess unique biochemical effects 
that have played a role in improving their therapeutic activities. In carboplatin for example, the 
chelate ring in cyclobutanedicarboxylate stabilizes the leaving ligand and slows the aquation rate 
[91-92]. This in turn slows the rate of adduct formation with DNA, which ultimately reduces the 
reactivity and toxicity of the compound compared to cisPt at high dosage [91, 34]. The non-leaving 
1,2-diamminocylohexane ligand in oxaliplatin protrudes into the major groove of DNA where it 
effectively blocks the replication machinery from bypassing the adduct [94, 96]. This is important 
in circumventing a form of resistance that occurs in cancer cells where the replication machinery 
is able to read through cisPt adducts. Although the second-generation antitumor platinum-based 
drugs have advantages over cisPt in terms of reduced toxic side effects and the ability to 
circumvent resistance, they are limited by their low efficacy [16]. The compounds also require 




There is still a need to develop platinum-based compounds that can balance high potency, 
reduced resistance, and low toxicity in cells. Since cisPt and second-generation platinum drugs 
are known to target dGuo residues of DNA, platinum-based compounds that have alternative 
target residues or biomolecules such as RNA could trigger unique biochemical events compared 
to cisPt. However, there has been limited success in finding platinum-based compounds that 
preferentially platinate alternative non-cisPt targets. Previous work in our lab showed that amino 
acid-linked platinum(II) (AAPt) compounds coordinate with RNA residues [106]. The work in this 
thesis focused on synthesis of AAPt compounds and characterization of the non-canonical 
adducts that form with adenosine (Ado) residues. The reaction kinetics, impact on glycosidic bond 
stability, potency, and accumulation of AAPt compounds in cancer cells were also investigated. 
AAPt compounds are generated by attaching amino acids to a platinum metal center [106, 
103-105]. In Chapter 2, the synthesis and characterization of three AAPt compounds (AlaPt, 
OrnPt, and ArgPt) were described. The structural characterization of the compounds 
demonstrated that the respective amino acid is chelated with the Pt(II) center through the 
backbone nitrogen and oxygen atoms giving a five-membered ring ((N,O) type of structure) [104-
105]. Even though the (N,N) type structure in OrnPt was not observed in the X-ray crystal 
structure, it was not ruled out since crystallization conditions may have favored only the (N,O) 
type structure [107]. 
CisPt predominantly targets the N7 position of Guo residues and results in formation of 
bifunctional and monofunctional types of adducts. Compared to cisPt, the AAPt compounds have 
a wider range of reactivities and targets because of the diversity of the side chain functional 
groups together with the contribution of backbone atom metal coordination. AAPt compounds 
form adducts with non-cisPt targets including Ado/dAdo residues of RNA and DNA. In Chapter 
3, the non-canonical adducts formed by AAPt compounds (AlaPt, OrnPt, and ArgPt) were 
characterized. The adducts formed are monofunctional isomeric adducts that vary at the 




nucleobases. In this thesis, mass spectrometry and 1D-NMR spectroscopy methods were used 
to identify the types of adducts formed. However, these methods give limited information on the 
structural orientations of the adducts which are modulated by factors such as steric hindrance 
and hydrogen-bonding properties. The 1H-NMR spectroscopy is also limited in differentiating 
between N1 and N3 platination sites because of their similar proximity to H2 proton.  Future 
studies could employ X-ray crystallography or 2D-NMR spectroscopy to differentiate between N1 
and N3 platination. 
Kinetic studies in Chapter 4 indicate that monoaquated AlaPt, OrnPt, and ArgPt have 
altered reactivity and different target preferences compared to cisPt [105]. AlaPt has nine to 20-
fold higher selectivity for dAdo over all other purines. OrnPt exhibits a four to six-fold increased 
reactivity with Ado/dAdo nucleosides over Guo/dGuo, whereas ArgPt has four- to five-fold higher 
reactivity with dAdo/dAdo than with Guo/dGuo. Since cisPt only has the (N,N) type of structure 
while the amino acid complexes can have (N,O) type of structures, the altered reactivity 
preferences suggest that the mode of amino acid coordination together with the ligand side chain 
play a role in modulating the nucleoside preferences and rates of reactivity. Furthermore, the 
selectivity of cisPt for dGuo is attributed to formation of a hydrogen bond between the cisPt 
ammine ligand and the 6-oxo group of Guo during transition state [27]. In contrast, the preferences 
of AlaPt, OrnPt, and ArgPt could be due to hydrogen-bonding interactions with Ado/dAdo 
functional groups. The trans adduct structures of AAPt-Ado are stabilized because of hydrogen 
bonding between the 6-amine of Ado and carboxylate ligand of the AAPt compound. The lower 
reactivities of the selected AAPt compounds with Guo/dGuo are likely lower due to the lack of 
such an interaction. HPLC fitted with a C18 column was used to monitor the rate of diminishing 
reactants prior to extracting the rate constants. It was challenging to monitor rate of formation of 
individual products since there is possible conversion from one type of adduct to another with 
different retention time. There are other methods available such as NMR spectroscopy and mass 




based compounds [32, 34, 149, 158] and could also be used to confirm the reactivities and 
preferences of AAPt compounds with their nucleic acid targets. 
The reaction kinetics of AAPt compounds (and cisPt) with 5′-UUAUU-3′ and 5′-TTATT-3′ 
oligonucleotides were also studied in which monofunctional and doubly platinated adducts were 
observed. The reactivities of the compounds with these oligonucleotides generally increased 
compared to reactions with nucleosides, as exhibited by the increased k values. The local 
environment flanking the target residues in DNA or RNA oligonucleotide, such as the phospho-
diester backbone, likely enhances reactivity with AAPt compounds. The negatively charged 
phosphate groups could interact with the positive ligands of the AAPt compounds (OrnPt and 
ArgPt). The functional groups of the backbone could also hydrogen bond with functional groups 
of AAPt, which would stabilize the coordination of the compounds with their targets. OrnPt was 
also observed to have a two-fold higher preference for the RNA oligonucleotide than the 
corresponding DNA, which means that its structural features could be important in development 
of nucleic acid-selective platinum-based compounds. To further understand the impact of local 
environment on the reactivities of AAPt compounds, other oligonucleotides aside from 5′-UUAUU-
3′ and 5′-TTATT-3′, could also be used in reaction kinetics. Oligonucleotides with varied lengths, 
different sequences flanking target sites, or changing positions of Ado residues would provide 
further understanding on how target positions in relation to flanking sequences or oligonucleotide 
length could affect the reactivities of AAPt compounds. 
Platination of nucleosides could influence the stability of nucleic acids as reported in 
Chapter 5. Collision induced dissociation (CID) and glycosidic bond survival yield analysis were 
applied to determine the impact of platination on the relative glycosidic bond strength of non-
canonical AAPt-Ado adducts. When either AlaPt, OrnPt, or ArgPt coordinate to the N7 position of 
Ado, they destabilize the glycosidic bonds to a greater extent than when they coordinate at the 
N1 or N3 positions. Depending on the proximity of the platinum atom, the ligands of the selected 




destabilization of the glycosidic bonds. Overall, AlaPt-Ado adducts are observed to predominantly 
fragment via cleavage of the glycosidic bond. In contrast, fragmentation of OrnPt-Ado involves 
cleavage of the glycosidic bonds and other neutral loss pathways. Activation of glycosidic bond 
cleavage is particularly unique to the selected AAPt compounds considering that cisPt is reported 
to have no destabilizing effect on the glycosidic bonds of target dGuo residues [26]. 
Destabilization of glycosidic bonds could be biologically relevant considering that AAPt 
compounds could exert formation of abasic sites in nucleic acids. Irreparable abasic sites, 
especially in RNA, could trigger apoptosis and provide an alternative cytotoxic pathway that averts 
cisPt resistance. 
To explore features of ligands that improve activity and selectivity of platinum-based 
compounds, the potency and accumulation of AAPt compounds was investigated in Chapter 6. 
The MTT assay was used to investigate cellular potency, whereas ICP-MS was used to assess 
accumulation of AAPt compounds in comparison with cisPt. While cisPt is potent in both cancer 
and normal prostate cells, ArgPt selectively accumulates and is more potent in prostate cancer 
cells. ArgPt has a 30-fold higher accumulation and a six-fold selective potency in cancer cells 
compared to normal cells. The unique uptake and potency of ArgPt compared to cisPt could be 
attributed to its ligands. The positively charged guanidinium ligand side chain in ArgPt likely has 
favorable electrostatic interactions with plasma membranes, which could recruit the compound 
and enhance cell penetration. Unique features of cancer cells such as the net negative charge on 
the surface of cell membranes and presence of higher levels of negative sulfated glycoproteins 
[193, 195, 194, 201, 197-198] could also recruit ArgPt towards cancer cells and promote selective 
uptake of the compound. Other factors that modulate the extent of chemosensitivity in cancer 
cells include their tumor suppressor p53 status. Cell lines with downregulated or mutated p53 are 
less sensitive towards cisPt treatment [209, 206]. This tumor suppressor may also play a role in 





Overall, the different attributes of the selected AAPt compounds (AlaPt, OrnPt, and ArgPt) 
investigated in this thesis work are important in development of cisPt analogues that have 
improved anticancer activity. These aspects, which include unique platination sites, formation of 
non-canonical adducts, reaction kinetics, selective potency, and high accumulation in cancer 
cells, could enable platinum-based compounds to have robust and unique antitumor activities that 
avert chemoresistance and adverse toxicity. To ascertain if the complex of platinum center 
together with the amino acid ligand induce the potent activity of AAPt compound as opposed to 
free amino acid alone, MTT assays could be carried out using respective free amino acids as 
controls. Studying competitive cellular uptake and accumulation of free amino acids and AAPt 
compounds may give further information on the mode of uptake or possible transporters that could 
be aiding the cell penetration of AAPt compounds. 
7.2 Future directions 
7.2.1 Impact of platinum adducts on hydrolytic cleavage of RNA oligonucleotides 
The impact of platination on cleavage of glycosidic bonds of nucleoside adducts was 
investigated using glycosidic bond survival yield analysis as described in Chapter 5. It would be 
of interest to follow up on these experiments by investigating the rates of depurination of 
oligonucleotides using HPLC or UV analysis. The presence of alkylated or non-canonical bases 
in nucleic acids may promote cleavage of the glycosidic bonds [212-213], and modifications could 
promote hydrolysis of glycosidic bonds leading to damage of DNA through depurination [213]. 
Modification of DNA/RNA oligonucleotides by AAPt compounds may also promote hydrolysis of 
glycosidic bonds. The impact of platination on hydrolysis and damage of DNA/RNA 
oligonucleotides could be investigated by platinating nucleic acids with AAPt compounds (and 
cisPt) under physiological conditions and monitoring depurination kinetics using HPLC/UV 






7.2.2 Quantification of AAPt compounds bound to cellular DNA and RNA 
In Chapter 6, the whole cell abundance of AAPt compounds in comparison with cisPt was 
described. It would also be of interest to quantify the number of adducts formed by platinum-
based compounds with cellular biological targets so as to understand their distribution, 
localization, and preferred targets. Platinum metals bound to RNA versus DNA need to be 
quantified and compared to understand the preferred nucleic acid target of the compounds. These 
studies would involve treating cells with platinum-based compounds followed by isolation of DNA 
and RNA. Because of the elemental quantification capability and robust detection limit of ICP-MS, 
it could be employed to quantify the platinum-based compounds bound to the respective nucleic 
acids. 
7.2.3 Downstream effects of AAPt platination of mRNA 
Since platination by AAPt compounds occurs preferentially with Ado/dAdo sites of nucleic 
acids as described in Chapters 3 and 4, their cellular activities could lead to inhibition of unique 
downstream protein functions that are dependent on Ado/dAdo-rich sites. Cancerous cells have 
an upregulation of mRNA polyadenylation [214-215], which could provide an important selective 
target over normal cells. The mRNA has been reported to be platinated by cisPt [55] and could 
also be one of the biological targets of AAPt compounds. The poly(Ado) tail of mRNA would 
provide an Ado-rich region for which the selected AAPt compounds (AlaPt, OrnPt, and ArgPt) 
could platinate preferentially. Since mRNA associates with a number of proteins such as 
poly(Ado) binding protein (PABP), which are crucial in facilitating nuclear export and translation 
processes [216], it would be of interest to understand the impact of platination on such RNA-
protein interactions and their downstream effects. Such in vitro experiments could be analyzed 








PROTOCOL FOR HUMAN CANCER AND NORMAL CELL CULTURE 
This information describes the protocol for maintaining both cancer and normal cell lines used in 
Chapter 6. 
General 
Cell culturing was carried out in an aseptic laminar flow hood to ensure protection from 
contaminants. The hood was cleaned with 70% ethanol before and after every use. Before 
introducing items such as media into the hood, their container surfaces were sterilized with 70% 
ethanol. Autoclaved tubes/tips and sterile cell plates/dishes were used in all experiments. For 
cancer cells, Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine 
serum (FBS), penicillin (5 units/mL), and streptomycin (0.1 mg/mL) was used. For normal cells, 
keratinocyte serum free medium (K-SFM) supplemented with human recombinant epidermal 
growth factor 1-53 (EGF 1-53), bovine pituitary extract (BPE), penicillin (5 units/mL), and 
streptomycin (0.1 mg/mL) was used. The cell culture incubator was always kept at 37 °C and 5% 
CO2. All the cell lines used in this thesis work are monolayer cell cultures that attach to the bottom 
of plate/dish when they are viable and are only suspended when treated with trypsin or if they are 
dead. 
Recovery of cryopreserved cells 
Cells are usually cryopreserved in liquid nitrogen in a cryovial with DMSO/media solution. 
Their recovery should ensure minimal cell death and removal of DMSO from cell solution before 
cell growth is reestablished. The cryovial with cells was removed from the liquid nitrogen and 
quickly placed in 37 °C waterbath. After one minute of agitating, the vial was sterilized with 70% 
ethanol before opening the cap. The cell solution was transferred into a centrifuge tube with an 
additional 1 mL of appropriate media and centrifuged at 1000 rpm for 4 min at 25 °C. The 
supernatant was removed, mixed with another 1 mL of media to resuspend the cells, and 




mL media before transferring all contents into a cell culture dish (60 x 15 mm) with an additional 
3 mL of media. The seeded dish was stored in the incubator to allow the cells to attach to the 
plate and grow. 
Some cells usually die due to stress conditions of storage and therefore the cell growth of 
new culture is recovered by seeding the dishes with a high density of cells. The dishes should be 
checked periodically under microscope to ensure cell growth, confluency, and availability of 
media. Fresh media can be added after 3-5 days. 
Trypsinizing and passaging monolayer cells 
When cells reach over 80% confluency, they were passaged (split) into secondary dishes 
as described below. 
Cancer cells 
To split the cell culture, the media was first removed from the dish. The cell dish was 
washed with 2 mL of PBS. Trypsin-EDTA (0.25%, 0.5 mL) was added into the dish and incubated 
for 2-5 min at 37 °C to detach the cells from surface of dish. Fresh media (2.5 mL) was added to 
the dish to inactivate the trypsin. Equal volume of cell suspension were distributed into secondary 
dishes.  More media was added into the secondary plates for a total volume of 8 mL in each 100 
x 20 mm secondary dish (or 3 mL if using 60 x 15 mm dishes). The cells were then stored in the 
incubator until they were used for experiments or until they reached over 80% confluency (where 
they were split again into tertiary dishes).  
Normal cells 
The normal cells are treated differently from cancer cells because their media do not 
contain FBS to deactivate the trypsin. The media was first removed from the confluent cell culture 
dish and washed with 2 mL of PBS. Trypsin (0.05%, 0.5 mL) was added and incubated for 2-5 
min at 37 °C to suspend the cells. To the dish, 0.5 mL of 10% FBS is added, agitated, and 
transferred into a centrifuge tube. The tube was centrifuged at 1000 rpm for 4 min at 25 °C 




media. Equal volume of cell suspension were distributed into secondary dishes.  More media was 
added into the secondary plates for a total volume of 8 mL in each 100 x 20 mm secondary dish 
(or 3 mL if using 60 x 15 mm dishes). The cells were then stored in the incubator until they were 
used for experiments or until they reached over 80% confluency (where they were split again into 
tertiary dishes). 
Storage of cells for future experiments 
Cancer cells 
The cells were resuspended with 0.5 mL trypsin (0.25%). Appropriate media (1.5 mL) was 
added to the suspension and mixed. The contents were transferred into a centrifuge tube and 
centrifuged at 1000 rpm for 4 min at 25 °C. The supernatant was removed and 1 mL of appropriate 
fresh media was added to the tube. Another 1 mL of DMSO was also added into the tube and 
mixed. The contents were transferred into sterile cryovial, capped and placed in -80 °C overnight. 
The cryovials were then placed in liquid nitrogen freezer for long term storage. 
Normal cells 
The cells were resuspended with 0.5 mL trypsin (0.05%). After the cells were dispersed, 
0.5 mL of 10% FBS was added into the dish and mixed. The contents were transferred into a 
centrifuge tube and centrifuged at 1000 rpm for 4 min at 25 °C. The supernatant was removed 
and 1 mL of appropriate fresh media was added to the tube. Another 1 mL of DMSO was also 
added into the tube and mixed. The contents were transferred into sterile cryovial, capped and 










ICP-MS CALIBRATION AND INTERNAL STANDARDS 
The ICP-MS was calibrated in four different tune modes using 195Pt and two internal 
standards (209Bi and 115In). The calibration graph with R value closest to 1 and stable internal 
standards was selected for quantification of samples (Fig. 1A-4A). 
 
 
Figure 1A. ICP-MS Calibration graph with no gas tune mode. The calibration graph together 
with measurements of internal standards (Bi-209 and In-115) in the same mode are given. DL is 






Figure 2A. ICP-MS calibration graph in helium tune mode. The calibration graph together with 
measurements of internal standards (Bi-209 and In-115) in the same mode are given. DL is 







Figure 3A. ICP-MS calibration graph in high energy helium (HEHe) tune mode. The 
calibration graph together with measurements of internal standards (Bi-209 and In-115) in the 







Figure 4A. ICP-MS calibration graph in hydrogen tune mode. The calibration graph together 
with measurements of internal standards (Bi-209 and In-115) in the same mode are given. DL is 
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Although cisplatin (cisPt) has been used for several years in cancer therapy, its application 
has faced challenges of adverse toxicity, lack of selectivity, and cellular resistance. Several 
second-generation cisPt analogues have been synthesized, but only a few have been approved 
worldwide for anticancer usage. The approved analogues, which include carboplatin, oxaliplatin, 
and nedaplatin, have advantages in averting adverse toxicity and resistance in their antitumor 
application. However, compared to the parent cisPt, these analogues have low potency and 
usually require to be administered with other compounds in order to be effective. There is still a 
need to develop alternative platinum-based compounds with balanced potency, selectivity for 
cancer cells, and reduced side effects. 
CisPt is known to target deoxyguanosine (dGuo) residues of DNA and coordinate at their 
N7 positions. New analogues could be developed to selectively coordinate with alternative targets 
and form non-canonical adducts that could potentially be important in avoiding resistance and 
lack of selectivity. Efforts to find compounds that coordinate with alternative sites of DNA or RNA 
have had limited success. Previous work in our lab showed that positively charged amino acid-
linked platinum(II) (AAPt) compounds have altered reactivity compared to cisPt when reacting 
with folded RNA. In this thesis, AAPt compounds of alanine, ornithine, and arginine (AlaPt, OrnPt, 




one chelating amino acid and two chlorido ligands that coordinate with the platinum center to form 
a five-membered ring. The objectives of this thesis were to characterize the non-canonical 
adducts formed by AAPt compounds, investigate their reaction kinetics with nucleic acids, study 
their impact on glycosidic bond stability, and investigate their cellular potency and accumulation. 
AlaPt, OrnPt, or ArgPt react with Ado nucleosides to form multiple products that were 
isolated from HPLC and further characterized using mass spectrometry and NMR spectroscopy. 
The compounds coordinate with Ado to predominantly form isomeric monofunctional adducts that 
vary at their platination sites (N1, N3, or N7). The compounds also react with oligonucleotide 
sequences 5′-d(TTATT)-3′ and 5′-UUAUU-3′ in which monofunctional and doubly platinated 
adducts are observed. Kinetic reactions of AAPt compounds with purine nucleosides indicate that 
AlaPt, OrnPt and ArgPt have reactivity preferences for Ado/dAdo residues over Guo/dGuo 
residues. These AAPt compounds have between five- to nine-fold higher reactivity with Ado/dAdo 
nucleosides than with Guo/dGuo. The reactivity of these compounds with DNA/RNA 
oligonucleotides is enhanced compared to their reactivity with nucleosides. This preference is 
likely because the negatively charged backbone phosphate groups could interact favorably with 
the AAPt compounds or provide hydrogen-bond acceptors that stabilize the interactions of AAPt 
with the oligonucleotides. 
Changes in the chemical composition of a molecule affect its stability. Modification of 
nucleoside residues due to coordination with platinum-based compounds could also impact their 
adduct bond stabilities. The fragmentation and stability of glycosidic bonds were investigated 
using collision induced dissociation (CID) and glycosidic bond survival yield analysis. It was 
observed that platination by AlaPt and OrnPt at the N7 position destabilizes the glycosidic bonds 
more than platination at the N1 or N3 positions. Comparatively, AlaPt activates fragmentation of 
the adducts predominantly through glycosidic bond cleavage, while OrnPt activates fragmentation 




The cellular potency of AAPt compounds in human cancer and normal cells was 
investigated using MTT assays. The potent activity of these compounds was observed in several 
cell lines including prostate cancer cell line (DU145). While cisPt exhibits potency in both prostate 
cancer and normal cell lines, ArgPt is more selective with a six-fold higher potency in prostate 
cancer cells over normal cells. The uptake and accumulation of platinum-based compounds could 
contribute to the selective potency of platinum-based compounds. Therefore, the accumulation of 
the compounds was investigated in prostate normal and cancer cells using inductively coupled 
plasma mass spectrometry (ICP-MS). ArgPt exhibits a thirty-fold higher accumulation in cancer 
cells compared to normal cells, which likely translates to its observed selective potency. 
The work in this thesis could be important in providing important structural and chemical 
information that can be applied in the development of newer platinum-based drugs that have 
improved anticancer activities. Characteristics that enable formation of non-canonical adducts 
and altered reactivity preferences could be important in circumventing cellular resistance. 
Features that promote selective potency and increased uptake by cancer cells are also crucial in 
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